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Abstract 
 
Morphogens are signalling molecules that play a significant role in modulation of cell 
fate and development. Hedgehog proteins (Hh) are morphogens that have been shown to 
be involved in the development of immune cells. In this study, it is demonstrated that 
treatment of B cells with rShh, can increase B cell activation and also promote survival 
of B cells at 18hours post-stimulus. Also, at this time point, there was found to be an 
increase in secretion of antibody isotypes and IL-6. By 40hours post-stimulus, it was 
observed that the level of B cell activation was apparently arrested in treated B cells, 
whereas the level of activation continued to rise in untreated B cells. Interestingly, it 
was observed that there was an increase in the percentage of; CD23-CD25+ B cells 
when B cells were treated with rShh and this was accompanied by an increase in 
apoptosis. Consistent with this finding in relation to apoptosis, there was an increased 
expression of the pro-apoptotic protein Bnip3 in B cells treated with rShh by 40hours 
post-stimulus. It was observed that there were three subsets of B cells arising in our 
culture at 40hours, which were all found to possess different characteristics. It was 
demonstrated that treatment with rShh can increase B cell differentiation towards FO-I 
at 18hours post-stimulus. By 40hours post-stimulus, Hh signalling can divert 
differentiation away from the FO-I B cell towards the T2-MZP, which was 
accompanied by an increase in IL-10 secretion. Gene expression analysis revealed that 
Hh signalling could modulate a number of molecules involved in delivering the BCR 
signal into the cells such as Btk, Nfatc1 and Traf2. Additionally, deletion of Dhh, 
showed that there was a skewed peripheral B cell development in the Dhh-/- mice. 
Overall, our data demonstrate that Hh signalling can regulate the development of B cells 
in response to an activation stimulus by strengthening the BCR signalling pathway.  
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Chapter 1: Introduction 
 
 
1.1. B cells 
 
1.1.1. B cell development in the bone marrow  
 
B-lymphocytes (B cells) are a population of cells that express clonally diverse cell 
surface immunoglobulin receptors recognising specific antigen epitopes and are capable 
of producing high affinity soluble antibodies (LeBien and Tedder, 2008, Cooper, 2015). 
They play a prominent role in preventing and combating infections. The development of 
B cells occurs in multiple stages that begin in the primary lymphoid tissue, the bone 
marrow, before subsequent developmental stages occur in the secondary lymphoid 
organs such as the spleen. The endpoint of the development of B cells is antibody 
production by terminally differentiated plasma cells as well as the differentiation of 
activated B cells into memory B cells (LeBien and Tedder, 2008).  
 
In mammals, B cells are derived from hematopoietic stem cells (HSC) and are produced 
in the fetal liver, yolk sac and fetal marrow during gestation and in the bone marrow 
after birth. HSCs are pluripotent stem cells that gives rise to common lymphoid 
progenitor (CLP) which is restricted to all lymphoid cells (T cells, B cells and Natural 
killer cells) and common myeloid progenitor (CMP) which is restricted to all myeloid 
cells (erythrocytes, megakaryocytes) (Pieper et al., 2013, Nagasawa, 2006, Ichii et al., 
2014, Hardy and Hayakawa, 2001, LeBien and Tedder, 2008, Tobon et al., 2013).  
 
In the bone marrow, the early precursor of B cells, the CLP, lacks a B cell lineage 
marker and it is characterised by the expression of c-kit and IL-7 receptor α chain. 
Following CLP, B cell lineage restriction can be recognised by expression of the B220 
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isoform of CD45 (Hardy and Hayakawa, 2001, Matthias and Rolink, 2005). In the bone 
marrow, early development and commitment to the B cell lineage after CLP depends on 
the expression of several transcription factors including the early B cell factor (EBF), 
PU.1, E2A, IKAROS and paired box protein 5 (PAX5) (Shapiro-Shelef and Calame, 
2005, Hardy and Hayakawa, 2001, Matthias and Rolink, 2005, Eibel et al., 2014, Smith 
and Sigvardsson, 2004). Pax5 is a fundamental transcription factor for commitment to 
the B cell lineage. Expression of this molecule is essential for immature and mature B 
cell development. Additionally, the bone marrow creates a microenvironmental niche 
that allows the development of B cells. It contains adherent stromal cells, which are 
crucial for B cell development by providing growth factors and cytokines such as 
interleukin 7 (IL-7) for the survival and differentiation of B cells as well as the Fims-
like tyrosine kinase 3 (FI3-L) (Nagasawa, 2006, Eibel et al., 2014). IL-7 cytokine has 
been shown to be crucial in the development of B cells in mice but not in human 
(Busslinger, 2004). All these factors, facilitates CLP differentiation into precursor 
progenitor (pre-pro) B cells, which are B220+CD19-. These pre-pro B cells differentiate 
rapidly into CD19+ progenitor (pro-) B cells, which marks full commitment to the B 
cell lineage (Rumfelt et al., 2006). 
 
B cell maturation depends on the successful rearrangement of the Immunoglobulin (Ig) 
DNA locus in the lymphoid stem cells. Expression of the immunoglobulin heavy and 
light chains ensures that the developing B cells express a membrane bound B cell 
receptor (BCR) which acts as an antigen receptor (LeBien and Tedder, 2008, Tobon et 
al., 2013). BCR is a membrane bound immunoglobulin consisting of a heterodimer 
composed of identical pairs of Ig heavy and light chains which are responsible for the 
clonal diversity of the B cell repertoire. The BCR complex also contains within it, a 
heterodimer of Igα (CD79a) and Igβ (CD79b), which is non-covalently attached with 
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the BCR.  This Igα/Igβ heterodimer is required for the surface expression and signalling 
functions of the receptor (Perez-Vera et al., 2011, Matthias and Rolink, 2005, Kurosaki 
and Hikida, 2009, Eibel et al., 2014). In order to achieve BCR clonal diversity, the Ig 
heavy and light chain genes are composed of a constant and variable region with the 
variable region being responsible for the diversity of the antibody repertoire. In the case 
of the heavy chain, the variable region is formed by a series of segments termed 
variable (V), D (diversity) and J (Joining), which are brought together by site-specific 
recombinases in a process termed VDJ recombination. This is a highly regulated 
process that involves firstly the rearrangement of the D and J fragments before they join 
to the V fragment processed by recombinase associated genes 1 and 2 (RAG1 and 
RAG2). This process occurs in the heavy chain first prior to recombination in the light 
chain (Smith and Sigvardsson, 2004, Perez-Vera et al., 2011). 
 
In the pro- B cell stage during development of B cells in the bone marrow, Igα and Igβ 
heterodimer together with chaperones such as calnexin are expressed on the surface of 
the cell before the Ig heavy chain gene locus rearrangement has taken place. Initially, 
expression of the heavy chain occurs intracellularly. After assembly, the heavy chain 
associates with components of the surrogate light chain, which include Lambda-5 (λ5) 
and VpreB, together these form the pre B cell receptor (pre-BCR) (Smith and 
Sigvardsson, 2004, Perez-Vera et al., 2011) and the cells are called pre- B cells at this 
stage. Expression of the pre-BCR is a crucial checkpoint in early B cell development at 
which the functional competence of the rearranged heavy chain is monitored in order to 
avoid immuno-incompetent B cells, which are removed by apoptosis. Only pre-B cells 
expressing a functional heavy chain are allowed to differentiate further. Signalling 
through the pre-BCR allows for allelic exclusion of the heavy chain locus thus 
preventing the expression of more than one receptor in a single B cell. Signalling via the 
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pre-BCR, induces a burst of proliferation allowing for clonal expansion of the large pre- 
B cells, which leads them to further differentiate into small pre-B cells (Matthias and 
Rolink, 2005, Tobon et al., 2013, Eibel et al., 2014). Small pre-B cells, up-regulate 
expression of the RAG1/2 genes required for the rearrangement of the Ig light chain 
thus allowing the production of a functional BCR with a unique specificity that is 
expressed as IgM on the surface of immature B cells.  
 
Immature B cells are subjected to additional checkpoints, to test the BCR for 
functionality and autoreactivity. Potential autoreactive B cells are forced to a secondary 
immunoglobulin gene rearrangement process in a processing event called receptor 
editing (Matthias and Rolink, 2005, Tobon et al., 2013). Receptor editing involves 
reactivation of expression of the RAG genes and expression of a new Ig light chain to 
pair with the existing heavy chain in an effort to generate a non-self reactive BCR. B 
cells that fail this negative selection are either killed by apoptosis or inactivated by 
anergy (an induced state of unresponsiveness) (Cambier et al., 2007, Matthias and 
Rolink, 2005). B cells that pass through this tolerance undergo further differentiation 
resulting in the expression of IgD on their surface. These immature B cells exit the bone 
marrow and enter the periphery (Hardy and Hayakawa, 2001, LeBien and Tedder, 2008).  
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Figure 1.1. B cell development in mouse 
B cells develop in the bone marrow in a culminated manner to become immature B cells. 
Immature B cells enter the periphery as transitional B cells. Transitional B cells can 
differentiate to become either FO or MZ B cells.  Upon encounter with an antigen, B cells 
are activated to proliferate and form a germinal centre where they differentiate to become 
either plasma antibody producing cells or Memory B cells.  Adapted from (Cambier et al., 
2007). 
 
1.1.2. Peripheral B cell development 
 
Immature B cells migrate to a peripheral lymphoid organ such as the spleen via terminal 
branches of the central arterioles. Upon entry into the spleen, immature B cells 
differentiate from short-lived transitional B cells 1 (T1) to become T2 and, in certain 
circumstances, T3 (Matthias and Rolink, 2005, Pillia and Cariappa, 2009). Transitional 
B cells can be distinguished from mature B cells by their cell surface marker expression 
(CD93, CD23, IgM, and CD21), their short half-life and the sensitivity to apoptosis 
induced by antibodies specific for IgM. Immature T1 B cells are subjected to negative 
selection in the spleen, which is crucial for the generation of mature B cells, which lack 
specificity for self-antigens. Expression of B cell activating factor (BAFF) a member of 
tumour necrosis family and its counterpart B cell activating factor receptor (BAFFR) 
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play crucial roles in the transitioning of transitional B cells through to mature B cells. 
The ligation of BAFF to its receptor mediates survival of B cells in the periphery by 
activating different signalling cascades including the NfκB pathway thus inducing pro 
survival functions (Eibel et al., 2014). After passage through the transitional stages, B 
cells become long-lived mature follicular (FO) (Follicular type I or Follicular type II) 
and marginal zone (MZ) B cells of the spleen or cortical cells in the lymph node.  The 
decision of the B cells to become either FO or MZ B cells depends on the strength and 
nature of the BCR signal and also the subsequent expression of Notch2 (Pillai and 
Cariappa, 2009, Tobon et al., 2013). For example, differentiation to become MZ B cell 
would normally require a signal to be delivered through a Toll-like receptor as well as 
the BCR. It has been shown that immature B cells that are specific for phosphocholine, 
a constituent of the cell wall of encapsulated bacteria normally found in the gut flora, 
selectively develop into MZ B cells. Another mechanism of tolerance in the spleen 
involves anergy, and it is thought that T3 cells may either be anergic B cells (Merrell et 
al., 2006) or be a developmental intermediate for mature B cells; however, this is still 
under debate (Allman and Pillai, 2008, Hardy et al., 2007). 
 
In the periphery, upon encounter with it’s cognate antigen, B cells play a key role in 
driving the immune response by presenting antigens to the adaptive CD4+ T cells 
through presentation on MHC class II molecules. This in turn leads to the cross-linking 
of the BCR, and thus activation of the B cells. This type of B cell activation is called 
thymus dependent (TD) B cell activation. It also involves the binding of the CD40 
ligand on the T- cell binding to the CD40 receptor on the B cell. The FO B cells plays 
the major role in TD immune responses (Allman and Pillai, 2008). B cells can also be 
activated independently of T cell and this is known as a thymus independent response 
(TI), this involves ligation of the toll Like Receptors (TLR) expressed on the surface of 
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B cells by antigens such as lipopolysaccharide (LPS), which is a component of the outer 
membrane of most Gram- bacteria. MZ B cells due to their unique location within the 
marginal zone of the spleen encounter TI antigens preferentially.  
 
When B cells are activated via the CD40 ligand as well as the BCR, they form a 
germinal centre (GCs). GCs are distinct regions in the secondary lymphoid organs and 
contain proliferating B cells, follicular TfH cells, follicular dendritic cells (FDCs) and 
dark zone stromal cells (Eibel et al., 2014). The GC reaction is characterised by clonal 
expansion of activated cell, class switch recombination of the Ig locus, somatic 
hypermutation of the Vh genes and affinity maturation (LeBien and Tedder, 2008, 
Matthias and Rolink, 2005). Somatic hypermutation introduces point mutations in the V 
region of heavy and light chain genes which results in a subtly mutated BCR expressed 
on the mature B cells and this process is reliant on the expression of the enzyme that 
catalyses this process, activation induced deaminase (AID) (Eibel et al., 2014, Pieper et 
al., 2013). The GC reaction leads to the differentiation of B cells to become plasma 
cells and memory B cells, which can then reside in the periphery or migrate back to the 
bone marrow (Pieper et al., 2013). B cell development in the bone marrow and 
periphery of a mouse is illustrated in Figure 1.1. 
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1.1.3. Mature B cells  
 
Peripheral B cells in mice can be divided into two major B cell subsets, B-1 and B-2 B 
cells that can be distinguished from one another based on their anatomical location, 
phenotype and function. B-2 B cells includes FO and MZ B cells (Hardy and Hayakawa, 
2001).  
 
1.1.3.1. B-1 Cells  
 
B-1 cells are located in the peritoneal and pleural cavities, the gut lamina propria and a 
small proportion are located in the spleen and account for 5% of B cells in the mouse 
(Hardy et al., 2007).  They are a unique subset of B cells further subdivided into B-1a 
cells, which are CD5+ and B-1b, which are CD5- (Hardy and Hayakawa, 2001, Shapiro-
Shelef and Calame, 2005, Berland and Wortis, 2002). B1 B cells derive mostly from 
fetal progenitors cells and express a BCR repertoire skewed towards TI antigens such as 
pathogen expressed molecules (Allman and Pillai, 2008, Berland and Wortis, 2002). B-
1 B cells are considered innate immune cells and provide innate protection against 
bacterial infection in naïve hosts by producing antigens and spontaneously secreting 
natural IgM. Furthermore, B1 B cells can contribute to the production of IgA at mucosal 
sites. Additionally, B-1 B cells have self-renewing capacities (LeBien and Tedder, 2008, 
Shapiro-Shelef and Calame, 2005, Berland and Wortis, 2002, Allman and Pillai, 2008).  
1.1.3.2. MZ B cells 
 
MZ B cells are found mainly in the marginal zone of the spleen, which harbours a major 
antigen filtering and scavenging area. MZ B cells are uniquely positioned in the spleen 
to be in contact with blood borne pathogens (Hardy et al., 2007). MZ B cells carry a 
BCR that preferentially bind to blood borne antigens such as cell wall components of 
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bacteria and thus encounters mainly TI antigens. MZ B cells, upon activation rapidly 
differentiate into short-lived plasma cells (Eibel et al., 2014, Allman and Pillai, 2008). 
MZ B cells and B1 B cells are crucial for the early humoral response. 
 
1.1.3.3. FO B cells 
 
FO B cells are the major contributors to TD immune responses. In the spleen, FO B 
cells are positioned in the follicles of the spleen where they can encounter T cells. Upon 
activation, these cells can either give rise to short lived plasma cells or form GCs, where 
proliferation and differentiation towards plasma and memory B cells may occur 
(Allman and Pillai, 2008).  
 
1.1.3.4. Plasma Cells 
 
Plasma cells are terminally differentiated B cells; they are essential for protective 
immunity. In plasma cells the production of immunoglobulin changes from a membrane 
bound form to a secreted form (Eibel et al., 2014). Plasma cells are terminally 
differentiated, non-dividing cells and can be classified as either short-lived or long-lived 
cells. Short-lived IgM producing plasma cells can arise from FO B cells or MZ B cells. 
The BCRs expressed on these B cells do not go through somatic hypermutation and 
hence the affinity of these antibodies does not change over time. Long-lived plasma 
cells go through somatic hypermutation and can home back to the bone marrow where 
they continue secreting antibodies and become part of immunological memory (Eibel et 
al., 2014). A range of transcription factors drives plasma cell development and 
differentiation including X box binding protein (XBP-1) and B cell induced maturation 
protein (Blimp-1). Blimp-1 initiates a plasma cell specific transcription program by 
inducing the transcriptional repression of Pax5 and Bcl6. Additionally; expression of 
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XBP-1, a stress response gene is up-regulated as part of the cell adaptation process 
required for sustained antibody secretion. Other transcription factors such as IRF-6, 
IRF-4 and IL-21 also drive plasma cell differentiation (Eibel et al., 2014, Matthias and 
Rolink, 2005, Shapiro-Shelef and Calame, 2005). 
 
1.1.3.5. Memory B cells 
 
B cells can differentiate to become non- antibody secreting memory B cells during the 
GC reaction, which can persist independently of antigenic stimulation (Kurosaki et al., 
2015). Memory B cells have the ability to differentiate into plasma cells upon second 
re-encounter with antigen being responsible for the rapid secretion of high affinity, class 
switched antibody which is typical of the secondary immune response (Kurosaki et al., 
2015). 
 
1.1.3.6. Regulatory B cells 
 
B cells also have the ability to negatively regulate the immune response giving rise to a 
recently described subset of B cells termed regulatory B cells. Regulatory B cells 
(Bregs) are a subset of B cells that are described to play a pivotal role in the prevention 
of pathogenesis of several autoimmune diseases as well as allograft tolerance. This 
unique cell population has been found to inhibit the function of other cells of the 
immune system by production of the anti-inflammatory cytokine Interleukin 10 (IL-10) 
(Goode et al., 2014). 
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1.2. Morphogens 
 
1.2.1. Morphogens  
 
 
Morphogens are long range signalling molecules that determine cell fate and 
organogenesis.  They emanate from a restricted region of the tissue and diffuse across 
tissues from a localised source forming a concentration gradient with the high 
concentration close to the source and the lower concentration further away from the 
source (Rogers and Schier, 2011, Muller et al., 2013). The dose of morphogen that a 
cell perceives will depend on where the cell sits within this concentration gradient 
(Figure 1.2). The graded activity of morphogens in the tissue leads to differential target 
gene expression between cells, which are dependent on the dose of morphogen the 
individual cell encounters. Thus, cells exposed to a high concentration gradient activate 
different transcriptional genes and have different fates compared to those cells exposed 
to a lower morphogen concentration (Figure 1.2). Thus, the graded activity of the 
morphogen differentiates tissues into different cell types that are arranged as a function 
of their distance from the source (Ingham and McMahon, 2001, Stathopoulos and Iber, 
2013, Rogers and Schier, 2011). Morphogens act in developing tissues to control spatial 
arrangement of cellular differentiation and it has been shown that not only does the 
concentration of the morphogen affect the cell fate but also the length of exposure to the 
morphogen as well as the state of the cell (Rogers and Schier, 2011).  
 
Morphogens have been implicated in the development of many developmental 
processes in Drosophila including that of the wing, the vertebrate limb bud and the 
neural tube (Mehlen et al., 2005, Tabata and Takei, 2004). Morphogens play an 
essential role in the patterning of tissues during embryogenesis and are expressed 
constitutively during this process but also play a role in the control of the homeostasis 
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of adult tissues and are tightly regulated by numerous regulatory proteins during this 
later process (Tabata and Takei, 2004). 
 
Several morphogens have been identified in vertebrates such as humans, mice and chick 
embryo and they include hedgehog protein (Hh), wingless/int (Wnt) family of proteins, 
the notch proteins and the transforming growth factor (TGF-β) family, which includes 
bone morphogenic protein (BMP) (Bijlsma et al., 2006, Rogers and Schier, 2011).  
 
 
Figure 1.2. Morphogen concentration gradient 
A diagram illustrating morphogen concentration gradient. The concentration gradient of 
the morphogen determines the cell fate. The cells secrete morphogens and they diffuse 
forming a concentration gradient. There is a higher concentration of morphogen produced 
in the source (red cells), and farther away is a low concentration of the gradient (orange 
cells). At different threshold of the morphogen, the cells have different cell fates (Adapted 
from Eldar et al., 2002).  
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1.2.2. Morphogens in B cell development 
 
Several morphogens including hedgehog protein, BMP and notch proteins have been 
shown to play a role in B cell development. In peripheral B cell development, signalling 
via Notch protein, Notch2, have been shown to be required for the development of MZ 
B cells. In the spleen, Notch2 can interact with its ligand, Delta-Like-1 (DL-1). This 
leads to signalling cascade that can provoke a transcriptional complex thus inducing B 
cell commitment towards MZ B cells (Pillai and Carriappa, 2009), hence indicating a 
role for this morphogen in B cell development. Additionally, BMP have been shown to 
inhibit B cell lymphopoiesis in the bone marrow (Kersten et al., 2005), inhibit 
plasmablasts differentiation and proliferation (Huse et al., 2011) thus suggesting a role 
of this morphogen in B cells. 
 
Hedgehog proten (Hh), has also been shown to play a role in B cell development. In this 
thesis, the role of Hh signalling in B cell development has been investigated. 
 
1.3. Hedgehog protein  
 
1.3.1. Hedgehog protein: discovery and function 
 
The hedgehog proteins (Hh) form a family of morphogens that are all secreted 
signalling molecules that were first discovered in Drosophila melanogaster in 1980 
(Nusslein-Volhard and Wieschaus, 1980). While carrying out a large scale screening for 
mutations that impair or change the development of the fruit fly larvae body plan, gene 
mutations were identified, that resulted in disruption to the dorsal ventral body plan of 
the larval. The disruption resulted in abnormal distribution of hair like projections on 
the ventral surface denticles thus resembling a hedgehog. So, this gene product was 
termed hedgehog protein (Nusslein-Volhard and Wieschaus, 1980). 
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Several homologues of Hh have been identified in all vertebrates including humans, 
frogs, fish, mouse and birds (Ingham, 2012, Ingham and McMahon, 2001).  In the 
human embryo, Hh was first described as being expressed in the notochord, floor plate 
of the neural tube, the zone of polarising activity (ZPA), the region of the developing 
limb bud that specifies digit type and number (Briscoe and Rohatgi, 2012) during gut 
and developing limbs (Ingham and McMahon, 2001). Whilst in Droshophila only one 
Hh gene has been shown to be expressed to date, there are three homologues of Hh 
described to be expressed in vertebrates, each showing a different spatial and temporal 
distribution pattern. These include, Desert hedgehog (Dhh), Indian hedgehog (Ihh) and 
Sonic hedgehog (Shh) protein with the latter being the most extensively studied and 
broadly expressed in mammals and has been shown to be essential for the development 
of many tissues (Burglin, 2008). During embryogenesis, Shh is first expressed in the 
notochord and later in the floor plate of the neural tube, where it produces a gradient of 
activity in the ventral neural tube. It is also expressed in the zone of polarising activity 
of the limb and digit formation (Burglin, 2008). Shh and Ihh are also essential for gut 
development and are expressed by the epithelial cells in the stomach and the colon. 
They are both also important for cardiovascular development. Ihh has a function in bone 
formation and in the cartilage (Burglin, 2008, Varjosalo and Taipale, 2007). Dhh 
expression is largely restricted to gonads including the sertoli cells of the testis and 
granulosa cells of the ovaries (Varjosalo and Taipale, 2008).  Dhh is required for testes 
formation, schwann cell function, erythrocyte development and proper recovery from 
stress–erythropoiesis (Lau et al., 2012). In mouse development, Shh and Ihh are 
essential for development of the mouse as demonstrated by the lethal phenotype of the 
knockout mutants (Chiang et al., 1996), however, mice deficient in Dhh are normal and 
healthy albeit males are infertile (Bitgood et al., 1996). 
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Hh signalling has also been shown to play a role in the development of a number of 
haematopoietic cells such as thymocytes (Outram et al., 2000), HSC (Bhardwaj et al., 
2001, Trowbridge et al., 2006) and erythroid cells (Lau et al., 2012) T cells (Chan et al., 
2006, Furmanski et al., 2013, Rowbotham et al., 2007) and B cells (Sacedon et al., 
2005).  The Hh signalling pathway is interconnected other morphogen and growth 
factor signalling pathways including, Wnt (β -cantenin) pathway, TGF-β BMP pathway, 
notch pathway and fibroblast growth factor (FGF) pathway.  The correct integration of 
these different signalling pathways plays a critical role in morphogenic processes 
including tissue morphogenesis, homoeostasis, organogenesis and stem cell renewal in 
adults (Heretsch et al., 2010, Bijlsma et al., 2006). 
 
1.3.2. Hedgehog protein: structure, synthesis and signalling 
 
 Hh proteins are synthesised inside the cell as precursor proteins of approximately 
45kDa and require multiple processing events to take place in order to form a functional 
protein. The precursors are approximately 400- 460 amino acids and contain a series of 
motifs and domains, which include a signal peptide, a secreted amino-terminal (19kDa) 
that has signalling abilities and a carboxyl terminal (25kDa), which has autocatalytic 
activity (Burglin, 2008, Varjosalo and Taipale, 2007, Varjosalo and Taipale, 2008). 
 
The signal peptide targets the newly synthesised precursor protein to the endoplasmic 
reticulum where the intramolecular auto-processing reaction of the protein occurs. The 
precursor protein first undergoes cleavage of the signal sequence. The autocatalytic C –
terminal mediates the auto-processing reaction of the Hh precursor protein. There are 
two sequential stages of nucleophilic displacements that are involved. The first involves 
the rearrangement to replace the main chain peptide linkage between the glycine and 
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cysteine residues with a thioester involving the Cys side chain. The second step of the 
auto-processing reaction involves attack upon the carbonyl by a second nucleophile thus 
displacing the sulphur and severing the link between Hh-N and Hh-C (Mann and 
Beachy, 2004, Varjosalo and Taipale, 2008). The addition of cholesterol causes the Hh 
protein to be linked to the membrane and it is essential for the proper functioning of the 
protein including the long range signalling of the protein (Varjosalo and Taipale, 2007, 
Varjosalo and Taipale, 2008). The final step of processing involves the addition of a 
palmitol moiety, which is added to a cysteine residue via an amide bond of the N-
terminus of the Hh protein by a transmembrane acyltransferase termed skinny 
Hedgehog and hedgehog acyltransferase in Drosophila and mammals respectively 
(Heretsch et al., 2010, Varjosalo and Taipale, 2008). The gene Rasp encodes the 
enzyme likely located within the endoplasmic reticulum required for the Hh acylation 
and the production of active Hh (Gupta et al., 2010). Thus, this process generates a fully 
active lipidated Hh protein that can form multimeric complexes and interact with 
lipoproteins (Burglin, 2008, Varjosalo and Taipale, 2008). 
 
The lipid modifications of the protein allows it to adhere to the membrane of the Hh 
synthesising cells, enabling short range signalling to neighbouring cells. After 
processing of the protein, the Hh protein is released from the cell via a 12 multi-pass 
transmembrane protein called Dispatched (Disp) which has a sterol-sensing domain 
(Burglin, 2008, Heretsch et al., 2010). Disp, may promote the Hh protein to assemble 
into multimeric micelle-like complexes or its incorporation into lipoprotein particles 
(Briscoe and Therond, 2013). Once out of the cell, Hh protein interacts with 
extracellular proteins, which include heparan sulphate proteoglycans (Hsps), dally-like 
(Dlp), iHog (in Drosophila) and growth arrest-specific 1 (GAS-1), which are positive 
regulators of Hh signalling and aid in long-range signalling activities. Hsps play a key 
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role in Hh transport and it is required for stable retention of the Hh on the cell surface 
(Tabata and Takei, 2004). Hh also interacts with hedgehog interacting protein (HIP), 
which is a negative regulator that acts by sequestering the modified Hh-N (Burglin, 
2008, van den Brink, 2007). 
 
All Hh proteins signal via a common pathway. The membrane receptors to which they 
bind to are called patched (Ptch) and smoothened (Smo) (Varjosalo and Taipale, 2007, 
Varjosalo and Taipale, 2008).  
 
Ptch is a 12-pass transmembrane receptor with two hydrophilic extracellular loops with 
a sterol sensing domain, which in the absence of Hh localises in the primary cilium of 
an Hh responsive cell and it functions as a platform for Hh intracellular signal 
transduction. Ptch is a core receptor for Hh signalling, binding Hh ligands with an 
affinity in the low nanomolar range (Robbins et al., 2012, Varjosalo and Taipale, 2007). 
In addition to Ptch, other molecules that bind Hh and promote signalling have been 
identified. They include CAM related/ down-regulated by oncogenes (CDO), brother of 
CDO (BOC) (iHog and Boi in Drosophila) and growth-arrest specific 1(Gas1) (Briscoe 
and Therond, 2013). Smoothend (Smo) is a member of the frizzled (FZD) class of G-
protein coupled receptors and functions as the key transducer in the Hh signalling 
pathway. It is an integral membrane protein containing seven membrane spanning alpha 
helices, a long N-terminal extracellular peptide and a C-terminal intracellular peptide. 
Smo also contains a membrane integrated heptahelical domain (Wang and McMahon, 
2013). Ligand binding to Smo is essential for its regulation because mutations in the 
heptahelical domain render the protein either inactive or constitutively active. Smo is 
negatively regulated by pro-vitamin D3 and it is positively and indirectly regulated in an 
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allosteric manner by naturally occurring compounds produced through the oxidation of 
cholesterol called oxysterols (Wang and McMahon, 2013).  
 
A schematic diagram, demonstrating Hh signalling in vertebrates is shown in Figure 1.3. 
In the absence of Hh, Ptch receptor is located in the basal cilium where it represses the 
activity of Smo, in a poorly understood mechanism, and thus represses the Smo-
dependent downstream signal in to the cell (Ingham, 2012, Varjosalo and Taipale, 2007). 
In the presence of Hh, the Hh binds to Ptch and a number of accessory proteins, 
Cdo/Boc, which are integral membrane proteins and this binding results in a 
conformational change that allows the translocation of Smo from the endocytic vessel to 
the cilium and thus activation of the signalling pathway (Ingham, 2012, Heretsch et al., 
2010, Varjosalo and Taipale, 2007, Varjosalo and Taipale, 2008) The ligand binding of 
Hh to Ptch also results in the translocation of Ptch out of the primary cilium whereupon 
it is degraded by lysosmes (Heretsch et al., 2010)  As a result, Smo signalling may now 
take place in the primary cilium and a signal is transmitted into the cell. This leads to 
the activation of a family of oncogenic transcription factors termed the Glioma (Gli) 
five zinc finger transcription factors (Cubitus Interruptus (Ci) in Drosophila) (Varjosalo 
and Taipale, 2008, Briscoe and Therond, 2013). The Gli transcription factors enter the 
nucleus where they induce the transcription of Hh signalling target genes. Smo is 
critical for Hh signalling, as most Hh antagonist targets the Smo protein, cycloplamine, 
a naturally alkaloid is an inhibitor of Hh protein, works by inhibiting Smo signalling 
(Porro et al., 2009, Briscoe and Rohatgi, 2012). However, Hh signalling can occur 
independent of Smo signalling, as evidences suggests that Ptch can induce apoptosis in 
cells independently (Brennan et al., 2012). 
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Gli are bi-functional transcriptional regulators inhibiting transcription in the absence of 
Hh signalling but activate transcription after Hh signalling (Briscoe and Rohatgi, 2012). 
Three closely related Gli transcription factors are involved in the Hh signalling pathway 
with distinct temporal and spatial expression patterns; these include Gli1, which has a 
strong positive effect on expression of Hh target genes, and is itself a transcriptional 
target of the Hh signalling pathway. Gli2 and Gli3 function by exhibiting both 
repressing and activating signals for expression of Hh target genes. Gli2 functions 
primarily as a transcriptional activator downstream of Hh signalling and it is crucial to 
initiate the first transcriptional changes induced by the Hh signal. The main downstream 
functions of the Gli transcription factors signalling include leading cells to enter the cell 
cycle, inhibition of apoptosis, regulation of stem cell differentiation, angiogenesis, 
axonal guiduance and modulation of tissue polarity (Porro et al., 2009, Ditzel, 2011). 
 
Target genes which Hh signalling has been described to activate, include genes involved 
in cell survival and apoptosis like Bcl2, other morphogens such as Bmp4 and also genes 
involved in the control of the cell cycle including cyclin D, Myc, VEGF and Snail 
(Porro et al., 2009, Gupta et al., 2010). 
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Figure 1.3. Hh Signalling 
Ptch represses Smo in the absence of Hh and thus there is no transcription of target genes 
(left).  Upon activation of Ptch by a member of the Hh family, Smo is relieved from 
inhibition and it signals to activate Gli transcription factors that enters the nucleus to 
induce gene transcription of target gene (right).  Adapted from (Pasca di Magliano and 
Hebrok, 2003). 
 
 
1.3.3. Hh signalling in B cells and B cell lymphomas 
 
Hh signalling has previously been implicated in the development and differentiation of 
cells of the haematopoietic lineage including haematopoietic stem cells (HSc) 
(Bhardwaj et al., 2001, Trowbridge et al., 2006), T cells (Outram et al., 2000, Chan et 
al., 2006, Rowbotham et al., 2007, Furmanski et al., 2013), dendritic cells (Varas et al., 
2008), NK cells ( Zhu et al 2012) and macrophages (Schumacher et al., 2012). In 
contrast, the role of Hh signalling in immune cells such as B cells is still to be fully 
explored. Subsets of B cells in the early stages of B cell development in the bone 
marrow including pro-B cells and pre-B cells have been shown to express Ptch, Smo 
and Gli-1, which are all components of the Hh signalling pathway. The expression of 
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Ptch and Smo decreased as the B cells became more mature (Cooper et al., 2012) 
suggesting Hh proteins may play a role in early B cell development. Additionally, a role 
for Indian Hedgehog (Ihh) protein in early B cell development has recently been 
demonstrated (Kobune et al., 2008).  
 
Ihh, a member of the Hh family, was first described to be expressed in chondrocytes of 
early cartilaginous skeletal elements (Bitgood and McMahon, 1995). It is involved in 
chrondocyte hypertrophy and bone formation in the developing skeletal system (Mak et 
al., 2008). Ihh has previously been shown to be involved early T cell development by 
controlling homeostasis in the thymus (Outram et al., 2009) and is capable of mediating 
an interaction between hematopoietic progenitor/ stem cells and bone marrow stromal 
cells thus leading to proliferation of the hematopoietic progenitor/stem cells in vitro.  
Using a single stranded adenoviral vector, which caused high level of ectopic Ihh 
expression, Kobune et al., (2008) showed that Ihh expression causes an increase in the 
number of immature splenic B cells and a decrease in the number of IgM+ mature 
splenic B-lymphocytes. This suggests Ihh inhibits the maturation of B cells (Kobune et 
al., 2008). These findings were further supported by studies using murine B-cell 
progenitors (BM) co-cultured with the Smo antagonist, cyclopamine, or Hh neutralising 
antibody, 5E1. Inhibition of Hh signalling prevented the proliferation of pro- B cells 
suggesting a key role in the maintenance of early B cell haematopoiesis (Cooper et al., 
2012).  Hh signalling has also been shown to take place in the stromal cells of the bone 
marrow promoting B cell lymphoid differentiation (Cooper et al., 2012). Taken together, 
these data, suggest Hh signalling has a key role in modulating early B cell maturation 
and development. 
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The role that Hh signalling plays in the later developmental stages of B cells in the 
periphery has not been fully explored. Sacedon et al., (2005), showed that FDCs 
contained within the GC secrete Shh. Additionally, they showed that GC B cells express 
the receptors for Shh signalling. They also showed that all the B cells in the GC express 
the Ptch receptor and of that population, approximately 30% co-expressed Smo protein. 
This indicates that although GC B cells express the Shh receptor, Ptch, only 30% of the 
cells are capable of transducing this signal via Smo into the cell. Smo expression was 
up-regulated to approximately 50% upon activation of GC B cells by anti-CD40 and 
anti-IgM thus indicating that GC B cells are themselves targets for Shh produced by 
FDCs, indicating that Hh signalling maybe required to play a role in directing a B cell 
mediated immune response in the periphery. The authors also showed in vitro that there 
was increased GC B cell apoptosis with inhibition of Shh and that the GC B cells were 
rescued from Fas mediated apoptosis upon addition of exogenous Shh. Thus, indicating 
that Shh is one of the biological conditions required for the survival of GC B cells. 
Furthermore, they reported that Shh could increase antibody production and 
proliferation of GC B cells (Sacedon et al., 2005).    
 
Conversely, aberrant Hh signalling has been linked to the development of lymphoid 
tumours such as B cell lymphoma and multiple myeloma (MM). In the case of B cell 
chronic lymphocytic leukaemia, (B-CLL), a disease characterised by accumulated 
neoplastic B cells in the bone marrow, blood and peripheral lymphoid tissues, stromally 
induced Hh has been shown to play a role in the survival and proliferation of the tumour 
cells (Hegde et al., 2008). In diffuse large B cell lymphoma, Shh proteins have been 
shown to be over-expressed and the presence of Shh promotes proliferation and survival 
in the lymphoma cells (Kim et al., 2009, Singh et al., 2010).  
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In multiple myeloma (MM), a plasma cell malignancy of the bone marrow, which is 
characterised by abnormal proliferation of plasma cells known as Myeloma cells, these 
myeloma  cells have been shown to secrete Shh themselves and this in turn, enhanced 
the proliferation of nearby MM plasma cells and protected them against stress-induced 
apoptosis and chemotherapy-induced apoptosis (Liu et al., 2014). Additionally, it has 
been shown that inhibition of Smo prevented the growth of the MM, thus suggesting 
that Hh signalling is required for the maintenance of the proliferative and clonally 
differentiated state of the MM plasma cells (Peacock et al., 2007).  
 
Taken together, these findings indicate a role for Hh signalling in promoting the 
survival and proliferation of both normal and neoplastic B cells (Porro et al., 2009). 
Thus, understanding the mechanism by which Hh signalling regulates B cell 
development might lead to the development of novel strategies for modulating B cell 
function or treatment of B cell lymphomas. 
 
1.4. Aims and objectives of research  
 
1.4.1. Overall aim 
 
Although the role of Hh signalling in T cell development is widely documented, the role 
of Hh signalling in peripheral B cell development is much less well understood. Initial 
investigations describe a positive regulatory effect of Hh signalling in driving peripheral 
GC B cell development (Sacedon et al., 2005). However, in T cells, Hh signalling can 
drive both a positive (Chan et al., 2006) and a negative (Rowbotham et al., 2007) 
regulatory effect to T cell development in the periphery and therefore, it may be 
conjectured that something similar may happen during B cell development. Thus, the 
major aim of the research presented in this thesis is to understand more precisely the 
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role of Hh signalling in B cell development in the periphery by gaining a better 
understanding of the cellular and molecular events that occur in the presence of 
exogenous Hh recombinant protein as well as in the absence of Hh signalling.  
1.4.2. Objectives 
 
 To determine the effects of rShh treatment on B cell survival and activation in a 
developmental time course. 
 To determine the effects of Hh signalling on B cell function, including cytokine 
secretion, antibody production and B cell differentiation. 
 To test the effect of the loss of Hh signalling on peripheral B cell development. 
 To identify the difference between the transcriptome profiles in B cells isolated 
from Dhh knockout mice and wild-type mice. 
 To identify target genes in B cells responding to Hh treatment in vitro. 
 
1.4.3. Research hypothesis 
 
Hh signalling can regulate B cell development and immune response in the periphery 
displaying both a positive and negative regulatory effect. These differential effects can 
explain, at least partially, the development of B cell lymphomas or autoimmune 
diseases in which Hh signalling is involved in its pathogenesis. 
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1.4.4. Original contribution to knowledge 
 
Up until now, there has been no detailed report on the effect of Hh signalling on the 
development of B cells in the periphery at the molecular level. The original contribution 
of this research is the demonstration that Hh signalling could not only accelerate the rate 
of peripheral B cell development as previously published but also play a role in 
dampening down the immune response at a later point. This provides a mechanism 
whereby Hh signalling might serve to up-regulate the B cell immune response on first 
seeing antigen but also have the capacity to down-regulate the immune response when it 
is no longer needed thereby controlling the homeostasis of the immune response. Hh 
signalling was also demonstrated to regulate the expression of a number of target genes 
that can in turn regulate B cell development. The data collected during this research 
project could be used to inform future research into how the Hh signalling pathway may 
be down-regulated in neoplastic B cells or during autoimmunity, thus ameliorating the 
pathology. In particular, target genes that have been identified may be used as novel 
therapeutic targets in the treatment of B cell lymphomas and also in autoimmune 
diseases such as systemic lupus erythematous. 
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Chapter 2: Methods and Materials 
 
 
2.1.  Mice 
 
Female BALB/c mice were purchased from Harlan Ltd U.K and maintained in the lab at 
University of East London, London.  Female C57BL/6 wild-type and Desert knockout 
(Bitgood et al., 1996) mice were obtained from Professor Tessa Crompton at University 
College London. Mice were used when they were 4-12 weeks old and at this time 
spleens were isolated and single cell suspensions were prepared by crushing the spleen 
between a pair of frosted slides in AIM-V (Life Technologies, USA) medium 
containing, 10% Fetal Calf Serum and 100µM β-mercaptoethanol (β-ME) (Sigma- 
Aldrich, USA). 
2.2.  Cell culture 
 
Splenic B cells were cultured at 3 x 106 to 5 x 106 cells/ml in AIM-V medium (Life 
Technologies, USA) per well in a 96 micro-titre plate (Thermo Fisher Scientific, UK). 
B cells were stimulated using 5μg/ml anti-mouse CD40 functional grade purified (anti-
CD40) (e-Bioscience, CA, USA) and F(ab)2 anti-mouse IgM µ chain functional grade 
purified (anti-IgM) (e-Bioscience, CA, USA). Recombinant mouse sonic hedgehog 
protein (rShh) (e-Bioscience, CA, USA) was added at varying doses ranging from 
0.005-5μg/ml (Shah et al., 2009). In some experiments, recombinant mouse desert 
hedgehog (rDhh) (R&D systems, Minneapolis, USA) or recombinant mouse Bone 
morphogenic protein 4 (rBMP4) (R&D Systems, USA) was added in varying 
concentrations ranging from 0.005-5µg/ml. For BMP interplay experiments, 
recombinant Noggin (e-Bioscience, USA) was added at a concentration of 5µg/ml 
(Kersten et al., 2005).  For B cell RNA extraction, cells were cultured in a 24 well plate 
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or 48 well plate (Thermo Fisher Scientific, UK). B cells were cultured at 37oC and 5% 
CO2.  
2.3.  B cell purification  
 
Single cell suspensions obtained from spleen of mice were subjected to purification 
using the Easy Sep Mouse B cell enrichment kit (Stem Cell Technologies, U.K.).  
Purified B cells were isolated by using negative selection using biotonylated magnetic 
beads and the method was performed according to the manufacturer’s instructions. 
Briefly, spleen homogenate is suspended in 1X Phosphate buffered saline (PBS) 
(Sigma-Aldrich, USA) containing 2% Fetal Calf Serum (FCS) (Lonza, Switzerland) 
before Rat serum and B cell enrichment cocktail is added for 15mins at 4oC. Then, 
Biotin selection reagent is added for 15mins at 4oC before magnetic beads are added to 
bind to non- B cells. The eluate containing the B cells is removed and the non B cells 
bound to magnetic beads are retained within the magnet. Efficiency of purification 
ranged from 97% to 99% and purity was assessed using mouse B cell surface marker 
B220 and CD19 on the Accuri C6 Flow cytometer (BD, Bioscience, UK). Purified B 
cells were cultured as described above in Section 2.2. 
2.4.  Antibodies and flow cytometry 
 
2.4.1. Cell surface staining 
 
Activation and differentiation analysis on B cells was carried out by staining 
splenocytes with a combination of fluorescently conjugated antibodies supplied by e-
bioscience (CA, USA) unless otherwise indicated. In other to avoid non-specific Ig 
trapping by the antibodies to FC receptors, cells were first blocked with CD16/CD32 (e-
Bioscience, CA, USA). Cells were stained using fluorescently labelled anti-mouse 
markers. The following markers were used including anti–B220Pe-cy5 anti-CD23PE, anti-
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CD25FITC (BD-Bioscience, CA, USA), anti-CD27FITC, and anti-CD80APC. 
Characterisation of B cell subsets in the spleen was carried out using IgMPE, IgDFITC, 
anti-CD21APC (Biolegend, UK), anti-CD23-PeCy5, and anti-CD24PE. Combinations of 
antibodies were mixed in staining buffer (Sterile PBS supplemented with 2% FCS 
(Lonza, Switzerland)). Staining of cells were carried out on ice and incubated for 30 to 
60mins. After incubation, cells were washed with FACS washing buffer (Sterile PBS 
supplemented with 2% FCS (Lonza, Switzerland)). The mixture was then centrifuged at 
1200rpm, for 5mins at 5oC before analysis by the Accuri C6 Flow cytometer (BD-
Bioscience, UK).  
2.4.2. Annexin-V apoptosis staining assay 
 
Annexin-V- staining was carried out using an Annexin-V-FITC apoptosis detection kit 
(e-Bioscience, CA, USA) according to manufacturer’s instruction. Briefly, cells were 
stained as described above in Section 2.4.1, after which they were washed with 
Annexin-V binding buffer. The cells were then stained with Annexin-V-FITC (e-
Bioscience, CA, USA) for 15mins at room temperature in the dark before collecting 
data using Accuri C6 Flow cytometer (BD-Bioscience, UK). 
2.4.3. Carboxyfluoroescein diacetate succinimidyl ester (CFSE) dye proliferation 
assay 
 
CFSE (e-Bioscience, CA, USA) staining was carried out to assess proliferation. Purified 
B Cells were washed with 1X PBS and then re-suspended in 1X PBS before staining 
with 10µM of CFSE (e-Bioscience, CA, USA) in the dark at 37oC for 15mins. Labelled 
cells are then washed with 1X PBS containing 5% FCS (Lonza, Switzerland) to stop the 
reaction before washing with AIM-V medium (Life technologies, USA). Cells were 
cultured in AIM-V medium with 5µg/ml anti-CD40/anti-IgM with or without 
0.005µg/ml and 0.05µg/ml rShh before addition of 5µg/ml Interleukin-4 (IL-4) (e-
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Bioscience, USA) and incubated at 37oC and 5% CO2 for 72hours and 96hours. 
Cultured cells were stained with anti-CD23PE and anti-CD25PeCy5.5 (BD,Pharmigen, San 
diego, CA) as described above in Section 2.4.1 and analysed by flow cytometry on the 
Accuri C6 (BD, Bioscience). 
2.4.4. Intracellular staining for IL-10 
 
IL-10 intracellular expression was detected using the BD cytofix kit (BD-Bioscience, 
CA, USA). For IL-10 expression, cells are stimulated with cell stimulation cocktail plus 
transport inhibitor (e-Bioscience, CA, USA) for the last 5hours of culture. Intracellular 
staining for IL-10 was carried out using anti-mouse IL-10FITC (e-Bioscience, CA, USA) 
or mouse IgG2bFITC (BD Pharmigen) as isotype control, cells were stained with a 
combination of CD23PE and CD25APC. Cells were washed twice with FACS buffer. The 
cells were then fixed using the cytofix permeabilized using the BD cytofix/cytoperm 
fixation / permeabilization solution with BD golgi stop (B.D. Bioscience, CA, USA) for 
30mins in the dark. Following this, cells were washed twice with BD perm wash before 
staining with IL-10FITC in permeabilization buffer (e-Bioscience, CA, USA). After 
staining, samples are washed with FACS buffer and analysed on Accuri C6 cytometer 
(BD-Bioscience, UK).  
2.4.5. Functional sorting assays  
 
Purified B cells were cultured for 40hours as described above in Section 2.2, the cells 
were treated with unlabelled CD16/32 before staining with the appropriate antibodies, 
CD23FITC, CD25PE (e-bioscience CA, USA). The cells were washed and maintained on 
ice during the entire procedure. The cells were then sorted using the FACSAria III (BD-
Bioscience) at the Institute of Child Health (ICH) Unit (University College London) 
into three populations, CD23+CD25-, CD23+CD25+ and CD23-CD25+. The sorted 
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populations were reactivated using anti-CD40/anti-IgM and cultured overnight before 
analysis for cell surface markers using the Accuri C6 Flow cytometer (BD-Bioscience, 
UK).  The morphology of activated sorted B cell subsets was captured using the 
EVOS® line of Cell Image System (Advanced Microscopy Group, Washington, USA). 
Supernatant was collected and analysed for secretion of antibody, IL-6 and IL-10 using 
ELISA (e-Bioscience). Characterisation of sorted B cell subsets was done as described 
in Section 2.4.1. 
2.4.6. Gating strategy 
 
Cells were stained and collected using the Accuri C6 flow cytometer (BD-bioscience, 
UK). To distinguish between viable and dead cells, a side scatter (SSC-A) and forward 
scatter (FSC-A) plot was plotted. Higher granularity indicates higher SSC-A and thus 
dying cells. Peripheral B cell subsets were identified by following the protocol 
published by Carsetti, 2004 and Pillia and Carriappa, 2009 (Carsetti 2004, Pillia and 
Cariappa, 2009). 
2.5.  Enzyme linked immunoabsorbent assay (ELISA) 
 
2.5.1. Antibody ELISA 
 
Supernatants obtained from purified B cells cultured with or without rShh at 18 and 
40hours were analysed for the presence of different isotopes of immunoglobulins using 
the Mouse Ig isotypes detection ELISA kit (e-Bioscience, CA, USA). The procedure 
was followed as per instructions of the kit. Briefly, Coastar 96 well plate was coated 
overnight at 4oC with capture antibody. It is then blocked for 24hours at 4oC. Plates 
were washed using 1X PBS containing 0.05% Tween-20 (Sigma-Aldrich, UK) before 
50µl of supernatant samples were added accordingly for a 1hour incubation. Plate was 
washed and a detection antibody linked to horseradish peroxidase (HRP) was added. 
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The substrate was added before the addition of the stop solution (1N H2SO4). An 
internal positive control was used and the negative control used was cell culture 
medium. The plates were read at λ= 450nm and λ= 570nm and values were subtracted 
to get actual values using the Thermo Multiskan plate reader (Thermo,USA). 
2.5.2. Cytokine ELISA 
 
For IL-10 secretion and IL-6 secretion, supernatants was analysed using the mouse IL-
10 ELISA ready set go kit (e-Bioscience, CA, USA) and Mouse IL-6 ELISA ready set 
go kit (e-Bioscience, CA,USA) respectively. The procedure was followed as per 
instructions of the kit. Briefly, Coastar 96 well plate was coated overnight at 4oC with 
capture antibody IL-10 or IL-6. After washing with ELISA wash buffer (1X PBS/0.05% 
Tween-20) to remove unbound antibody, it was then blocked for 2hours at room 
temperature. The plate was washed before adding 100μl of supernatant samples along 
with a serial dilution of recombinant protein accordingly before an overnight incubation 
was carried out. The plate was washed and a detection antibody for each individual 
cytokine was added. The plate was washed again before addition of secondary antibody 
conjugated to HRP for 30mins. After washing of the plate, the substrate was added and 
colour was allowed to develop for 15mins. Then a stop solution was added to the plate 
(1N H2SO4). The plates were read at λ= 450nm and λ= 570nm and values were 
subtracted to get actual values using the Thermo Multiskan plate reader (Thermo,USA). 
A standard curve was plotted from the recombinant protein in order to get the 
concentration of the unknown values. 
2.6.  RNA extraction and complimentary DNA (cDNA) synthesis  
 
Cultured B cell suspensions were pelleted and re-suspended in appropriate amounts of 
lysis buffer containing β-ME (Sigma-Aldrich). RNA was extracted according to the 
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protocol of the PureLink® RNA Mini Kit (Life technologies, UK) including a DNase 
digestion step using PureLink® DNase set (Life technologies, UK).  The quality and 
quantity of RNA was assessed using the Nanodrop ND-1000 spectrophotometer 
(Nanodrop technologies, Wilmington, US). Samples with a λ= 260/280nm ratio 
between 1.8 and 2.1 were used in experiments. cDNA was synthesised from this RNA 
using the iScriptTM Select cDNA Synthesis Kit (Bio-Rad, CA, USA). The reaction was 
made up of 300-400ng RNA and the components provided in the kit including reverse 
transcriptase, Oligo(dt) primers according to the manufacturer’s protocol. A total 
volume of 20μl was made and incubated using the Biorad T100TM Thermal Cycler (Bio-
Rad, Inc., US) at 42oC for 65mins to allow elongation and it was heated to 85oC for 
5mins to inactivate the reverse transcriptase and terminate the reaction. RNA was stored 
at -80oC and cDNA at 4oC or -20oC. 
2.7.  Quantitative real- time reverse polymerase chain reaction (qRT-PCR) 
 
Quantitative real time polymerase chain reaction (qRT-PCR) was performed in 
triplicate on cDNA samples synthesised from cultured B cells RNA using Mx 3000pTM 
Stratgene Real-Time PCR system (Stratagene, US) using the iTaqTM Universal SYBR® 
Green Supermix (Bio-Rad, USA) following the manufacturer’s instruction. The house-
keeping gene Hypoxanthine guanine phosphoribosyl transferase (Hprt) was used to 
allow quantification of template and normalisation of each gene. Amplification of Hprt 
was quantified using a dilution series of neat cDNA, 1:10, 1:100, 1:1000 and 1:10000 
prepared from embryo head RNA or control stimulated B cells RNA and relative 
standard curve for the gene of interest was generated by a 1:10 serial dilution of RNA 
prepared from cultured B cells. The efficiency of the qRT-PCR was determined for each 
gene with the slope of a linear regression model (Pfaffl, 2001). The efficiencies (E) 
were calculated according to the equation: E= (10(-1/slope-1) x100) (Fraga et al., 2008). 
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The primers used for the reaction are listed below in Table 2.1. All primers were 
purchased from Qiagen (Quantitect primer assay) and the primer sequences are 
protected (Qiagen, Inc, US). Each reaction contained approximately 100ng of cDNA, 
300nM of forward and reverse primers, 10μl of SYBR green super-mix (containing, 
iTaq DNA polymerase, dNTPs, MgCl2). The reaction was made up to 20μl using 
nuclease free water (Qiagen Inc., US) in a 96 well plate (Thermo Scientific, U.K). 
qRT-PCR reaction was performed under these conditions for each primer used 
according to the manufacturer’s protocol: initial denaturation at 95oC, for 30s followed 
by 40 cycles of denaturation at 95oC for 30s and annealing at 60oC for 30s. In each 
experiment, a melting curve was obtained according to the manufacturer’s programme 
in order to check the melting temperatures of the products so as to avoid contamination 
with primer-dimer and confirm the product size was as expected (Appendix 2.1). 
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Table 2.1. List of Quantitect primers (Qiagen, US) 
Primer Annealing 
Temperature 
Primer Sequence Catalogue 
Number 
Hypoxanthine guanine 
phosphoribsyl 
transferase (Hprt) 
 
 
 
 
 
 
60oC 
 
 
 
 
 
Primer sequence 
protected 
(Quantitect Primer 
Assay) 
(Qiagen Inc, U.S) 
QT00166768   
 
Tumour Necrosis 
receptor associated 
factors 2 (Traf2) 
QT00103082 
Bone Morphogenic 
Protein 2  (Bmp2) 
QT01054277 
Bone Morphogenic 
Protein 4  (Bmp4) 
QT00111174 
Bruton’s Tyrosine 
Kinase (Btk) 
QT00102179 
Nuclear Factor of 
activated T Cells c1 
(Nfatc1) 
QT00167692   
BCL2/ adenovirus E1B 
interacting protein 
(Bnip3) 
QT00100233 
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2.8.  Microarray and data analysis  
 
Purified B cells isolated from Dhh-/- and Dhh+/+ were cultured for 18hours and 
40hours with or without 0.05μg/ml rShh and cells were lysed. RNA was purified using 
the PureLink® RNA Mini kit (Life Technologies, USA) as described in Section 2.6. An 
additional ethanol precipitation step was carried out in order to improve the quality of 
RNA. Purity of the RNA was assessed using a Thermostat Nanodrop spectrometer and 
Bioanalyser 2100 (Agilent, UK) University college London genomics, ICH, processed 
total RNA and RNA was hybridised to an Affimetrix Mouse Gene 1.0 ST platform. 
Data analysis was carried out as described in Furmanski et al., 2013. Briefly, CEL files 
produced were normalised using Robust Multi Array (RMA) algorithm. Differentially 
expressed genes were identified using the eBaye’s method t-test by p ≤ 0.05 considering 
a false discovery rate by Limma (Bioconductor). Principal component analysis (PCA) 
was performed using the CRAN package (Bioconductor, U.S). Genes identified from 
PCA was verified using qRT-PCR as described in Section 2.7.  
2.9.  Data analysis 
 
Statistical analysis were performed using GraphPad Prism Software (Version 5.0; 
GraphPad Software Inc., USA) or Microsoft Excel. Error bars represent standard error 
of the mean (S.E.M). Dot plots and histograms were generated by Accuri C-flow 
software (BD- Bioscience, UK). P- Values were generated using unpaired Student t test 
and denoted as follows: *p≤ 0.05, **p ≤ 0.01, ***p≤0.001. P values less than or equal 
to 0.05 were considered significant. Student t test was used because we are comparing 
the treated B cells with the control, and the samples have unequal variance. 
For qRT-PCR data analysis, relative expression data were obtained using the relative 
standard curve method (Bolha et al., 2001). To do this, relative standard curves were 
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generated for the target gene and the housekeeping gene by plotting the Ct value against 
the logarithmic value of the cDNA concentrations. Ct is defined as the threshold cycle 
where fluorescent signal of the reporter dye increases significantly. The numerical value 
of Ct is inversely related to the amount of amplicon in the reaction (Schimittgen and 
Livak, 2008).  
After obtaining the standard curves for both the target gene and housekeeping gene, 
gene expression in the samples was calculated using the equation of the standard curve. 
To calculate relative expression of the gene of interest, the data was normalised to the 
house-keeping gene, Hprt as follows (gene expression in target gene/ gene expression in 
housekeeping gene) (Appendix 2.2). Statistical analysis for RT-PCR result was carried 
out as described above.  
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Chapter 3: The role of Hh and BMP signalling in B cell 
activation and survival in a mixed splenocyte 
population. 
 
3.1.  Introduction 
 
3.1.1. Hh signalling in the spleen microenvironment  
 
The spleen is a unique lymphoid organ that is important for the maintenance of immune 
homeostasis. The spleen combines the innate and the adaptive immune system in a 
bgcompartments including marginal zone, red pulp and white pulp with each area 
having different functions (Cesta, 2006, Mebius and Kraal, 2005, Rosado et al., 2014). 
The spleen contains a variety of cells including macrophages, erythoid progenitors, T 
cells, B cells and dendritic cells that each have discrete functions. The majority of the B 
cells produced in the bone marrow enter the secondary lymphoid tissue, most 
commonly the spleen, which is the major site for early peripheral development and 
exposure of these immune cells to foreign antigen (Su et al., 2004, Carsetti et al., 2004). 
The spleen contains cells and factors that can support this maturation of B cell 
development in the periphery (Su et al., 2004). 
 
Stromal cells of the spleen have been previously shown to secrete Shh (Dierks et al., 
2007, Perry et al., 2009) and Dhh (Lau et al., 2012) as well as the receptor components 
of the Hh signalling pathway (Lau et al., 2012). Sacedon et al., 2005 showed that Shh is 
secreted by FDCs in the spleen and furthermore, the GC B cells of the spleen express 
the receptors of the Hh signalling pathway, Ptch and Smo, thus indicating that they can 
respond to this signalling pathway (Sacedon et al., 2005). In 2002, Lowrey et al., had 
previously shown that activated and resting CD4+ T cells in the spleen of the mouse 
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express the components of the Hh signalling pathway including Smo, Shh, Ptch and 
Gli-1 (Lowrey et al., 2002) and that these T cells were capable of responding to Shh 
thus indicating a role for Hh signalling in driving T cell maturation in the spleen. 
Additionally, Hh produced in the spleen has been shown to have an effect on splenic 
cell development in terms of inducing immune cells themselves to secrete further 
morphogens in response to Hh signalling. Dierks et al., 2007, showed that Hh produced 
in the spleen by the stromal cells could support the proliferation and survival of B cell 
lymphoma (Dierks et al., 2007). Perry et al., (2009), showed that secretion of Hh by the 
splenic stroma could induce BMP-4 expression in bone marrow cells, which in turn has 
an effect on the development of erythoid precursors in the spleen in response to stress 
(Perry et al., 2009). 
 
Taken together, these data indicate that Hh signalling plays a number of distinct roles in 
the development and maturation of different haematopoietic lineages in the spleen. 
 
3.1.2. Bone morphogenic protein and its role in B cell function. 
 
 
Bone morphogenic proteins (BMP) are glycoslyated secreted signalling molecules that 
belong to the Transforming Growth Factor beta family (TGF-β) of cytokines. They 
control cellular processes such as proliferation, apoptosis, migration and differentiation 
of many cell and tissues (Ali and Brazil, 2014, Brazil et al., 2015). There are more than 
20 members of the BMP protein family, which have been sub-grouped according to 
their sequence homology, structure and function (Nohe, 2004, Miyazono et al., 2010).  
BMPs play a role in embryogenesis and are potent stimulators of bone formation in 
adults, hence their name. They are also involved in the regulation of the hematopoietic 
stem cell (Huse et al., 2011, Bhatia et al., 1999).  
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BMP proteins are synthesised as precursor proteins with a hydrophobic stretch of 
approximately 50-100 amino acids which must be proteolytically removed from the 
carboxy-terminus to form functional protein (Ali and Brazil, 2014). BMP proteins 
signal via two types of serine-threonine kinase receptors, type I (BMPR-I) and type II 
(BMPR-II) to which they bind to with different affinities (Huse et al., 2011, Miyazono 
et al., 2010). Activation of type II receptors by a ligand leads to the activation of the 
type 1 receptor thus leading to the dimerization of the complexes. The activated type I 
receptor complex phosphorylates the intracellular R-Smads (receptor regulated Smads), 
which include Smad1, 5, 8. (Guo and Wang, 2009, Huse et al., 2011, Kersten et al., 
2005). Activated R-Smad interact with Smad4 to form a complex that translocates to the 
nucleus where it regulates the expression of specific target genes through the interaction 
with a range of DNA binding proteins and transcriptional co-activators and repressors 
(Ali and Brazil, 2014, Brazil et al., 2015, Guo and Wang, 2009). A schematic diagram 
illustrating BMP signalling pathway is shown in Figure 3.1. 
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Figure 3.1. BMP signalling pathway 
 
A scheme illustrating the BMP signalling pathway. Binding of BMP ligand to type 
II receptor, leads to type I phosphorylating R-Smads, which pairs with Smad-4 to 
form a complex. This complex translocates to the nucleus where it acts on target 
genes. Antagonists of the BMP pathway include Noggin and Chordin, which acts to 
prevent the binding of the BMP ligands to the receptors. Adapted from (Lo et al., 
2014). 
 
In immune cells, BMP signalling controls a myriad of events that includes apoptosis, 
cell proliferation, differentiation and effector functions (Miyazono et al., 2010, 
Yamashita et al., 1996). In lymphocytes, BMP signalling has been shown to inhibit T 
cell lymphopoiesis (Varas et al., 2009, Yoshioka et al., 2012) and B cell lymphopoiesis 
(Kersten et al., 2005). In B cells, Huse et al., (2011) using a system in which purified 
human CD19+ B cells co-cultured with CD40L/IL-21 induced differentiation of 
plasmablasts. They showed that upon addition of BMP 2, 4, 6 or 7 to the cultures, there 
was an arrest in the differentiation towards plasmablasts. Co-culture with BMPs was 
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also shown to reduce Ig production by purified B cells and down-regulate proliferation 
of naïve and memory B cells (Huse et al., 2011). The results obtained show that BMPs 
can provide a negative regulatory signal to B cell development. Kertsen et al., 2005, 
have reported that BMP-6 can inhibit B cell lymphopoiesis in the bone marrow by 
impeding B cell proliferation via the upregulation of transcription factors inhibitors of 
differentiation (Id) 1 and 3. Id1 and Id3 are important target genes of BMP signalling 
(Kersten et al., 2005, Miyazono et al., 2005) and are negative regulators of B cell 
maturation and function (Sugai et al., 2004, Tsalavos et al., 2011) and other cells 
including neoplastic cells such as prostate cancer cells (Strong et al., 2013).  
 
Twisted gastrulation (TWIGS1) a regulator of BMP signalling, which is secreted by 
activated B cells but not naïve B cells, can display both an agonist and antagonist effect 
on BMP function. TWIGS1 has also been shown to synergistically interact with chordin 
(Figure 3.1) to regulate BMP activity (Tsalavos et al., 2011). Using TWIGS1 knockout 
mice, Tsalavos et al., (2011) highlighted the negative regulatory effects of BMP 
signalling in B cell function showing KO cells were hyperresponsive to T independent 
antigen such as LPS, resulting in decreased apoptosis, increased plasma cell production 
and a corresponding increase in antibody secretion (Tsalavos et al., 2011). 
 
3.1.3. Objectives 
 
In previous studies by Sacedon et al., 2005, Hh signalling was shown to enhance GC B 
cell survival and proliferation. Hh has also been implicated in a variety of B cell cancers 
including B cell lymphoma (Dierks et al., 2007) and MM (Peacock et al., 2007). 
However, the role of Hh signalling in B cells is still unclear and thus requires further 
research. The aim of the work presented within this chapter is to test the role Hh 
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signalling plays in its activation and survival of B cells in a mixed splenocyte 
population during a developmental time-course. The specific role of BMP signalling in 
mediating the effects of Hh signalling and activities of the BMP inhibitor Noggin in B 
cell activation and survival are also explored within this chapter.  
 
3.2. Results 
 
3.2.1. The positive and negative regulatory effect of treatment of exogenous rShh 
on B cell activation and survival in a mixed splenocyte cell population.  
 
Spleens from BALB/C mice were isolated and homogenised before seeding into culture 
dishes. B cells within these cultures were activated using 5µg/ml anti-CD40/IgM 
(Sacedon et al., 2005). Anti-CD40 and anti-IgM mimics the in vivo activation of B cells, 
which involves the CD40 ligand (CD40L) on T cells binding to the CD40 receptor on 
an antigen-presenting cell such as B cell thus mimicking T-dependent B cell activation. 
Anti-IgM antibody binds to the B cell sIgM thus leading BCR crosslinking and 
providing a polyclonal B cell activation signal mimicking T independent B cell 
activation (Wortis et al., 1995, Sacedon et al., 2005). The role Hh signalling plays in B 
cell activation and development within these cultures was investigated by the addition 
of recombinant Shh (rShh) at varying concentrations ranging from 0.005-5µg/ml (Shah 
et al., 2004). Shh was used because it is the most broadly expressed homologue of Hh 
protein (Varsiojo and Tiapale, 2008). Cells were harvested and analysed using flow 
cytometry for activation and survival status using B cell activation surface marker 
CD23 (Bonnefoy et al., 1995) and apoptosis marker annexin–V (van Engeland et al., 
1998) after 18 and 40hours of culturing. B cells in the cultures were characterized from 
other cell types by co-staining with the murine B cell lineage marker B220. B220 is an 
isoform of CD45, which is generated by alternative splicing and differs from the other 
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isoforms of CD45 by having a higher molecular mass (Nikolic et al., 2002).  
Combinations of B220-PE-Cy5, CD23-PE and Annexin-V-FITC were used for the 
staining. The 18 and 40hours post-activation time points were chosen in order to assess 
any effects Hh signalling might have on early B cell activation response and late B cell 
activation responses. 
 
The activation marker CD23, a 45kD surface membrane glycoprotein expressed 
primarily by B cells and monocytes; is the low-affinity receptor for the immunoglobulin 
E (IgE). It is a type II integral membrane protein with a single transmembrane region. In 
B cells, CD23 is up-regulated after B cells are activated and it is proposed to play a role 
in B cell auto-stimulation and regulation of IgE synthesis (Bonnefoy et al., 1995). CD23 
is also involved in priming B cells for antibody production and promoting the survival 
of GC B cells (Corominas et al., 1993, Olteanu et al., 2011). 
 
Apoptosis is programmed cell death; it is a normal physiological procedure that is 
necessary for the removal of damaged and infected cells and it plays an important role 
in the maintenance of tissue homeostasis in multi-cellular organisms (Ditzel, 2011, 
Fukuda et al., 2006, van Engeland et al., 1998). Annexin-V is a Ca2+ lectin 
phospholipid, which binds to an early marker of apoptosing cells, phosphatidylserine 
(PS), which is translocated, from the inner side of the cell membrane to the outer side. 
(van Engeland et al., 1998).  
 
Figure 3.2 and 3.3, shows dot-plots from representative experiments showing dual-
staining for expression of CD23 and annexin-V on B220+ cells treated with rShh at 18 
and 40hours post-activation stimulus respectively. It was observed that treatment of B 
cells with rShh can affect B cell activation and survival. At 18hours post-activation 
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stimulus (Figure 3.2), the data shows that the percentage of CD23+Annexin-V- cells has 
increased from 72.1% in the untreated control to 80.9% in B cells treated with 
0.005μg/ml rShh and this is associated with a reduction in Annexin-V+ CD23+ cells 
from 11.8 to 5.7% respectively, indicating a pro-survival signal delivered to B cells 
treated with rShh at 18hours post-activation stimulus. 
 
Figure 3.2. The activation and survival status of B cells at 18hours post-treatment with 
rShh 
The dot-plots shown in the figure show the result of one experiment representative of four 
independent experiments. The activation and survival status of B-cells treated with varying 
levels of rShh at 18hours post-treatment is shown. Live cells were gated for their 
expression of B cell lineage marker B220 and positive cells analysed for the expression of 
CD23 and Annexin-V.  
 
At 40hours post-activation stimulus, (Figure 3.3), 77.6% of B cells were 
CD23+Annexin-V- in the untreated control compared to 58.0% CD23+Annexin-V- B 
cells treated with 0.005µg/ml rShh. This was associated with a dramatic increase in 
death of the CD23+ cells as indicated by the presence of only 5.9% CD23+Annexin-V+ 
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cells in the untreated control (Figure 3.3) compared with 16.7% CD23+Annexin-V+ 
cells in B cells treated with 0.005µg/ml rShh (Figure 3.3). Interestingly, at 40hours 
post-activation stimulus, a decrease in activation as judged by reduced CD23 expression 
was observed (Figure 3.3). 
 
Figure 3.3. The activation and survival status of B cells after 40hours post-treatment with 
rShh 
The dot-plots shown in the figure show the result of one experiment representative of three 
independent experiments. The activation and survival status of B-cells treated with varying 
levels of rShh at 40hours post-treatment is shown. Live cells were gated for their 
expression of B cell lineage marker B220 and positive cells analysed for the expression of 
CD23 and annexin-V. At 40hours, the expression of CD23 is decreased in rShh treated 
cells. A similar pattern was seen with the annexin-V staining with rShh treatment 
increasing the number of apoptotic cells in rShh treated cells.  
 
To further quantify this data, the percentage of CD23+ and annexin-V + B cells was 
analysed independently. Figure 3.4, shows bar charts representing the statistical 
significance of activation and survival of B cells treated with varying concentrations of 
rShh in the mixed splenocyte cell population at 18 and 40hours post-activation stimulus. 
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B cells were identified, and gated on, using expression of the B220 surface marker 
before CD23 and annexin-V was analysed in this sub-population of cells.  
 
At 18hours post-activation stimulus (Figure 3.4A), there was a small increase in the 
number of activated B cell as judged by CD23 expression in the presence of 0.005-
0.5µg/ml of rShh. For example, there was a significant 10% increase in activation of B 
cells as judged by the up-regulation in expression of B220+CD23+ in the presence of 
0.005 and 0.5µg/ml of rShh compared to the untreated control, thus suggesting a 
positive regulatory effect of Hh signalling on B cell activation at 18hours post-
activation stimulus as judged by CD23 expression.  
 
Additionally, there was a significant increase in survival of B cells in relation to 
untreated control in treated B cells at 18hours post-activation stimulus (Figure 3.4C) in 
all the doses of rShh. For example, there was approximately 40% decrease in the 
number of apoptotic B cells after treatment with 0.005µg/ml rShh as compared to the 
untreated control (Figure 3.4C). Interestingly, by 40hours post-activation stimulus, 
treatment with rShh induced a corresponding increase in the number apoptotic B cells in 
the culture (Figure 3.4D) and decrease in activation (Figure 3.4B). Additionally, when 
rShh was added to unstimulated B cells (result not shown) at 18hours and 40hours post-
activation stimulus, there was no effect observed on B cell activation and survival, thus 
suggesting that the rShh effect observed in the B cells is dependent on B cell activation. 
This first result obtained at 18hours post-activation stimulus is consistent with the 
results obtained by Sacedon et al. (2005), which showed that rShh, inhibited Fas 
mediated apoptosis in B cells in the GC (Sacedon et al., 2005), the latter result obtained 
at 40hours is entirely novel as exogenous rShh has not previously been shown to induce 
apoptosis in B cells and therefore requires further investigation. .  
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This negative effect of rShh on B cell activation and survival has not been observed 
before. However, treatment with rShh has been shown previously to inhibit peripheral T 
cell development and activation (Rowbotham et al., 2007).  
 
Figure 3.4. The activation and survival of B cells in a mixed splenocyte population after 
treatment with Shh 
B cells were activated with 5µg/ml anti-CD40/IgM and were treated with rShh (0.005-
5µg/ml). Cells were collected and analysed at 18hours (A) and 40hours (B) post-
stimulation for B cell activation using early activation marker anti -CD23. The results 
shown in the bar chart are representative of three independent experiments. The 
significance of the differences observed in fold changes in CD23+ cells was assessed by 
student t test (*p≤0.05). B cell survival was analysed at 18hours (C) and 40hours (D) post-
activation stimulus. The results shown in the bar chart are representative of three 
independent experiments. The significance of the differences observed in fold changes in 
annexin-V+ cells was assessed by student t test (*p≤0.05, **p≤0.01, ***p≤0.001).  
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3.2.2. Co-culture with BMP-4 promotes B cell death in a mixed splenocyte 
population 
 
 
Hh signalling has been shown previously to induce BMP-4 expression in vitro in chick 
cells (Roberts et al., 1995) and in erythroid cells during murine stress erythropoiesis in 
the spleen (Perry et al., 2009). Perry et al., (2009), showed that treatment of bone 
marrow cells with Shh induced them to become BMP-4 responsive cells. They showed 
that Hh dependent signalling induces BMP-4 expression and they both act together to 
promote the differentiation of bone marrow progenitor cells to stress (Perry et al., 2009). 
Fukuda et al., 2006, showed that in response to BMP-4 signalling, mouse B cell 
hybridoma cells showed increased apoptosis through a p53 dependent pathway (Fukuda 
et al., 2006). In our mixed B cell cultures and with treatment with rShh, it was observed 
that at 40hours post-activation stimulus, there was an increased cell death in B cells 
(Figure 3.3D). It is possible that Hh signalling in the B cells, is leading to the induction 
of expression of one of its target genes, BMP-4, which itself has been shown to have a 
negative effect in B cell development (Fukuda et al., 2006, Tsalavos et al., 2011). To 
test if rShh induced BMP-4 expression could be responsible for its effects on B cell 
activation and survival, B cells in mixed splenocytes cultures were treated r-BMP-4 and 
then analysing at 18 and 40hours post-stimulus as previously described in Section 3.2.1.  
 
At 18hours post-activation stimulus (Figure 3.5A), there was a significant decrease in B 
cell activation in B cells treated with rBMP-4 as judged by CD23 expression. This is 
associated with a dramatic increase observed in B cell apoptosis at 18hours post-
activation stimulus in the presence of all doses of rBMP-4 (Figure 3.5C).  However at 
40hours post-activation stimulus, there was a decrease in the number of activated B 
cells (Figure 3.5B) and an increase in the number of apoptotic B cells after treatment 
with rBMP-4 (Figure 3.5D). This may reflect the fact that these apoptotic cells observed 
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at 18hours post-activation stimulus have now undergone extensive apoptosis and no 
longer form part of the live gate and therefore not included in the gated cells that were 
being analysed for expression of both CD23 and annexin-V.  
 
Taken together these results suggest that BMP-4 signalling delivers a negative 
regulatory signal to B cell reducing their activation and promoting early apoptosis. 
 
Figure 3.5. Treatment of B cells with rBMP-4 decreases B cell activation and survival 
  
B cells were activated with 5µg/ml anti-CD40/IgM and were treated with rBMP-4. Cells 
were collected and analysed at 18hours (A) and 40hours (B) post-stimulation for activation 
B cells using anti-CD23, an early B cell activation marker and analysed for survival at 
18hours (C) and 40hours (D) post-activation stimulus. The bar chart shown is 
representative of three independent experiments. The significance of the differences 
observed in fold changes in CD23+ and annexin-V+ cells was assessed by student t test 
(*p≤0.05).  
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3.2.3. Interplay between Hh signalling and BMP signalling. 
 
After observing the negative regulatory effect of BMP-4 signalling on B cells activation 
and survival in vitro in a mixed splenocyte population, it became important to 
investigate if this BMP-4 mediated effect is also observed in the case of rShh treated B 
cells. To investigate this possibility, Noggin was also added to cultures. Noggin is a 
potent inhibitor of BMP signalling and mediates its effect by binding to several BMP 
proteins including BMP-2, BMP-4 and BMP-7 (Figure 3.1). By tightly binding to BMP, 
noggin blocks the sites on the protein required for their interaction with BMP receptors 
thus antagonizing BMP signalling (Figure 3.1) (La Rosa et al., 2011, McMahon et al., 
1998).  
 
Mouse splenocytes were isolated and the B cells were activated as previously described 
in Section 3.2.1 along with co-treatment with the BMP inhibitor, Noggin (5µg/ml) 
(Kersten et al., 2005). As this experiment was designed to analyse the negative 
regulatory effect of co-culture with rShh observed at 40hours post-stimulus, only these 
cultures were investigated. At 40hours post-activation stimulus, the splenocyte cells 
were collected and the B cells analysed by flow cytometry as previously described 
Section 3.2.1. Figure 3.6, shows dot-plots representing expression of CD23 and 
annexin-V on B cells at 40hours post-activation stimulus.  
 
Co-culture of splenocytes with rShh results in a decreased level of B cell activation and 
increased B cell death compared to the untreated control following 40hours in culture. 
However, the effects of rShh are inhibited upon addition of Noggin. For example, 
Figure 3.6, CD23+Annexin-V- has decreased from 54.4% in the untreated control to 
49.3% in B cells treated with 0.05μg/ml rShh and this result is associated with an 
increase in Annexin-V+CD23+ from 17.8% to 25.5%. Addition of Noggin to 0.05μg/ml 
  
 51 
rShh treated B cells increased CD23+Annexin-V- to 55.1% and reduced annexin-
V+CD23+ B cells to 18.7%. These data suggest that in our splenocyte experiments, Hh 
signalling was shown to significantly affect late B cell development at 40hours post-
activation stimulus by decreasing levels of activation and promoting apoptosis. The 
effects of rShh could be partially recapitulated by addition of Noggin, a BMP inhibitor 
to the cultures indicating the effects of Hh signalling is due, in part, to downstream 
BMP signalling. Thus Hh and downstream BMP signalling may play a significant role 
in peripheral B cell development. 
 
Figure 3.6. Noggin inhibits the effects of rShh treatment on B cells at 40hours post-
activation stimulus 
 
The dot-plots shown in the figure show the result of one experiment representative of three 
independent experiments. The activation and survival status of B-cells treated with varying 
levels of rShh and also in the presence of Noggin at 40hours post-treatment is shown. Live 
cells were gated for their expression of B cell lineage marker B220 and positive cells 
analysed for the expression of CD23 and annexin-V.  
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3.3. Discussion 
 
 
It has been reported previously that Hh signalling can induce a positive regulatory effect 
on B cell function by regulating the apoptotic pathway thus increased B cell survival 
and increasing B cell antibody production (Sacedon et al., 2005). Similarly, Hh 
signalling has also been shown to be involved in the survival of neoplastic B cells such 
as B-CLL (Hedge et al., 2008) and MM (Peacock et al., 2007). 
 
Activation of Hh signalling pathway can suppress the apoptotic pathway by up-
regulating the expression of anti-apoptotic proteins. Hh signalling can promote P13K 
activation, which in turn degrades p53, which is a stimulator of apoptosis thus 
enhancing survival of target cells. Hh signalling can also induce other anti-apoptotic 
proteins such as Bcl2 (Ditzel, 2011). However, Hh signalling can also induce the 
apoptotic pathway through different mechanisms involving the transcriptional up-
regulation of potent inhibitors of both the extrinsic and intrinsic apoptotic pathways. 
Shh can induce apoptosis via the up-regulation of the Ptch receptor, Ptch is a tumour 
suppressor protein that when mutated is associated with neoplasia. Ptch can induce 
apoptosis via a caspase cleavage site at Asq 1392 and it also promotes DNA 
fragmentation (Ditzel, 2011,Mille et al., 2009). Ptch has been shown to be pro-apoptotic 
in a number of different systems, In the neural tube, Ptch induces apoptosis by binding 
to capase and this is independent of expression of the Smo receptor and Gli activity 
(Atwood et al., 2013, Mille et al., 2009). 
 
Based on this idea, we hypothesised that Hh signalling can positively regulate B cell 
function by increasing B cell activation and survival and also negatively regulate B cell 
function by decreasing B cell activation and survival at different time points. The data 
presented in this chapter showed that Hh signalling could induce a positive signal at 
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18hours possibly by strengthen the BCR signal and inducing target genes that are anti-
apoptotic such as Bcl2 thus increased B cell activation and survival.  At 40hours, a 
negative regulatory effect on B cell activation and survival was observed in the presence 
of Hh signalling.  The negative regulatory effect observed at 40hours might also be as a 
result of the delayed induction of expression of another Hh target gene such as the 
secreted morphogen, BMP-4 (Ditzel, 2011). Hh signalling would appear to be able to 
fine tune the BMP and TGF-B signalling cascades through the regulation of expression 
of multiple ligands and inhibitors (Katoh and Katoh, 2009) thus allowing constant 
negative feedback in order to regulate the signalling effects mediated by these 
morphogens. BMP-4 has not only been shown to be a Hh target gene but has also been 
shown to promote death of B cells (Fukuda et al., 2006). The data showed in this 
chapter suggests that Hh signalling and BMP signalling interplay to regulate B cell 
development in the periphery. 
 
Taken together, these data are consistent with the repeated findings that immune 
responses must first be activated by the presence of antigen but they must subsequently 
be down-regulated in order to prevent the onset of pathology caused by inappropriate 
activation of the immune response. In B cell lymphomas such as B-CLL (Hedge et al., 
2010) and MM (Peacock et al., 2007), where Hh signalling has been shown to be 
involved in their pathogenesis, it is possible that the Hh signalling pathway is defective. 
The ability to induce the transcriptional up-regulation of pro-apoptotic proteins such as 
BMP proteins is possibly silenced in these cancerous cells thus increased survival of 
these cells. Hh signalling induction of down-stream BMP signalling could be 
investigated in B cell lymphomas.  
Having identified these regulatory effects on B cell development, it will be important to 
repeat these studies on purified B cells in order to determine whether this effect was 
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intrinsic to B cells or required the presence of another cellular subset provided by the 
spleen. 
3.4.Conclusion 
 
In this chapter, rShh was shown to induce a positive regulatory signal soon after the 
onset of antigen mediated signalling events that can drive enhanced B cell activation 
and survival at 18hours post-activation stimulus as judged by levels of CD23 and 
annexin-V expression. Also, Hh signalling could deliver a negative signal to B cell 
activation and survival at 40hours post-activation stimulus. The negative regulatory 
effect observed at 40hours post-stimulus, was thought to possibly involve BMP 
expression. Consistent with this idea, the addition of BMP-4 to the cultures delivered a 
negative regulatory signal to B cell activation and survival at 18 and 40hours post-
stimulus. Co-treatment of cultures with Noggin, was shown to reverse the pro-apoptotic 
effects mediated by the presence of rShh at 40hours post-stimulus, suggesting that these 
later pro-apoptotic events were indeed mediated by BMP signalling. The next chapter 
extends these findings of this chapter by investigating the effect of Hh signalling in 
purified B cells.  
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Chapter 4: The effects of Hh signalling in purified B cells. 
 
4.1. Introduction 
4.1.1. B cell maturation in the spleen 
 
B cells undergo early maturation in the bone marrow and then once they express a 
functional antigen receptor (BCR) that does not recognise self-antigen, they leave the 
bone marrow and travel to the peripheral organs such as the spleen. They enter the 
spleen as transitional B cells, T1, T2 or T3. B cell maturation in the spleen is illustrated 
in Figure 1.1. Depending on the type and strength of the B cell receptor (BCR) signal, 
transitional B cells can then differentiate to become follicular (FO) or marginal zone B 
cells (MZ) (Pillai and Cariappa, 2009). It has been reported, that during peripheral B 
cell development, T1 B cells normally differentiate to become T2 B cells. Upon tonic 
BCR engagement, T2 B cells have been shown to differentiate towards FO B cells. 
However, TLR ligand activation in addition to BCR signalling in T2 B cell drives the 
differentiation of the B cells towards MZ B cell development (Su et al., 2004). FO B 
cells also have the ability to differentiate to Transitional type 2- Marginal zone 
Precursor B cells (T2-MZP). T2-MZP B cells form a reservoir for MZ B cells during 
depletion and have suppressive functions. Follicular B cells populate the B cells 
follicles of the spleen associating closely with follicular dendritic cells (FDCs).  FDCs 
are stromal cells in the germinal centre and they interact with B cells thus making them 
a crucial component for humoral immune responses (Park and Choi, 2005).  
 
Upon encounter of antigen, and with T cell help via CD40 ligand, FO B cells, also 
referred to as conventional or naïve B cells are stimulated to proliferate and thus form a 
germinal centre (GC). In the GC, B cells undergo affinity maturation, somatic 
hypermutation and isotype switching thus driving them to differentiate into effector 
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cells such as plasma cells capable of producing high affinity antibodies of different 
isotypes and memory B cells that are programmed to recognise and respond to antigens 
on repeat exposure (Natkunam, 2007, Su et al., 2004, Luu et al., 2014). Antibody 
production can be divided into T cell dependent (TD) or T cell independent (TI). TD 
antibody production requires activation of the B cells via a co-stimulation through the 
CD40, which is provided by CD40L on activated T cells. B cell activation, which does 
not require T cell help, is termed TI response and are mediated by antigens such as LPS 
(Tsalavos et al., 2011).  
 
4.1.2. The production of cytokine and B cell maturation and function 
 
Cytokines are small non-structural proteins with molecular weight ranging from 8-
40kDa. Nearly all nucleated cells have the ability to synthesise cytokines and also 
respond to them. Cytokines can have a variety of functions, however they are primarily 
involved in host responses to disease (such as infection), the maintenance of cellular 
homeostasis, and are often secreted by immune cells in response to various stimuli. In 
the context of immune system, they can mediate both pro-inflammatory and anti-
inflammatory responses (Dinarello, 2000, Vazquez et al., 2015). Cytokines can also 
function as growth and/or differentiation factors that act via an autocrine or paracrine 
manner. Many cytokines share similar functions through binding of specific cell surface 
receptors thus initiating signal transduction (Moens and Tangye, 2014). 
 
B cells produce a variety of cytokines and cytokines play a major role in B cell 
development and differentiation (Lund, 2008). B cell differentiation is influenced by 
many cytokines including interleukin (IL) -2, IL-10, IL-6, IL-21, IL-13, IL-15, 
transforming growth factor beta (TGF-β) and IL-21 (Berglund et al., 2013, Luu et al., 
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2014). In early B cell development, the cytokine, interleukin 7 (IL-7), is involved in B 
cell development in the bone marrow, inducing the development of pro-B cells to pre B 
cells (Vazquez et al., 2015). In the peripheral organ such as the spleen, Lymphotoxin 
and TNF-α, produced by B cells have been shown to control the development of 
follicular dendritic cells. The development of B cells in the follicles and the 
development of specialized stromal cell subsets in the spleen is also regulated by 
lymphotoxin and TNF-α (Lund, 2008).   
 
B cells can make cytokines that amplify immune responses such as IL-6 and IL-4 but 
they also have the ability to make cytokines that can supress the immune system such as 
IL-10 and TGF-β (Vazquez et al., 2015). IL-10 has been shown to negatively regulate B 
cells and suppress harmful immune responses, regulating the balance between the 
different peripheral T cell responses such as Th1 and Th2 (Saraiva and O'Garra, 2010).  
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4.1.3. Objectives 
 
The data presented in Chapter 3 suggests that Hh signalling can exert an apparent 
positive and negative regulatory effect on B cell function in a mixed splenocyte 
population with regards to activation and survival. However, other cell types in the 
spleen can also respond to Hh signalling and thus may influence the effect observed on 
B cells. The aim of this chapter is to investigate the effect of Hh signalling in purified B 
cells. The objectives of this chapter are: 
 To determine the effect of Hh signalling in purified B cells, with emphasis on 
activation, survival, and differentiation.  
 To investigate the effect mediated by Hh signalling on antibody production and 
cytokine secretion in B cells as well as the effects of Hh signalling on the 
proliferation of B cells in the periphery.  
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4.2. Results 
4.2.1. The effect of exogenous rShh on B cell activation and survival in a purified 
B cell population 
 
After examining the effect of exogenous rShh on B cells in a mixed splenoctye 
population at 18 and 40hours post-stimulus with respect to activation and survival, it 
was important to look at the effect of exogenous rShh on purified B cell populations. 
This is because it is possible that the effect observed in mixed cultures was due to a 
factor secreted by other cellular subset, contained within the spleen. For example, it was 
recently shown that Hh signalling is capable of polarising splenic T cells to become Th2 
cells in certain pathological situations and Th2 cells in turn drive B cells to secrete IgE 
(Furmanski et al., 2013). Also, the effects of dendritic cells (DCs), or monocytes in the 
spleen might have an effect on the B cell function in response to Hh signalling. DCs are 
specialised antigen presenting cells that are involved in primary T cell response and it 
has been shown that human thymic DCs (Varas et al., 2008) and mouse FDCs (Sacedon 
et al., 2005) express the components of the Hh signalling pathway including Ptch and 
Smo. Varas et al., 2008, showed that the human thymic DCs secrete Shh which acts in 
an autocrine manner promoting the survival of the cells as well as influencing DC 
activation and allostimulatory capacity (Varas et al., 2008). 
 
 
One factor complicating the results presented in Chapter 3 is that the marker B220, used 
to differentiate the B cells from other cells in the mixed splenocyte cultures can also 
sometimes be expressed by natural killer cells (NK) (Nikolic et al., 2002), T cells (Oka 
et al., 2000) and DCs (Segura et al., 2009). Oka et al., (2000), reported that B220 is 
constitutively expressed in a cytoplasmic form in T cells which may translocate to the 
cell membrane during apoptosis (Oka et al., 2000). These other potential B220+ cellular 
subsets might have an effect on the results observed using the mixed splenocyte culture. 
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In order to exclude this possibility, it became important to analyse the role of Hh 
signalling in B cells purified by negative selection rather than on the basis of B220 
expression. To this end, purified B cells were obtained using negative selection (Stem 
Cell Technology) and the role of Hh signalling was analysed in B cell activation, 
survival, proliferation and differentiation as before.  
 
Spleens were isolated from BALB/C mice, and cell suspensions were derived by 
homogenization. The spleen cells that were not required are then removed out from the 
mixed cell suspension using magnetic beads leaving only the desired population of B 
cells by the process of negative selection. The resultant B cells were enriched with a 
purity of 97-99% as confirmed using CD19 and B220 expression in flow cytometry. 
Purified B cells were then activated with 5µg/ml anti-CD40/IgM and then treated with 
varying concentration of rShh ranging from 0.005-5µg/ml (Shah et al., 2009). At 18 and 
40hours post-activation stimulus, cells were analysed for their degree of activation and 
survival. A combination of B220-PE-Cy5, CD23-PE, Annexin-FITC was used to analyse 
activation and survival.  
 
Figure 4.1 shows data on B cell activation and survival. As observed with the mixed 
splenocyte B cell culture, there was a significant increase in CD23 expression and 
decrease in apoptosis as judged by loss of annexin-V staining in B cells treated with 
rShh compared to the untreated control at 18hours post-activation stimulus (Figure 4.1A 
and Figure 4.1C respectively). At 40hours post-activation stimulus, there was a 
significant decrease in CD23 expression and an increase in apoptosis of B cells treated 
with rShh (Figure 4.1B and 4.1D respectively). For example, there was a significant 
increase of approximately 1.5 fold in CD23 expression in B cells treated with 
0.005µg/ml rShh at 18hours post-activation stimulus (Figure 4.1A) and a significant 
decrease in annexin-V staining of 60% (Figure 4.1C). This data indicated that B cell 
  
 61 
survival was greatly enhanced in B cells treated with 0.005µg/ml rShh at 18hours post-
activation stimulus. This is followed by a decrease in CD23 expression at 40hours 
(Figure 4.1B) and a significant increase in death of approximately 1.5 fold as judged by 
annexin-V expression in B cells treated with 0.005µg/ml rShh (Figure 4.1D). These 
results confirm that, the results obtained using purified B cells mirrored the results 
obtained using mixed splenocyte cultures, it would appear that the positive and negative 
regulatory effect of rShh on B cell activation and survival at 18 and 40hours post-
activation stimulus respectively was intrinsic to B cells and not due to any other cell 
type present in the mixed splenocyte cultures.  
 
Interestingly, the effects of addition of rShh to the purified B cell cultures with respect 
to CD23 expression and survival were enhanced when using purified B cells in 
comparison to the data obtained using mixed splenocyte cultures (Chapter 3). This 
would indicate that the other cell types contained within the mixed cell cultures had the 
effect of ‘dampening down’ the regulation of the B cell response in the presence of Hh 
signalling. 
 
We have previously used CD23 expression (in Chapter 3) to assess the status of B cell 
activation as it is reported that CD23 expression goes up on B cells upon activation  
(Bonnefoy, 1995). However, expression of CD23 along with other surface markers may 
also be used to characterise the developmental status of B cells in the spleen, as 
different subsets in the spleen, namely T1, T2, T2-MZP and follicular B cells all express 
varying amounts of CD23 on their cell surface (Pillai and Cariappa, 2009). For this 
reason, we chose to analyse expression of another cell surface marker associated both 
with B cell activation and B cell differentiation, CD25.  
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Figure 4.1. Treatment of purified B cells with rShh can affect B cell activation and 
survival at 18hours and post-activation stimulus 
 
Purified B cells were activated with 5µg/ml anti-CD40/IgM and were treated with varying 
concentrations of exogenous rShh (0.005-5µg/ml). Cells were collected and analysed at 
18hours (A) and 40hours (B) post-activation stimulus for B cell activation using anti-CD23, 
an early B cell activation marker. Cells were also analysed at 18hours (C) and 40hours (D) 
post-activation stimulus for apoptosis using annexin-V, an apoptotic marker. The results 
shown in the bar chart are representative of three independent experiments. The 
significance of the differences observed in fold changes in CD23+ cells and Annexin-V+ 
cells was assessed by Student t test (*p≤0.05, **p≤0.01). 
 
4.2.2. CD25 expression in purified B cells treated with rShh 
 
CD25 (IL-2Rα) is a 55kDa polypeptide with an extracellular domain, transmembrane 
domain and a cytoplasmic domain. The gene encoding this protein is located on 
chromosome 10 in humans and 2 in mice (Anderson et al., 1995). The CD25 protein, 
which forms part of the IL-2 receptor (Burlinson et al., 1996), is a molecule normally 
found on particular subsets of B cells; the main function of CD25+ B cells is still 
unclear. CD25 expression on B cells have been characterised in activated B cells, 
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memory B cells and also in regulatory B cells (Amu et al., 2010, Brisslert et al., 2006). 
In mice, CD25 expressing B cells from secondary lymphoid organs showed a mature 
and activated phenotype with high expression of the co-stimulatory molecule CD80 and 
CD86 (Amu et al., 2010). Thus, after observing the effect of Hh signalling on CD23 
expression in B cell activation, we also wanted to investigate the role of Hh signalling 
in B cell activation using expression of CD25 as a marker of late activation. 
 
Purified B cells were activated and then treated with or without rShh as previously 
described in Section 4.2.1. At 18 and 40hours post-activation stimulus, B cells were 
stained with a combination of CD25-FITC, B220-Pe-CY5 and CD23-PE. Initially, activated 
B cells were analysed for their expression of CD25 alone at 18 and 40hours post-
activation stimulus. Figure 4.2, shows CD25 expression in purified B cells treated with 
or without varying concentrations of rShh. At 18hours post-activation stimulus, relative 
to the untreated control, similar low levels of CD25 were expressed, indicating that this 
marker had not yet been expressed on the activated B cells to any significant degree. 
Thus, there was no significant difference in expression of CD25 in the untreated control 
B cells and B cells treated with rShh.  
 
However, at 40hours post-activation stimulus, there was a very significant increase in 
the expression of CD25 expression on B cells treated with 0.005µg/ml rShh. 
Interestingly, an increase in CD25 expression at 40hours in the presence of all doses of 
rShh was observed with the highest increase in expression of 75% observed in the 
presence of the lowest dose of rShh (Figure 4.2).  
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Figure 4.2. Treatment of purified B cells with rShh increases CD25 expression at 40hours 
post-activation stimulus 
 
Purified B cells were activated with 5µg/ml anti-CD40/IgM and were treated with varying 
concentrations of exogenous rShh (0.005-5µg/ml). Cells were collected and analysed at 18 
and 40hours post-activation stimulus. B220+ cells were analysed for anti-CD25, a late B 
cell activation marker. The results shown in the bar chart are representative of three 
independent experiments. The significance of the differences observed in fold changes in 
CD25+ cells was assessed by Student t test (*p≤0.05). 
 
 
We then analysed the co-expression of CD23 and CD25 on the purified B cells 
following co-culture with the activating antibodies and treatment without or with rShh. 
Figure 4.3 and 4.4, shows dot-plots of B cells positive for activation marker CD23 and 
late activation marker CD25 at 18 and 40hours post-activation stimulus respectively. 
Similar low levels of CD25 expression was observed in B cells at 18hours post-
activation (Figure 4.3) indicating that CD25+ B cells do not appear at this early time 
point in our system. At 18hours post-activation stimulus, the percentage of cells that are 
CD23+CD25- was higher in B cells treated with rShh when compared with the 
untreated control.  
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Figure 4.3. CD23 and CD25 co-expression in rShh treated B cells 18hours after activation  
The dot-plots shown in the figure show the result of one experiment representative of three 
independent experiments. The co-expression of CD23 and CD25 of purified B cells treated 
with varying concentrations of rShh (0.005-5µg/ml) at 18hours post-activation stimulus is 
shown where it was observed that CD23+CD25- B cells increases with rShh treatment. 
 
 
Surprisingly, at 40hours post-activation stimulus (Figure 4.4), it was observed that there 
are three populations of B cells, these include, CD23+CD25-, CD23+CD25+ and 
CD23-CD25+ B cells. It was observed that there was an increase in the percentage of 
CD23-CD25+ B cells treated with rShh. For example, as shown in Figure 4.4, in the 
untreated control, the percentage of CD23-CD25+ B cells was 13.7%, which increased 
approximately two-fold to 28.2% in B cells treated with 0.005µg/ml rShh. As observed 
with the previous data, the lowest dose of rShh gave the most dramatic effect. At the 
same time as the appearance of this new subset of CD23-CD25+ cells, there is a 
decrease in the presence of CD23+CD25- cells indicating that as one subset might 
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appears the other disappears. It is interesting to note that the very high dose of rShh 
(5µg/ml) had little effect on the purified B cell subsets at 40hours post-activation 
stimulus.       
 
Taken together this data, it suggests that treatment of B cells with rShh, can increase the 
expression of CD23-CD25+ B cells at 40hours post-activation stimulus, thus indicating 
that Hh signalling can increase B cell differentiation. It would be important to 
characterise these cells further, as they may play a role in the effects of Hh signalling 
observed on B cell activation and survival in our purified B cell culture and mixed B 
cell culture. 
 
Figure 4.4. Treatment of purified B cells with exogenous rShh increases CD23-CD25+ B 
cells 
 
The dot-plots shown in the figure show the result of one experiment representative of three 
independent experiments. The co-expression of early activation marker anti-CD23 and late 
activation marker anti-CD25 in purified B cells at 40hours post-activation stimulus is 
shown.  
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4.2.3. rShh treated B cells differentiate into different subsets.  
 
Upon the observation that, in our system, rShh induces an increase in the representation 
of a subset of B cells that are CD23-CD25+- at 40hours post-activation stimulus, it was 
important to characterize these subsets further. CD25+ B cells have been described to 
play an important role in the immune system and may participate in the pathogenesis of 
inflammation (Amu et al., 2006). In mice deficient for CD25+ B cells, mice suffer from 
a range of auto-reactive diseases including inflammatory bowel disease and rheumatoid 
arthritis (RA) (Amu et al., 2010) thus indicating a regulatory role for CD25+ B cells. In 
T cells, CD25+ T cells have regulatory features and have been shown to supress 
effector T cell functions (van Amelsfort et al., 2004). In mice, Amu et al., 2010, showed 
that CD25+ B cells secrete IL-10 following CpG, LPS and Pam3Cy5 stimulation 
indicating that these B cells may be regulatory B cells (Bregs). They also showed that 
CD25+ B cells had the ability to secrete higher levels of class switched immunoglobulin 
including IgA, IgG thus also having the properties of memory B cells (Amu et al., 
2010). Brisslert et al., 2006, showed that 65% of CD25+ B cells express the memory B 
cell marker CD27 compared to 20% CD25- B cells (Brisslert et al., 2006). Hence, 
CD25+ B cells may either be regulatory B cells (Bregs) as they have been shown to 
secrete IL-10 or memory B cells that secrete class switched immunoglobulins post-
activation. 
 
 
In our system, at 40hours post-activation stimulus, there was an increase in expression 
of CD25+ B cells in B cells treated with rShh (Figure 4.4). It is possible that the 
apparent down-regulation of activation and increased levels of apoptosis induced by 
rShh signaling in B cells at 40hours post-activation stimulus in our system might be due 
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to the increased numbers of CD25+ B cells that are capable of producing IL-10. Thus, 
in order to identify if these CD25+ B cells are Bregs or memory B cells, we analyzed 
expression of IL-10 (Mauri and Bosma, 2012)  and CD27 (Agematsu et al., 2000) as 
surrogate markers of Bregs and memory B cell respectively.  
 
Based on previous findings using varying concentration of rShh in mixed B cell cultures 
and purified B cell cultures, we determined that the optimal concentrations of rShh that 
gave the clearest result were 0.05µg/ml and 0.005µg/ml based on the data on activation 
and survival (Figure 3.4A&C and Figure 4.1A&C) and thus for further experiments, 
these two concentrations would be used either together or alone. 
 
Purified murine B cells were activated and at 40hours post-activation stimulus, cells 
were stained with a combination of anti-CD23-PE, anti-CD25-Pe-Cy5.5, anti-CD27-FITC or 
IL-10-FITC. At 18hours post-activation stimulus, neither IL-10+ B cells nor CD27+ B 
cells were observed in our culture. As previously described, at 40hours post-activation 
stimulus (Figure 4.7), we observed three distinct subsets of B cells and named them 
subset I (CD23+CD25-), subset II (CD23+CD25+) and subset III (CD23-CD25+). We 
then analyzed these subpopulations for their expression of CD27 and IL-10. This was 
done in order to identify if the CD23-CD25+ population observed in B cells treated with 
rShh at 40hours post-activation stimulus in purified B cells were either memory B cells 
or possibly Bregs.  
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Figure 4.5. Three subsets observed at 40hours post-activation stimulus 
 
Purified B cells were activated with 5µg/ml anti-CD40/IgM either with or without rShh. At 
40hours post-activation stimulus, co-expression of CD23 and CD25 was analyzed. Three 
subsets, named subset I, II and III were identified and analyzed for their expression for 
CD27 and IL-10. The histogram shown is from one experiment representative of three 
independent experiments. It shows subset I, II, III and their expression of IL-10 and CD27.  
 
 
At 40hours post-activation stimulus (Figure 4.5), we observed that B cells in subset I 
(CD23+CD25-) do not express IL-10 neither do they express CD27 suggesting that this 
subset of B cells is neither memory B cells nor regulatory B cells. Interestingly, we 
observed that subset II (CD23+CD25+) B cells were positive for IL-10 expression but 
not subset III (Figure 4.5). For example, subset II have 22.4% of B cells positive for IL-
10 compared to the 4.2% and 1.2 % observed in subset I and III respectively (Figure 
4.5).  
 
 
When we analyzed CD27 expression, we observed that subset III (CD23-CD25+) B 
cells express the highest level of CD27 (Figure 4.5). This led to the conclusion that in 
our system, upon activation the B cells may develop to become at the minimum, one of 
three different populations. These populations include subset I, which we speculate 
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includes early activated B cells or FO B cells as they are high in the activation marker 
CD23, subset II, which we speculate include regulatory B cells as they express IL-10 
and subset III which we suggest could be memory B cells as they are high in expression 
for the human memory B cell marker CD27.  
 
4.2.4. Hh increases the expression and secretion of IL-10 
 
The human and murine IL-10 cytokine is a non-covalent linked homodimer consisting 
of 160 amino acids. IL-10 is a potent anti-inflammatory cytokine expressed by cells of 
both the innate and adaptive immune system including B cells, T cells, and 
macrophages. It is a multifunctional cytokine with diverse effects, which include 
inhibition of inflammation via several mechanisms including down regulation of the 
production of pro-inflammatory cytokines such as IFN-α, IL-6, IL-12 (Couper et al., 
2008) and prevention of autoimmune pathologies such as those observed in murine 
collagen induced arthritis models (Saraiva and Garra, 2010, Mauri et al., 2003). The 
term “regulatory B cells” was first presented by Mizoguchi et al., 2000, in which B cells 
were able to suppress auto-immune disease in a mouse inflammatory bowel disease 
model (Mizoguchi et al., 2000). Since this initial study, Bregs have also be shown to 
ameliorate the onset of experimental autoimmune encephalomyelitis (Evans et al., 
2007). Bregs are distinguished from other B cell populations by their ability to secrete 
the anti-inflammatory cytokine IL-10. Bregs have been suggested to develop from the 
immature B cell pool, T2-MZP in the spleen following CD40 and TLR stimulation 
(Mauri and Bosma, 2012, Mauri and Blair, 2014, Kalampokis et al., 2013).  
 
 
Having identified these different subsets of differentiating B cells in our culture at 
40hours post-activation stimulus and showing that subset II (CD23+CD25+) were 
positive for IL-10 (Figure 4.5), we then further analyzed IL-10 production in subset II 
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(CD23+CD25+) in B cells treated with or without exogenous rShh. Intracellular IL-10 
staining was carried out at 40hours post-activation stimulus; Figure 4.6A, shows 
histograms representing IL-10 expression at 40hours post-activation stimulus. The 
percentage of B cells expressing IL-10 has increased from 11.0% in the untreated 
control to 16.5% in B cells treated with 0.05μg/ml rShh (Figure 4.6A). This increase of 
IL-10+ cells was significant as seen in Figure 4.6B; there was approximately 1.5 fold 
increase in IL-10 expression in the treated B cells in the late 40hours time point as 
compared to the untreated control.  
 
 
To confirm the increase detection of intracellular IL-10+ cells correlates with an 
increase in IL-10 secretion by B cells, the supernatants were analyzed for the presence 
of IL-10 protein in culture using an ELISA assay. Consistent with the results observed 
when analyzing intracellular IL-10 expression, there was also a significant increase in 
the levels of IL-10 being secreted by B cells treated with 0.05μg/ml rShh at 40hours 
post-activation stimulus (Figure 4.6C). For example, the mean of the untreated control 
B cells secreted was 22ng/ml of IL-10 and this significantly increased to 26ng/ml of IL-
10 in B cells treated with 0.05μg/ml rShh. Addition of rShh has been previously shown 
to induce the expression of IL-10 via STAT-3 in pancreatic acinar cells suggesting that 
this phenomenon may not be exclusive to B cells. In 2012, Zhou et al, showed that the 
presence of rShh induces expression of the Hh target gene, IL-10 and this reduced the 
inflammatory activities in acute pancreatitis in a mouse model (Zhou et al., 2012). 
 
 
Taken together, these results suggest that Hh signaling, can increases the differentiation 
to B cells that can secrete IL-10 at 40hours post-activation stimulus. 
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Figure 4.6. Treatment of B cells with exogenous rShh can increase IL-10+ B cells and IL-
10 secretion 
 
Purified B cells were activated and treated with 0.05µg/ml rShh. At 40hours post-
activation stimulus, B cells were gated on CD23+CD25+ and analyzed for intracellular IL -
10+ B cells. The histograms shown in (A) are from one experiment representative of three 
independent experiments and it shows IL-10+ B cells. A bar chart representing the IL-10+ 
B cells in (B). Supernatants from B cell cultured either with or without treatment with rShh 
were analyzed for IL-10 secretion and it is represented in a bar chart (C). The data 
presented in the bar chart is representative of three independent experiments. The 
significance of IL-10+ cells in fold change and IL-10 concentration was determined using 
Student t test (*p≤0.05, **p≤0.01). 
 
 
 
4.2.5. Hh signaling up-regulates the expression of CD27 
 
Memory B cells can either be formed in a T-dependent manner or T-independent 
manner (Kurosaki et al., 2015).  T-independent memory B cells are generated from the 
B1 B cell pool and in the peritoneal cavities of rodents. Memory B cells have the ability 
to respond, upon second reencounter with an antigen, in an accelerated fashion with 
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higher efficacy. They have the ability to rapidly differentiate into plasma cells secreting 
specific antibodies against their cognate antigen (Kurosaki et al., 2015). CD27 is a type 
1 glycoprotein with unique cysteine rich motifs that is expressed on some B cells and 
majority of T cells and is a member of the tumor necrosis (TNF) receptor family. 
Expression of CD27 has previously been used to characterize memory B cells in 
humans (Amu et al., 2007). These CD27 expressing B cells have been shown to 
produce more IgE, IgA, IgM and IgG subclasses suggesting that they are class switched 
primed B cells and thus memory B cells (Agematsu et al., 2000). It was demonstrated 
previously that, CD27 is expressed in subset III (CD23-CD25+) (Figure 4.5). To 
investigate whether the expression of this memory B cell marker is modulated by Hh 
signaling, expression of CD27 was analyzed in the in B cells treated with rShh at 
40hours post-activation stimulus in the subset III (CD23-CD25+).  
 
Figure 4.7A, shows histograms representing CD27 expression in CD23-CD25+ B cells 
at 40hours post-activation stimulus. CD27 expression has increased from 22.2% in the 
control to 28.5% in B cells treated with 0.05μg/ml rShh. This increase in expression of 
CD27 was significant as illustrated on the bar chart (Figure 4.7B).  
 
From these results, it may be concluded that Hh signaling is apparently capable of 
driving B cell development preferentially to become B cells that can secrete IL-10 and 
also B cells with a memory B cell like phenotype. 
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Figure 4.7. Treatment of purified B cells with rShh increases CD27+ B cells 
 
Purified B cells were activated and treated with 0.05µg/ml rShh. At 40hours post -
activation stimulus, CD27, a putative memory B cell marker was analysed. The histograms 
shown in (A) are from one experiment representative of three independent experiments and 
it shows CD27+ B cells that were analyzed in subset III. A bar chart representing the 
percentage of CD27+ B cells in (B). The data presented in the bar chart is representative of 
three independent experiments. The significance of CD27+ cells in fold change was 
determined using Student t test (**p≤0.01). 
 
 
 
4.2.6. The effect of exogenous rShh on antibody production by purified B cells. 
 
It has been reported that stromally produced Hh play a role in the proliferation and 
antibody production by GC B cells (Sacedon et al., 2005). Having looked at the effect 
of rShh on peripheral B cells with respect to activation, survival and differentiation, it 
was important to analyse the effect of rShh on the production of antibodies by B cells.  
Purified B cells were activated either with or without treatment with 0.05μg/ml rShh. At 
18 and 40hours post-activation stimulus, supernatants were collected and analysed for 
  
 75 
production of the different isotypes of antibody using an ELISA assay. Six-mouse 
antibody isotype were analysed and these include IgG1, IgG2a, IgG2b, IgG3, IgA and 
IgM. IgG antibodies make up to 90% of the blood sera, they play a role in the front line 
of immunity. IgG1 is more induced relative to the other IgG subclasses and is associated 
with Th2 function together with IgE (Vidarsson et al., 2014). IgG2 is usually secreted in 
response to bacterial antigens. IgG3 is a potent pro-inflammatory antibody and has 
effector functions (Vidarsson et al., 2014). IgA is an antibody that plays a role at the 
muscosal surfaces and it is involved in fighting off infection in the gut.  IgM is the main 
antibody secreted in a primary immune response and it functions mainly by opsonizing 
antigen for destruction and fixing complement (Schroeder and Cavacini, 2010). 
 
 
Figure 4.8, shows secretion of different antibody isotypes by activated purified B cells 
after rShh treatment. At 18hours post-activation stimulus, there was an increase in 
antibody production of each isotype of immunoglobuin in B cells treated with 
0.05μg/ml rShh when compared with the control (4.8A, B, C, D, E, and F). This finding 
is consistent with the fact that at 18hours post-activation stimulus, we are getting an 
apparent increased B cell activation with treatment with rShh, This is also consistent 
with results obtained by Sacedon et al., (2005) which showed that use of the Hh 
signalling antagonist, cylcopamine, reduced antibody production by GC B cells.  
 
 
For example, at 18hours post-activation stimulus, the levels of secretion of IgG2a 
(Figure 4.8B) in B cells treated with 0.05μg/ml rShh was significantly increased (1.3 
fold higher) when compared to untreated control B cells and this was true for all the 
isotypes analysed. Interestingly, although, there was an increase in antibody secretion 
by treated B cells at 18hours post-activation, at 40hours, a quite different effect was 
observed. At this time point, while the levels of the different antibody isotypes had 
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almost doubled from 18 to 40hours following activation in the untreated control 
supernatants, the levels of antibody production by B cells in the treated with rShh had 
not increased significantly between the 18 to 40hours time points. For example, with 
IgG1 (Figure 4.8A), the untreated control have significantly increased antibody 
production by approximately 1.7 fold change between 18 and 40hours compared to B 
cells treated with 0.05µg/ml rShh which have remained almost the same (Figure 4.8A).  
 
 
These results suggest that treatment of B cells can increase antibody production at 
18hours post-activation, which might be as a result of increased B cell activation. 
However, at 40hours post-activation stimulus, there is no further increase in antibody 
production, possibly as a result of the increased apoptosis observed at this time-point or 
as a result of an increased differentiation of B cells towards B cells secreting IL-10 or B 
cells that exhibit a memory B cell like phenotype. 
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Figure 4.8. Treatment of B cells with exogenous rShh can affect antibody production by 
purified B cells 
 
Purified B cells were activated with anti-CD40/IgM and treated either with or without 
treatment with 0.05µg/ml rShh. At 18 and 40hours post-activation stimulus, supernatants 
were collected and analyzed for the production of antibody isotypes including IgG1 (A), 
IgG2a (B), IgG2b (C), IgG3 (D), IgA (E) and IgM (F) using ELISA. The bar charts shown 
are representative of four independent experiments. The significance of antibody 
production in fold change was determined by Student t test (*p≤ 0.05, **p≤ 0.01).  
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4.2.7. IL-6 secretion is increased in the presence of rShh 
 
Interleukin 6 (IL-6) is a pleiotropic cytokine that has been initially characterized as a 
cytokine that enhances differentiation of B cells into antibody producing B cells (Amu 
et al., 2009, Kishimoto, 2010). IL-6 is a pro-inflammatory cytokine produced by 
antigen presenting cells (APCs) including macrophages, dendritic cells and B cells. IL-6 
binds to a receptor complex consisting of the specific IL-6Rα and the gp130 signal-
transducing unit that activates the transcription factor STAT-3 among other signalling 
molecules. Over expression of IL-6 in mice causes plasmocytosis, indicating it can 
promote differentiation of B cells into plasma cells (Dienz et al., 2009, Kishimoto, 
2010). IL-6 can also control B cell survival and proliferation as it regulates Blimp-1via 
STAT-3 which drives the production of immunoglobulin (Hunter and Jones, 2015). In 
multiple myeloma (MM), where Hh signalling has been shown to play a role in its 
pathogenesis, there is an observed increase in B cell proliferation (Peacock et al., 2007). 
Increased IL-6 production has also been shown to be correlated with increased 
inflammatory activity and may contribute to the onset of pathogenesis associated with 
chronic inflammatory disease and also Systemic Lupus Erythematosis (SLE) and RA 
(Urashima et al., 1996, Dayer and Choy, 2010). Conversely, IL-6 has also been shown 
to have anti-inflammatory properties via the induction of IL-10 and TGF-α (Scheller et 
al., 2011) indicating a complex role for this cytokine in regulating immune responses.  
 
 
In our experiments, at 18hours post-activation stimulus, we observed that there is 
antibody production in B cells treated with rShh. As IL-6 plays an essential role in 
promoting B cell differentiation into IgG secreting B cells (Maeda et al., 2010), we 
hypothesised that this increase in Ig production may be correlated with IL-6 secretion, 
which is able to drive B cells to secrete antibody in our culture. Additionally, it has 
previously been shown by Wakelin et al., (2008), that the Hh signalling pathway has the 
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ability to up-regulate the production of IL-6, IL-8, MCP-1, IP-10, MIG and RANTES 
by macrophages (Wakelin et al., 2008). Furthermore, the downstream effects of the Hh 
signalling pathway in fibroblasts have been shown to be mediated via the transcription 
factor GLI-1, inducing it to bind to the IL-6 promoter thus increasing IL-6 expression in 
a paracrine manner (Mills et al., 2013) 
 
Figure 4.9, shows the IL-6 secretion by B cells treated with or without 0.05μg/ml rShh 
at 18 and 40hours post-activation stimulus. At 18hours post-activation stimulus, there 
was a significant increase in secretion of IL-6 in B cells treated with rShh to 
approximately 0.23ng/ml compared to the level determined for the untreated control of 
0.10ng/ml. This is consistent with the finding that at 18hours, there is an increase in 
antibody produced by B cells in the treated with rShh compared to the control. At 
40hours post-activation stimulus, as observed for antibody secretion by B cells (Figure 
4.9), the level of IL-6 secretion doubled in the activated untreated control whereas in 
treated B cells, there was no further increase in IL-6 secretion from 18 to 40hours in 
culture. Indeed, there was a slight but insignificant reduction in secretion of IL-6 
(Figure 4.9).  
The increase in IL-6 from 18 to 40hours in the untreated control is correlated to the 
increased antibody being produced at 40hours whereas the apparent arrest in further 
secretion of IL-6 at 40hours correlates with the arrest in antibody production observed 
at 40hours in the presence of rShh. Taken together these data would suggest that 
enhanced Hh signalling at 18hours post-stimulus may induce the secretion of IL-6 
which in turn induces enhanced production of isotype switched antibodies. However, at 
40hours, post-activation stimulus, there may be no further secretion of IL-6 in B cells 
treated with exogenous rShh, possibly as a result of increased apoptosis of B cells 
  
 80 
secreting the cytokine, or as a result of increased differentiation of B cells towards B 
cells that no longer secrete IL-6. 
 
 
Figure 4.9. Treatment of purified B cells with rShh can affect IL-6 secretion 
 
Purified B cells were activated and treated with or without 0.05µg/ml rShh. At 18 and 
40hours post-activation stimulus, supernatants were collected and analysed for IL-6 
secretion using ELISA. The bar chart shown is representative of four independent 
experiments. The significance of IL-6 concentration was determined using Student t test 
(*p≤0.05). 
 
4.2.8. B cell proliferation in the presence of rShh 
 
The combination of B cell receptor and CD40 ligation, along with certain other signals 
thought to be derived from direct T-cell contact such as IL-4, leads to B cell 
proliferation or clonal expansion of B cells specific for a particular antigen. Several 
rounds of proliferation need to occur prior to antibody production in vivo. It was 
important therefore, to investigate the effect of Hh signalling on B cell proliferation. 
 
 
In order to analyse proliferation, we used CFSE conjugated to FITC. This is a cell 
proliferation dye, which enters the cell, where it crosslinks with certain intracellular 
proteins. Upon cell division, there is a successive halving of the fluorescence intensity 
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as the daughter cells share out the fluorescently labelled intracellular proteins (Hawkins 
et al., 2007). 
 
Purified B cells were stained with 10μm CFSE before activating with 5μg/ml anti-
CD40/IgM and IL-4 (5μg/ml). The cells are then cultured for 72hours and 96hours, 
these time points were chosen as there were few proliferating cells detected using CFSE 
at 18 and 40hours post-activation stimulus. At 72 and 96hours post-activation stimulus, 
the purified B cells were analysed for proliferation by flow cytometry. Proliferation was 
analysed by calculating the levels of CFSE staining remaining within the total 
population.  
 
Figure 4.10, shows CFSE staining at 72hours post-activation stimulus. It was observed 
that there was a significant decrease in percentage of resting B cells in B cells treated 
with rShh indicating that Hh signalling was driving B cell proliferation. For example, 
the percentage of resting B cells have decreased from 27.9% in the control to 23.1% in 
B cells treated with 0.005μg/ml rShh  and this was significant as shown in Figure 
4.10B. Consistent with this, there was also an increase of B cells that had entered the 1st 
and 2nd cycle of division in the presence of both doses of rShh (Figure 4.10C and D). 
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Figure 4.10. Treatment of purified B cells with rShh increases B cell proliferation at 
72hours post-activation stimulus 
 
Purified B cells were stained with CFSE, then activated and treated with rShh. At 72hours 
post-activation stimulus, B cells were measured for CFSE intensity. A representative dot -
plot from one experiment representative of three experiments is shown in (A). It shows B 
cells that are non-dividing (resting), in the 1st cycle and 2nd cycle of division. Bar chart 
illustrating B cells that are resting (B), 1st cycle (C) and 2nd cycle (D). The data in the bar 
chart is representative of three independent experiments. The significance of the data in 
fold change was assessed using Student’s t test (*p≤ 0.05, **p ≤ 0.01).  
 
At 96hours (Figure 4.11), the percentage of B cells in the resting phase, 1st, 2nd and 3rd 
cycle of division was analysed. There was a significant increase in percentage of B cells 
that had entered the third cycle of division in the presence of 0.05μg/ml compared to the 
untreated control (Figure 4.11D). These results suggest that Hh signalling can promote 
B cell proliferation in vitro. These findings are consistent with the results obtained by 
Sacedon et al. (2005), using cyclopamine; an inhibitor of the Hh signalling pathway, 
they showed that inhibition of the Hh signalling pathway can inhibit B cell proliferation 
(Sacedon et al., 2005). 
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Figure 4.11. Treatment of purified B cells with rShh increases B cell proliferation at 
96hours post-activation stimulus 
 
Purified B cells were stained with CFSE, then activated and treated with rShh. At 96hours 
post-activation stimulus, B cells were measured for CFSE intensity. The percentages of B 
cells are resting (A), 1st cycle (B) 2nd cycle (C) and the (D) 3rd cycle is shown in the bar 
charts. The data in the bar chart is representative of three independent experiments. The 
significance of the data in fold change was assessed using Student’s t test (*p≤ 0.05, **p ≤ 
0.01).  
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4.3. Discussion 
 
In the previous chapter (Chapter 3), data presented demonstrated that Hh signalling 
could have an effect on B cell activation and survival in B cells in a mixed splenocyte 
population. However, it was possible that the effect observed on B cells in the mixed 
splenocyte population was due to the presence of other cell types in the spleen or from 
soluble factors produced by these other cell types. Thus, the aim of this Chapter was to 
investigate the effect of exogenous rShh treatment on purified B cells. 
 
 
The data presented in this chapter demonstrates that treatment of purified B cells with 
exogenous rShh can increase B cell activation (as judged using CD23) and survival (as 
judged using Annexin-V) at 18hours post-activation stimulus and at 40hours, there was 
a decrease in B cell activation and increased apoptosis. The findings demonstrate that 
the effect of exogenous rShh treatment on B cells with emphasis to activation and 
survival was intrinsic to B cells and not due to any other cellular subset present within 
the spleen. The effect observed was more prominent in the purified B cell experiments 
when compared to the mixed cultures (Chapter 3) thus suggesting that in the mixed 
cultures, the other cell types may influence the response of B cells to exogenous rShh.  
 
 
Additionally, using late B cell activation marker, anti-CD25, it was observed that, 
treatment of B cells with rShh increases the expression of this late B cell activation 
marker at 40hours post-activation stimulus. Furthermore, it was demonstrated that at 
40hours post-activation stimulus, three populations of B cells was observed (Figure 4.7) 
and these were characterised as subset I (CD23+CD25-), subset II (CD23+CD25+) and 
subset III (CD23-CD25+), with rShh treatment increasing the representation of subset 
III and decreasing the representation of CD23+CD25- B cells at this time point. As 
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CD25+ B cells have been characterised as either Bregs or memory B cells, these subsets 
were analysed further using Bregs marker, IL-10 and memory B cell marker CD27. 
 
 
Co-analysis of IL-10 and CD27 showed that subset I, does not express either of these 
markers suggesting that this subset may represent B cells of an earlier, less mature 
lineage such as antibody secreting FO B cells. A proportion of subset II B cells express 
IL-10 and are potentially Bregs while the subset III were positive for CD27, suggesting 
they may be memory B cells (Figure 4.7).  It was demonstrated that treatment of B cells 
with exogenous rShh increases IL-10+ and CD27+ B cells. Additionally, it is possible 
that the enhanced production of IL-10 in the presence of rShh by B cells (Figure 4.8 and 
4.9) might be responsible for causing the observed down-regulation in B cell activation, 
antibody secretion and enhanced cell death observed at 40hours in our mixed splenocyte 
culture and purified B cell culture (Figure 4.2 and Figure 4.3). The increase of CD27 
expression and IL-10 in our culture suggests that Hh signaling can regulate B cell 
development in the periphery, possibly accelerating the process of B cell development 
preferentially into certain lineages. 
 
 
Furthermore, it was observed that treatment of B cells with rShh can increase antibody 
production and IL-6 secretion at 18hours post-activation stimulus and at 40hours post-
activation stimulus, the levels has not increased much compared to the untreated control. 
It is possible, that at 18hours, treatment of B cells with exogenous rShh can increase the 
immune response by B cells but at 40hours, it is possible that the increased B cell death 
is correlated to B cells that secrete antibody and IL-6. Additionally, it is possible that at 
40hours post-activation in our culture, Hh signalling induces the expression of another 
morphogen, which has the capacity to negatively regulate the production of antibodies 
such as BMP-4, which has been shown in Chapter 3 to exert a negative regulatory effect 
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on B cell activation and survival or alternatively, that the increased apoptosis, might 
represent the decrease in antibody secreting cells.  Additionally, when B cell 
proliferation was analysed using CFSE at 72 and 96hours, Hh signalling was shown to 
increase levels of B cell proliferation thus suggesting that Hh may act to accelerate 
many aspects of B cell differentiation in the periphery. 
 
 
In conclusion, the findings in this chapter demonstrate that Hh signaling can drive 
peripheral B cell differentiation, at 18hours, post-activation stimulus, Hh signaling 
appears to increase differentiation of B cells that secrete antibody and IL-6, possibly FO 
B cells. However, at 40hours post-activation stimulus, Hh signaling would also appear 
to be driving the B cells to differentiate into B cells that secrete IL-10 or B cells that 
display a memory like phenotype. This process of lineage commitment in B cells is not 
well understood and is no doubt driven by the expression of particular transcription 
factors that may indeed be transcriptional targets of Hh signaling. It is thus important to 
further characterize the subsets I-III in terms of the cellular subsets that would normally 
be observed in the mouse spleen in order to ascertain their true function in vivo. For this 
reason, sorting of the subsets was carried out so that the phenotype and function of each 
isolated subset could be observed in vitro. Having identified an effect caused by the 
presence of enhanced levels of exogenous Hh, it was also important to analyze the 
effects of the presence of reduced levels of Hh protein.  
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4.4. Conclusion 
 
The outcomes of this chapter demonstrate that Hh signalling can increase activation of 
B cells as assessed by CD23 expression and survival at 18hours post-treatment, as was 
also observed in the mixed splenocyte culture thus confirming that the effect of Hh 
signalling in B cell development is intrinsic to B cells and not due to any other cell type 
in the spleen. We showed that Hh signalling modulates antibody production, IL-6 and 
IL-10 secretion in B cells at these different time points. We have also shown, that Hh 
signalling appears to drive B cell differentiation towards both memory B cells and 
Bregs at 40hours post-activation stimulus.  
 
Taken together, these data suggest an important role for Hh signalling in driving 
development, survival and lineage commitment decisions in B cells following 
stimulation by a signal that mimics the presence of a TD antigen.  The next chapter 
extends the findings of this chapter by carrying out a functional sorting assay in order to 
identify the true function of the individual subsets in isolation. 
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Chapter 5: Characterisation and sorting of peripheral B cell 
subsets  
 
5.1.  Introduction  
 
5.1.1.  Peripheral B cell subsets and surface marker expression  
 
 
Newly generated antigen receptor bearing B cells in the bone marrow either mature in 
this site or migrate to the peripheral lymphoid organs such as the spleen. The naïve B 
cells leave the bone marrow as transitional B cells, where they are still functionally 
immature, have a short half-life and a tendency to undergo apoptosis rather than 
proliferate following BCR engagement (Allman and Pillai, 2008). Loder et al., (1999) 
first proposed that immature B cells or transitional B cells in the adult spleen may be 
subdivided into two distinct subsets (T1) and (T2) based on their expression of IgD and 
CD21 (Loder et al., 1999), and then subsequently a third transitional B cell was 
identified thought to be implicated in the development of autoimmunity, T3 (Allman et 
al., 2001).  Immature B cells enter the spleen as T1 B cells that can develop further 
upon BCR stimulation to become T2 B cells, follicular B cells (FO), T2-marginal zone 
B cells precursor (T2-MZP) and marginal zone (MZ) B cells. Depending on the surface 
marker expression on B cells, these different subsets of B cells in the spleen can be 
identified (Figure 5.1). In the mouse, subsets of B cells can be most easily distinguished 
by their expression of some or all of the markers including IgM, IgD, CD21, CD1d, 
CD23, CD24, CD93 (Blair et al., 2008). The cell surface markers expressed on human 
B cells show a pattern of expression that differs markedly from the mouse. 
 
Transitional B cell subsets express the B-lineage precursor marker CD93. They also 
express low to intermediate levels of CD21 and subsets are differentiated by levels of 
IgM and CD23 surface expression (Allman and Pillai, 2008). T1 B cells are 
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characterised as CD23-CD21-IgD-IgMhi. T1 B cells can differentiate to become T2 B 
cells, which are characterised as CD23+, IgDhi, IgMhi. T2 B cells can develop into T3 B 
cells, which are CD23+IgDhighIgMlow (Allman and Pillai, 2008, Pillai and Cariappa, 
2009, Carsetti et al., 2004). Depending on the type or strength of the signal received via 
the BCR, T2 B cells can give rise to mature B cells. This differentiation involves the 
activity of signalling pathways such as those mediated by BAFF, NF-κB, Notch2 and 
Bruton’s tyrosine kinase (Btk) (Pillai and Cariappa, 2009). 
 
 T2 B cells can differentiate to become FO B cell type 1 (FO-I) characterised as 
CD23+IgDhighIgMlowCD21mid, which requires strong BCR signalling triggered by high 
affinity antigens and Btk signalling or FO B cell type II (FO-II) characterised as 
CD23+IgDhighIgMhighCD21mid, which is Btk independent (Pillai and Cariappa, 2009). 
More recently, it has been suggested that FO-II serves as an intermediate for T2 
differentiation towards FO-I and MZ B cells (Figure 5.1) (Kleiman et al., 2015).  
 
FO-I B cells specialize in T cell dependent immune responses while the function of FO-
II B cells is unknown. However, FO-II B cells can potentially represent a reservoir from 
which to rapidly obtain MZ B cells, following depletion by blood borne pathogens by 
first differentiating to become T2-MZP and then MZ B cells (Pillai and Cariappa, 2009, 
Cariappa et al., 2007, Kleiman et al., 2015). 
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Figure 5.1. Peripheral B cell differentiation 
 
A schematic diagram, illustrating peripheral B cell differentiation and their surface marker 
expression. Peripheral B cells differentiate according to a signal strength model. When 
antigens weakly triggers the BCR, it results in insufficient Btk, which leads to activation 
of Notch2, thus differentiation towards MZ B cells. Conversely, strong BCR signal lead to 
the activation of Btk which increases differentiation of B cells into FO-I. Adapted from 
(Kleiman et al., 2015, Pillai and Cariappa, 2009). 
 
 
T2-MZP B cells can arise directly from the T1, T2 or FO-II B cell pool as a result of 
weak BCR signals and Notch2 signalling via Delta-like 1 (Kleiman et al., 2015, Pillai 
and Cariappa, 2009). T2-MZP B cells can be characterised as 
CD23+IgDhighIgMhighCD21high (Blair et al., 2008) and can differentiate into MZ B cells 
which are CD23-CD21highIgD+IgMhigh (Pillai and Cariappa, 2009). The surface marker 
expression of peripheral B cell subsets is shown in Table 5.1. 
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Table 5.1. Markers used to characterise different B cell populations in the spleen 
B cell 
phenotypes 
IgD IgM CD23 CD21 
T1 - + - - 
T2 +++ +++ + ++ 
FO-I +++ + + ++ 
FO-II +++ +++ + ++ 
T2-MZP +++ +++ + +++ 
MZ + +++ - +++ 
 
 
In the spleen, various B cell populations can be characterized using several surface 
markers. These markers can be used to distinguish between T1, T2, FO-I, FO-II and MZ B 
cells. +Low, ++mid, +++high (Allman and Pillai, 2008, Pillai and Cariappa, 2009, Su et al., 
2004, Carsetti et al., 2004). 
 
 
5.1.2. Objectives 
 
In Chapter 4, three subsets of B cells were shown to emerge at 40hours post-activation 
stimulus characterised by differential expression of CD23 and CD25. The objectives of 
this chapter are: 
 To isolate the different subset populations by cell sorting in order to assess the 
functional properties of each of these B cell subsets in isolation.  
  To extensively characterize the B cell subsets in the periphery after treatment 
with rShh at 18hours and 40hours post-activation stimulus.  
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5.2.  Results 
5.2.1. Functional sorting assay 
 
5.2.1.1.Morphological characteristics of sorted B cell population 
 
In Chapter 4, three subsets of B cells were shown to emerge at 40hours post-activation 
in culture and these were called subset I (CD23+CD25-), subset II (CD23+CD25+) and 
subset III (CD23-CD25+).  Subset II and III were shown to be positive for IL-10 and 
CD27 respectively, with treatment of rShh increasing the expression of these markers 
on B cells at this time point. Thus, it became important to ascertain, and to further 
characterize, the identity of these subsets and attempt to evaluate their individual 
contribution to the B cell immune response after treatment with rShh.  
 
Purified mouse splenic B cells were activated with 5μg/ml anti-CD40/IgM and treated 
without (Control (C)) or with (Treated (T)) 0.05μg/ml rShh and cultured for 40hours. 
Following 40hour post-activation stimulus, B cells were stained with a combination of 
anti-CD23-FITC and anti-CD25-PE before sorting into three subsets (Figure 5.2B); 
CD23+CD25-, CD23+CD25+ and CD23-CD25+. The subsets sorted from the control 
(C) and treated B cells (T) were then cultured once again either with 0.05μg/ml rShh (-
T) or without (-C) treatment overnight. A schematic illustration of the sorting 
experiment is shown in figure 5.2A. The nomenclature of the experimental conditions is 
shown in Table 5.2. Following overnight culture, sorted B cells were analysed 
morphologically, stained and analysed for cell surface marker expression. Supernatants 
were also collected and analysed for cytokine content and antibody production.  
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Figure 5.2. Sorting of B cell subsets  
 
A schematic diagram illustrating the functional sorting experimental design is shown in 
(A). Purified B cells were activated with 5μg/ml anti-CD40/IgM. At 40hours post- 
activation stimulus, B cells were stained with anti-CD23-FITC and anti-CD25-PE before 
sorting into three populations shown in the dot plot (B) CD23+CD25- (Blue), 
CD23+CD25+ (Pink) and CD23-CD25+(Orange). After sorting, (A), B cell subsets from 
the control and rShh treated were activated and cultured overnight either with or without 
treatment with rShh. The dot plot shown in (B) is from one experiment representative of 
four independent experiments. 
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Table 5.2. Nomenclature of experimental conditions 
 
 
 
 
 
 
Upon activation via the BCR, B cells form an immunological synapse, which is 
characterised by a cluster of key molecules at the interface between two 
‘communicating’ cells such as integrins. The expression of integrins at the cell surface 
allows two or more B cells to adhere to one another thus forming clumps or ‘micro-
clusters’ (Harwood and Batista, 2010, Yuseff et al., 2013). Hence, the extent of B cell 
activation can be visualised by determining the numbers and size of clumps or micro-
clusters of B cells observed in the cultures when analysed under the microscope. Sorted 
populations were first analysed morphologically under the light microscope to access 
for the presence of clumps of activated cells, to observe whether any of the subsets had 
gross phenotypic differences. 
In respect of the sorted CD23+CD25- (Subset I) B cells, clusters of B cells could clearly 
be seen in the control cultures (CC) within which many individual highly refractile cells 
could be observed (Figure 5.3A). This would be consistent with the idea that this subset 
contains within it mostly FO B cells, which are stable and able to respond readily to the 
presence of antigen. When treated with rShh subsequent to sorting (CT) these clusters 
could still be observed but now individual cells did not appear to be so refractile and the 
size of the cluster was reduced (Figure 5.3B). This may be attributable to the induction 
of apoptosis in individual cells within the clusters leading to a loss of cells within the 
clusters.  Interestingly, when analysing for the presence of clusters in CD23+CD25- B 
Codes 
Treated with 
rShh 
before sorting 
Treated with 
rShh 
after sorting 
CC - - 
CT - + 
TC + - 
TT + + 
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cells that had been treated with rShh prior to sorting, these pre-treated B cells (TC) did 
not appear to form clusters and did not look particularly refractile (Figure 5.3C). The 
same was the case for B cells treated with rShh prior to sorting and subsequent to 
sorting (TT) suggesting that treatment of these pre-treated cells with rShh after sorting 
had no consequence for these B cells in terms of activation and survival as apoptosis 
may already have been induced (Figure 5.3D). One possibility is that this induction of 
apoptosis in these cells is actually due to a strengthening of the BCR signal delivered to 
the B cells and thus induced cell death in these B cells (Metzler et al., 2015). 
 
Figure 5.3. CD23+CD25- B cells did not form clumps of activation after rShh treatment 
 
CD23+CD25- B cells were activated with 5µg/ml anti-CD40/IgM overnight with or 
without treatment with rShh. Pictures showing B cell morphology in (A) control (B) 
control B cells treated with 0.05μg/ml rShh, (C), treated B cells, (D), treated B cells 
retreated with 0.05μg/ml rShh. Representative images from three independent experiments 
are shown. 
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Trypan blue is a stain that permeates the nucleus of dead cells thus colouring them blue 
whilst leaving live cells uncoloured (Cooksey, 2014). In order to confirm the hypothesis 
that treatment of sorted CD23+CD25- B cells with rShh induces death in the cells, a 
trypan blue cell count was carried out and is shown in Figure 5.4. The percentage of live 
cells was counted in CD23+CD25- B cells after overnight culture. It was observed that 
CD23+CD25- B cells treated with rShh prior to sorting (TC) and also retreated (TT) had 
less live cells compared to the untreated control (CC). For example, the number of live 
CD23+CD25- B cells in the control (CC) was 11 x104cells/ml compared to 5 x 
104cells/ml in CD23+CD25- B cells treated with rShh (TC) (Figure 5.4.) thus indicating 
that this population of B cells were dying after treatment with rShh thereby highlighting 
a negative regulatory effect for Hh signalling on B cell survival in this subset. 
 
 
Figure 5.4. Decrease in live CD23+CD25- B cells after treatment with rShh 
Live cells from activated CD23+CD25- B cells with or without treatment with rShh was 
counted using trypan blue. Data presented in the bar chart is represent of an average live 
cell count of three independent experiments. 
 
 
After observing these effects in the CD23+CD25- subset, the morphology of 
CD23+CD25+ B cells was then investigated in order to investigate any morphological 
differences between the two subsets. It was observed that the apparently most active 
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subset of all three subsets is CD23+CD25+ as the clusters appeared to be more frequent 
and larger (Figure 5.5A) in the cultures of control cells (CC) compared to those cultures 
containing CD23+CD25- (Figure 5.3A) or CD23-CD25+ alone (Figure 5.6A), These 
findings suggest that this subset was more activated when compared to CD23+CD25- 
(Figure 5.3) and CD23-CD25+ subsets (Figure 5.6) perhaps indicating they have a 
greater potential to survive. While we did not formally quantify this, there were also 
bigger micro-clusters of activation observed in the cultures containing the untreated 
control B cells (CC) (Figure 5.5A) compared to the B cells treated with rShh (CT) 
(Figure 5.5B) suggesting that either less activation of B cells occurs when treated with 
rShh or a greater degree of apoptosis is induced. 
 
When CD23+CD25+ B cells were treated with rShh prior to sorting (TC) (Figure 5.5C) 
a drastically reduced number of clusters was observed and clusters were much smaller 
and less refractile possibly indicating some degree of apoptosis or lessened ability to be 
activated. Surprisingly, these pre-treated cells, when activated subsequent to the sort in 
the presence of rShh (TT) (Figure 5.5D) did appear to form a small number of large 
clusters, unlike CD23+CD25- B cells in which no clusters were formed by these double 
treated cells (Figure 5.3D). This either indicates that these cells survive the double 
treatment far better than the CD23+CD25- subset or retain the ability to be activated, 
possibly attributable to more immature B cells being newly differentiated to FO B cells 
in these cultures and retaining the capacity to be activated. 
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Figure 5.5. B cell activation decreases after treatment with rShh 
 
CD23+CD25+ B cells were activated with 5µg/ml anti-CD40/IgM overnight with or 
without treatment with rShh. Pictures showing B cell morphology in (A) control (B) 
control B cells treated with 0.05μg/ml rShh, (C), treated B cells, (D), treated B cells 
retreated with 0.05μg/ml rShh. Representative images from three independent experiments 
are shown. 
 
 
 
When investigating the morphology of CD23-CD25+, a new and different morphology 
was observed. Untreated control (CC) appeared to take on a more polymorphic 
appearance with some cells apparently becoming adherent and becoming polarised 
(Figure 5.6A). When treated with rShh (CT) cells lost this polymorphic appearance and 
appeared to form clusters of similar shaped cells (Figure 5.6B). When cells were treated 
with rShh prior to sorting (TC), there was an increase in the appearance of the adherent-
type cells and few round lymphocyte-like cells were observed (Figure 5.6C). Upon 
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double treatment of these cells (TT) (Figure 5.6D) the cells took on a similar appearance 
to those observed previously (TC).  
 
These data may suggest either the appearance of a non-lymphocytic cell contained 
within this CD23-CD25+ sorted population or that these cells may become 
differentiated after treatment with rShh to cells that no longer retains the typical 
lymphocytic appearance. Additionally, live cell imaging has shown that upon B cell 
activation, B cells initially bind antigen by forming cellular protrusions that extend from 
the B cell membrane before forming micro-clusters (Tolar et al., 2008). Therefore, there 
is a possibility that CD23-CD25+ B cells may be forming these cellular protrusions that 
would enable them attach to one another during B cell activation but because of the cell 
numbers in the well, these protrusions may become visible. 
 
Taken together these results suggest that treatment of B cells with rShh can regulate B 
cell activation and survival differently in the different subsets. The differences of 
morphology between these subsets indicate that these subsets exhibit different 
phenotype, which result in their unique functions. It also suggests that the treatment of 
rShh can induce different response in these B cell subsets and this can alter the 
differentiation of B cells in vitro. Thus, it is important to introduce the use of more 
markers in order to characterize these individual B cell phenotypes to achieve a better 
understanding of the role of Shh in B cell differentiation. After observing the 
morphological differences of the sorted B cell subset, the expression of surface markers 
was then analysed. 
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Figure 5.6. Morphology of CD23-CD25+ B cells 
 
CD23-CD25+ B cells were activated with 5µg/ml anti-CD40/IgM overnight with or 
without treatment with rShh. Pictures showing B cell morphology in (A) control (B) 
control B cells treated with 0.05μg/ml rShh, (C), treated B cells, (D), treated B cells 
retreated with 0.05μg/ml rShh. Representative images from three independent experiments 
are shown. 
 
 
5.2.1.2. The percentage of CD80+ B cells increases after treatment with rShh 
 
 
 In Chapter 4, it was reported that CD23-CD25+ B cells were positive for the human 
memory B cell marker CD27, which lead to the initial conclusion that this subset of B 
cells contained, amongst them, memory B cells. However, CD27 is a marker for 
memory B cells in humans and it is controversial as to whether or not it is also a marker 
for mouse memory B cells (Agematsu et al., 2000) and thus further characterisation of 
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this subset was required using an alternative marker for mouse memory B cells, CD80, 
(Good-Jacobson et al., 2012, Zuccarino-Catania et al., 2014). 
  
CD80, a B7 family member that can bind to CD28, CTLA-4 and PDL-2 is a marker that 
has been found to be up-regulated in human and murine memory B cells (Good-
Jacobson et al., 2012, Zuccarino-Catania et al., 2014). For this reason, we used CD80 to 
further characterise the CD23-CD25+ B cells.  The three sorted B cell subsets were 
stained using CD80-APC and then analysed for their expression using flow cytometry. 
  
Figure 5.7A, shows dot-plots representing the expression of CD23 and CD80 on the 
three populations of sorted cells. CD23+CD25- B cells are negative for CD80 as only 
7.7% of B cells are CD80 positive suggesting that this subset does not contain memory 
B cells. There is a higher level of expression of CD80 in the CD23+CD25+ B cells with 
18.9% of cells being positive for CD80. Finally, expression of CD80 is at its highest in 
the CD23-CD25+ B cells, as 39.5% of this subset are stained positive for CD80.  This 
data confirms that CD23-CD25+, which was positive for CD27 (as shown in Chapter 
4), and CD80high, does indeed include a memory-like B cell population.  
 
After observing that CD23-CD25+ contained cells that were positive for CD80, we 
asked whether the expression of this marker is modulated by Hh signaling. Indeed, 
CD80 expression was increased on cells contained within the CD23-CD25+ subset 
following treatment with 0.05μg/ml rShh. Figure 5.7B, shows data on B cells that were 
CD80+CD23-CD25+. There was a significant increase in CD80+ B cells that were 
treated twice with rShh of approximately 10% compared to the untreated control. It was 
previously observed in chapter 4, that rShh treatment increases CD27 expression on B 
cells at 40hours post-activation stimulus. The increase in percentage of CD80+ B cells 
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observed in the sorted CD23-CD25+ B cells after treatment with rShh further confirms 
that rShh drives the increased differentiation of B cells to become memory B cells or to 
a cell with a memory-like phenotype. 
 
Figure 5.7. CD80+ B cells increases after treatment with rShh 
 
The dot-plot shown in (A) is representative of one experiment from three independent 
experiments and it shows CD80 expression in the sorted B cell subsets. (B) CD80+ B cells 
in CD23-CD25+ B cells. The results shown in the bar chart are representative of three 
independent experiments. The significance of the difference observed in CD80+ B cells 
was assessed using Student t test **p≤0.01. 
 
5.2.1.3. Cytokine and antibody secretion by the sorted B cell populations 
 
 
In order to functionally characterise the sorted B cell population, we went on to 
investigate whether the different subsets could secrete lineage specific cytokines or 
antibody and whether the levels of secretion differed between the populations. 
  
 103 
Figure 5.8A, shows data on IL-6 secretion by the sorted B cell subsets. From the assay, 
it can be seen that more IL-6 is secreted by CD23+CD25+ B cells under all conditions 
analysed. For example, there was a significant 2.8-fold increase in IL-6 secretion by 
CD23+CD25+ B cells compared to CD23+CD25- in the untreated control (CC). 
Addition of rShh to the overnight cultures (CT) reduced the IL-6 secreted by 
CD23+CD25+ whereas secretion of IL-6 by CD23+CD25- appeared to have increased 
slightly. There was a significant 3.5-fold increase in secretion of IL-6 by cells contained 
within the CD23+CD25+ subset in the treated cells (TC) in comparison to the untreated 
control (CC). However, this increase in IL-6 secretion was lost when cells were treated 
twice with rShh (TT) from an average of 0.55ng/ml to 0.25ng/ml. it was observed that 
CD23-CD25+ secreted the least amount of IL-6 of all the subsets. These results suggest 
that it is the CD23+CD25+ cells that secrete most of the IL-6 and levels of secretion are 
regulated by Hh signalling (Figure 5.6 A). 
 
Figure 5.8B, shows data for IL-10 secretion by the sorted B cell subsets. Interestingly, 
all the sorted B cell subsets are capable of secreting IL-10 under all conditions. It was 
observed that the levels of IL-10 secreted by CD23+CD25- and CD23+CD25+ B cells 
were similar in B cells treated with rShh (TC) prior to sorting with a slight decrease in 
CD23-CD25+ B cells. Surprisingly, the IL-10 concentration decreased when these cells 
where treated twice with rShh (TT). Additionally, it was observed that CD23+CD25- 
cells secreted the most IL-10 of all the subsets in the control (CC). However, when 
control B cells were treated with rShh (CT) subsequent to sorting, IL-10 secretion 
decreased in B cell subsets with the exception of the CD23-CD25+ B cells, which 
showed a 1.5 fold increase in IL-10 secretion. Interestingly, CD23-CD25+ B cells 
secreted IL-10 in all conditions, this result was unexpected, as this subset has been 
characterised to contain memory-like B cells. However, memory B cells have been 
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described as having the capacity to secrete IL-10 after stimulation (Kalampokis et al., 
2013).  These results suggest that upon activation of B cell subsets, they can 
differentiate to become possibly T2-MZP that can secrete IL-10. However, the amount 
of IL-10 was very low and the differences between the amounts secreted by the 
different groups was not significant. 
 
Figure 5.8. Treatment of B cells with rShh can affect cytokine secretion and antibody 
production in sorted B cells 
 
Sorted B cell subsets were activated with 5µg/ml anti-CD40/IgM and were treated with 
rShh overnight. Supernatants were collected and analysed for IL-6 secretion (A), IL-10 
secretion (B), and IgG1 production (C), using ELISA assay. The results shown in the bar 
chart are representative of three or two (C) independent experiments. The significance of 
the difference observed in IL-6 secretion was assessed using Student t test (*p≤0.05). 
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Figure 5.8C, shows IgG1 secretion by all the subsets either with or without treatment 
with 0.05μgml rShh. In all cases, CD23+CD25- B cells secreted the most IgG1 
compared to the other subsets. Treatment with rShh reduced the amount of IgG1 
secreted by all sorted B cell subsets. This data is consistent with the previous findings 
that by 40hours in culture, rShh appears to arrest the production of antibody by B cells. 
From these cytokine assays, antibody secretion assay and cell surface characterisation a 
preliminary conclusion can be made about the different subsets as follows. 
CD23+CD25- B cells are most likely to be FO B cell as this subset showed the highest 
secretion of antibody of all the three subsets and FO B cells has been shown to be 
capable of secreting IL-6 following CD40 ligation, and also secrete antibody (Urashima 
et al., 1996). CD23+CD25+ B cells could secrete IL-6, IL-10 and IgG1 and are positive 
for CD80, which suggests they may be a heterogeneous population of cells containing 
FO and T2-MZP B cells (Blair et al., 2008). CD23-CD25+ B cells, were shown to be 
CD80high and had previously been shown to be CD27+ (Chapter 4). Thus, the CD23-
CD25+ subset contains cells that exhibit a memory-like B cell phenotype (Amu et al., 
2006, Agematsu et al., 2000, Good-Jacobson et al., 2012). Also, MZ B cells are CD23- 
and have been shown to be CD27+ (Garraud et al., 2012) hence it is possible that the 
CD23-CD25+ subset  also contain MZ B cells. Below is a table showing a summary of 
the functions of the sorted B cell subsets. 
 
 
 
 
 
  
 106 
Table 5.3. Summary of functions of sorted B cell subsets 
CD23+CD25- CD23+CD25+ CD23-CD25+ 
Secretes IL-6 Secretes IL-6 Secretes low IL-6 
Secretes IL-10 Secretes IL-10 Secretes IL-10 
Secretes the most Ig Secretes little Ig Secretes little Ig 
CD80- CD80low CD80high 
Possibly contains FO B cells 
(Urashima et al., 1996) 
Heterogeneous mixture 
containing T2-MZP and FO B 
cells (Garraud et al., 2012, 
Urashima et al., 1996) 
Contains memory B cells  
or MZ B cells 
(Amu et al., 2006, Garraud et 
al., 2012, Good-Jacobson et 
al., 2012) 
 
A table illustrating the functions of sorted subsets as observed  
 
 
 
5.2.2. Phenotypic characterisation of B cell subsets in the spleen 
 
5.2.2.1. Characterisation of B cells in the spleen 
 
 
Our data indicates that after rShh treatment, there is an increased differentiation of B 
cells possibly into FO B cells at 18hours post-activation and regulatory B cells and 
memory B cells by 40hours post-activation. It was also observed that the different 
subsets appeared to have different functions associated with these different 
differentiation outcomes. We therefore wanted to carry out further characterisation of 
these subsets in terms of expression of B cell developmental markers. Using surface 
markers that are characteristic of the various B cell subsets in the spleen such as T1, T2, 
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T2-MZP and FO-I or FO-II and MZ B cells, the different developmental stages of B 
cells could be better identified in our culture system.  
As before, B cells were purified by negative selection from the total splenic population. 
In order to identify the B cell population in the spleen that are emerging in our cultures, 
fresh uncultured purified B cells were first analysed and were stained with a 
combination of anti-IgM-PE, anti-CD23-Pe-Cy7, and anti-CD21-APC. B cell populations 
were gated following the protocol and characterisation published by (Carsetti, 2004, 
Kleiman et al., 2015, Pillai and Cariappa, 2009, Rosado et al., 2014). B cells were first 
gated on whether they were CD23+ or CD23-.  Expression of IgM and CD21 was then 
analysed on both the CD23+ and CD23- populations of B cells thus allowing 
identification of T1, T2, FO-I, FO-II and MZ B cells (Carsetti, 2004, Cariappa et al., 
2007, Kleiman et al., 2015, Pillai and Cariappa, 2009).  
 
Figure 5.9, shows dot-plots representing the peripheral B cell subsets in fresh purified B 
cells from the spleen. From our staining results, the B cells from the spleen were found 
to be majorly T2 and FO-II B cells comprising 39.5% of the population and a FO-I B 
cell population comprising 22.1%. Also present, were T1 population (17.8%), T2-MZP 
(8.6%). and MZ B cells of 10.7% (Figure 5.9).  
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Figure 5.9. Peripheral B cell subsets 
 
The dot-plots shown are from one experiment representative of three independent 
experiments in which fresh uncultured purified B cells were stained with anti -IgM, anti-
CD21 and anti-CD23 in order to distinguish peripheral B cell subsets in the spleen.  
 
 
5.2.2.2.Hh signalling increases B cell differentiation to FO and T2-MZP B cells 
 
After identifying our populations of B cells in fresh splenic cell preparations to be 
majorly T2 and FO-II B cells, it became important to ascertain the developmental fate 
of the cultured B cell subsets at 18hours and 40hours post-activation stimulus. Purified 
B cells were activated with 5µg/ml anti-CD40/IgM with or without treatment with 
0.05µg/ml rShh. At 18 and 40hours post-activation stimulus, the B cells were stained 
with combination of anti-IgM-PE, anti-IgD-FITC, and anti-CD23-PeCy7, anti–CD21-
APC. 
In our culture, as the B cells were activated with anti-CD40/IgM, thus B cells were 
activated via a T-dependent manner. Activation of B cells in a T-dependent manner 
drives B cell differentiation towards FO B cell differentiation and thus, MZ B cells 
would not be expected to emerge in increased numbers. T1 B cells would be expected to 
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die as they don’t survive other than for a short period of time in vitro or in the spleen 
(Su et al., 2004). 
Figure 5.10A, shows data on B cell differentiation at 18hours post-activation stimulus. 
In the unstimulated B cells, the major population of B cells, were T2 B cells and FO-II 
B cells which when the B cells are activated differentiate to become 
CD23+CD21midIgMlow FO-I B cells. However, treatment of B cells with 0.05µg/ml rShh 
induces increased B cell differentiation towards FO-I, from 41.6% in the control to 
58.8% in treated B cells and this was significant at this time point (Figure 5.10B). This 
suggests that Hh signalling can increase B cell activation and differentiation towards 
FO-I B cells at 18hours post-activation stimulus. 
 
Figure 5.10. FO-I differentiation increases after treatment with rShh at 18hours post-
activation 
The dot-plots shown in (A) is representative of one experiment from three independent 
experiments and it shows CD21 and IgM expression on CD23+ peripheral B cells after 
treatment with rShh with a bar chart representing this data shown in (B). The results shown 
in the bar chart are derived from three independent experiments. The significance of the 
difference observed in FO-I B cells was assessed using Student t test *p≤0.05. 
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At 40hours post-activation (Figure 5.11A), differentiation towards the FO-I subset has 
decreased with treatment of rShh compared to the untreated control. However, the 
increased emergence of T2-MZP B cells as well as FO-II was identified following 
treatment with rShh. The presence of T2-MZP B cells increases in B cells treated with 
rShh compared to untreated control from 8.7% in the control to 13.3% in the rShh 
treated B cells, however, this difference was not significant (Figure 5.11B). T2-MZP 
have been identified to display regulatory properties, they have been shown to secrete 
the anti-inflammatory cytokine IL-10 (Blair et al., 2008). There was also a reduced FO-
I population in B cells treated with 0.05μg/ml rShh, from 45.2% in the untreated control 
to 32.4% in treated B cells (Figure 5.11A). 
 
In chapter 4, it was shown that treatment of B cells with rShh increased IL-10 secretion 
at 40hours post-activation stimulus. This increase in T2-MZP B cells observed in the 
presence of rShh could account for the increased IL-10 expression and secretion by B 
cells in the presence of Hh signalling. 
 
These findings suggests that Hh signalling has the ability to accelerate B cells 
development to become FO-I, which is Btk signalling dependent, at 18hours post-
activation stimulus (Pillai and Cariappa, 2009) and then either these cells are induced to 
apoptose or the signal may become weakened as cells remain in culture for 40hours 
post-activation stimulus and this leads to the differentiation towards T2-MZP and FO-II 
cells. 
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Figure 5.11. Treatment of B cells with rShh increases differentiation towards T2-MZP at 
40hours post-activation stimulus 
 
The dot-plots shown in (A) is representative of one experiment from three independent 
experiments and it shows CD21 and IgM expression on peripheral B cells after trea tment 
with rShh with a bar chart representing this data shown in (B). The results shown in the bar 
chart are representative of three independent experiments.  
 
 
5.2.2.3. Characterisation of sorted B cell subsets 
 
After observing that treatment of B cells with rShh can affect the differentiation of B 
cells, it became important to better characterise the sorted B cell subset CD23+CD25-, 
CD23+CD25+ and CD23-CD25+, in order to ascertain if these subsets contain T2, FO-
I, FO-II or, T2-MZP B cells according to our classification. 
Purified B cells were cultured as previously described in Section 5.2.1.1. Sorted B cell 
population were then characterised using a combination of anti-IgM- PECy7 and anti-
IgD-APC or CD21-APC. 
  
 112 
 
Figure 5.12. Characterisation of sorted B cell subsets 
 
The dot-plots shown in (A) are representative of one experiment from three independent 
experiments and it shows CD21 and IgM expression on the sorted B cell subsets. The 
percentage of IgM+ and IgD+ B cells is shown in (B). The results shown in the bar chart 
are representative of three independent experiments. The significance of the difference 
observed in IgM+ and IgD+ B cells was assessed using Student t test ***p≤0.001. 
 
 
Figure 5.12A, shows the expression of IgM and CD21 on sorted B cell subsets. 
CD23+CD25- was identified to be FO-I cells as they were IgMlow CD21mid. There were 
no T2/ FO-II B cells neither any T2-MZP B cells present in this subset. CD23+CD25+ 
subset of B cells was found to contain a mix of FO-I, T2/FO-II and T2-MZP B cells. 
This suggests that FO-II are differentiating to become T2-MZP B cells as it has been 
reported that FO-II B cells form a reservoir and can differentiate to become T2-MZP 
(Cariappa et al., 2007). However, one unexpected finding was that CD23-CD25+ B cell 
population contained a mix of cells. This subset appears to contain 58.3% MZ B cells.  
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After analysing CD21 and IgM, we wanted to look at the levels of IgD on the different 
subsets, as memory B cells have been previously shown to be IgD negative (Tangye and 
Tarlinton, 2009, Tarlinton, 2006). Figure 5.12B, shows data for the expression of IgM 
and IgD on sorted B cell subsets. CD23+CD25- subset was identified to be CD21mid 
IgMlow (Figure 5.10A), however it was observed that this subset was also IgDhigh (Figure 
5.10B) thus, suggesting that this subset is FO-I B cells. The CD23+CD25+ was found to 
contain a mix of cells that were CD21highIgMhighIgDhigh as well as 
CD21mid,IgMhigh,IgDhigh , this suggests that these subset contains  T2-MZP as well as 
FO-I and FO-II B cells. 
Interestingly, CD23-CD25+ was IgMhigh, but had the lowest expression of IgD of all the 
sorted B cell subsets (Figure 5.10B). Memory B cells have been characterised as long-
lived IgD- B cells, thus indicating that they have undergone class switched 
recombination. Phenotypically, memory B cells are IgM+, CD80+, CD23- (Tangye and 
Tarlinton, 2009, Tarlinton, 2006) and also CD25+ (Amu et al., 2006). We have shown 
that after rShh treatment, an increase in memory-like B cells (subset III), which are 
CD25+, CD23-, CD27+ (Chapter 4) and IgM+, CD80high, and IgDlow.  However, it is 
also possible that these CD23-CD25+ subset contains MZ B cells, as they have been 
described to have a high expression of CD80 (Cerutti et al., 2013), IgDlow CD23-, 
CD21high(Allman and Pillai, 2008).  
Taken together, it can be concluded that, CD23+CD25- (subset I) contains B cells that 
are predominantly FO-I, CD23+CD25+ (subset II) contains FOI, FO-II, T2 and T2-
MZP cells and, finally, CD23-CD25- (subset III), possibly contains memory like B cells 
and MZ B cells. We have demonstrated, Hh signalling can increase B cell 
differentiation towards CD23-CD25+ (Chapter 4) indicating that there is an increase 
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differentiation of B cells towards memory like B cells and MZ B cells at 40hours post-
activation stimulus following treatment with rShh. 
 
5.3.  Discussion 
 
It has been reported in previous chapters that treatment of B cells with rShh can increase 
B cell activation and survival at 18hours post-activation and at 40hours the reverse was 
observed. At 40hours post-activation stimulus, three subsets were observed to arise and 
it was important to further characterise these subsets in order to identify the true 
function of each of the subset in isolation. 
The findings in this chapter demonstrates that CD23+CD25-, CD23+CD25+ and CD23-
CD25+ B cells, display different morphologies and functions that are modulated by Hh 
signalling. Additionally, it was observed that CD23+CD25- B cells were 
CD23+CD21midIgDhighIgMlow thus characterising them predominantly as FO-I B cells 
(Kleiman et al., 2015), which were shown to have a reduced ability to be activated and 
were surviving less well after treatment with rShh (Figure 5.3). In the periphery, 
differentiation towards FO-I B cells is Btk dependent (Cariappa et al., 2007). We 
hypothesise therefore, that treatment of activated FO-I B cells with rShh can induce a 
stronger BCR signal to be transmitted into the cell and this might induce activation 
induced cell death (AICD) in the cells (Metzler et al, 2015) thus might explain the 
reduced presence of live cells in this subset (Figure 5.3). Furthermore, it has been 
shown that FDCs secrete Shh in the GCs, which might represent a physiological 
condition in which GC B cells evade apoptosis (Sacedon et al., 2005). It is also possible 
that CD23+CD25- B cells, which are mostly FO-I, either require the presence of 
another B cell subset to provide either an autocrine or paracrine Hh secretion in order to 
evade apoptosis or may have lost the ability to respond to Hh signalling. It would be 
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important to investigate further, whether FO-I B cells, express Hh signalling receptors 
Ptch and Smo, as it may be that they no longer express one of these receptors and have 
therefore lost the ability to respond to exogenous Hh. 
 After observing the effects of rShh treatment on the sorted B cells, it became important 
to investigate the effect of rShh treatment on peripheral B cell differentiation. Data 
obtained showed that treatment of B cells with exogenous rShh could accelerate the 
process of peripheral B cell differentiation. Hh treatment at 18hours post-activation 
stimulus increased B cell differentiation towards FO-I, which requires strong BCR 
signalling and can then switch differentiation towards T2-MZP by 40hours, which 
requires a weak BCR signal (Pillai and Cariappa, 2009). These findings suggest that Hh 
signalling can strengthen the immune response by B cells possibly by potentiating a 
stronger BCR signal thereby accelerating peripheral B cell differentiation. However, at 
a later time point, Hh signalling can down-regulate the response by increasing apoptosis 
of FO-I B cells. Hh signalling has previously been shown to regulate differentiation of 
peripheral T cells. It has been shown that, Hh signalling can influence the differentiation 
of CD4+ T cells towards the Th2 subset. Furmanski et al. (2013) reported that Gli-2, 
which is part of the Hh signalling pathway, could modulate the transcription of genes in 
CD4+ T cells, by up-regulating genes such as Gata3 that would skew the differentiation 
of the T cells towards Th2 T cell phenotype and away from the Th1 phenotype 
(Furmanski et al., 2013).  
In conclusion, the sorting assay used in this study revealed that the subsets have 
different characteristics, capable of secreting different levels of antibody and cytokines 
and that this is modulated by Hh signalling. Treatment of B cells with exogenous rShh 
accelerates B cell activation and differentiation to FO-I B cells at 18hours post 
activation stimulus and arrests B cell activation in the periphery whilst increasing B cell 
  
 116 
differentiation towards T2-MZP B cells at 40hours post-activation stimulus. A situation 
where there is little or no Hh signalling present was investigated next in order to analyse 
whether the loss of a homologue of Hh would have an effect on B cell function and 
peripheral development in vitro.  
 
5.4. Conclusion 
 
It was demonstrated that CD23+CD25-, CD23+CD25+ and CD23-CD25+ B cells 
exhibit different B cell morphology, phenotype and function. Hh signalling was 
demonstrated to have an effect on the different subsets with Hh inducing death in 
CD23+CD25- B cells, which was characterised to be FO-I B cells. Additionally, this 
chapter demonstrates that treatment of B cells with rShh can have an effect on 
peripheral B cell differentiation. It is hypothesised that exogenous Hh signalling can 
affect peripheral B cell differentiation by strengthening the BCR signal. The next 
chapter extends findings of this chapter by investigating the effect of the loss of a Hh 
homologue on B cell development in the periphery. 
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Chapter 6: B cell development in the Dhh knockout mice  
 
6.1. Introduction 
 
6.1.1. Desert hedgehog protein (Dhh) 
 
 
There are three homologs of mammalian Hh that share a common signalling pathway. 
However, each homolog has a distinct pattern of expression, thus, play different roles in 
development in different tissues (Varjosalo and Taipale, 2008). 
 
Dhh is one such homolog of the vertebrate Hh family. Analysis of knockout mice in 
which the gene had been deleted revealed that it is essential for the maintenance of the 
male germ line and spermatogenesis (O’Hara et al., 2011). Mutations in Dhh in 46 
human XY male patients resulted in symptoms ranging from mild to complete gonadal 
dysgenesis including bilateral streak gonads, normally developed mullerian ducts and 
female external genital (O'Hara et al., 2011). In the murine embryo, Dhh is expressed in 
an array of tissues including the testis (Bitgood et al., 1996), granulosa cells of the 
ovaries (Wijgerde et al., 2005), circulatory system, including the heart and blood 
vessels (Bitgood and McMahon, 1995), fetal liver (Cridland et al., 2009) and peripheral 
nerve tissue (Bajestan et al., 2006, Parmantier et al., 1999). In the peripheral nerve 
tissue, Dhh is expressed by schwann cells and it plays a role in nerve sheath formation 
(O'Hara et al., 2011). Dhh has also been found to be involved in follicle development 
(Russell et al., 2007). The extensive expression pattern of Dhh suggests it has a wide 
range of functions in development.  
 
In the lymphoid tissues, Dhh is expressed in the thymus (Sacedon et al., 2003) and in 
the spleen (Perry et al., 2009, Lau et al., 2012). Dhh protein has also been shown to be 
expressed by non-hematopoetic cells of the spleen such as stroma (Hegde et al., 2008, 
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Perry et al., 2009).  Thus, Dhh expression in the spleen may have an effect on the cells 
of the spleen including T cells, B cells and erythrocytes. Dhh has been shown 
previously to drive the normal process of erythropoiesis in mice as well as being 
involved in recovery from stress erythropoiesis (Lau et al., 2012). Using Dhh knockout 
mice (Dhh-/-), Lau et al., (2012), showed that there was abnormal erythropoiesis 
present in the Dhh-/- mice, as the spleens of these mice were bigger and there was 
increased presence of erythroblasts and reticulocytes in the Dhh-/- compared to the 
wild-type mice (Dhh+/+). These data suggest that Dhh is a negative regulator for 
erythropoiesis in mice (Lau et al., 2012). 
 
Dhh has also been shown to play a role in T cells (Furmanski et al., 2013). CD4+ T cells 
can differentiate to become either T-helper 1 (Th1) or T-helper 2 cells (Th2). Th1 can 
be characterised by their expression of T-bet and express cytokines such as IFN-γ. They 
have the capacity to control immune response against infection by activating CD8+ T 
cells, B cells and macrophages. Th2 cells express gata3 and are important in the 
immune response against extracellular pathogens (Paul, 2010). Using Dhh-/- mice, 
Furmanski et al., 2013, showed that CD4+ T cells isolated from the Dhh-/- mice had a 
reduced gata3 expression and thus the T cells had an impaired ability to differentiate 
towards Th2 cells (Furmanski et al., 2013). The results obtained by Lau et al., 2012 and 
Furmanski et al., 2013, shows that in the absence of Dhh, there is reduced 
erythropoiesis and reduced differentiation to Th2 respectively, thus highlighting the 
importance of Dhh in cells of the immune system.  
 
Dhh has also been implicated in the emergence of B cell chronic leukaemia (B-CLL); a 
lymphoma of B cells. B-CLL is one of the most prevalent leukaemias and it is 
characterised by a progressive accumulation of functionally incompetent B cells in the 
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peripheral blood, bone marrow (BM) and lymphoid organs (Decker et al., 2012). 
Decker et al., 2012, showed that Dhh could be simultaneously induced in an autocrine 
manner and this can support the survival of B-CLL cells via ERK (extracellular signal 
regulated kinase) phosphorylation thus involving Dhh signalling in the pathogenesis of 
B-CLL (Decker et al., 2012). 
 
6.1.2. Objectives 
 
 
In peripheral haematopoietic processes, loss of the Dhh has been shown to cause 
impaired differentiation and function (Lau et al., 2012, Furmanski et al., 2013). The aim 
of the work presented in this chapter is to investigate the effect the loss of Hh signalling 
would have on peripheral B cell development using the Dhh-/- mice as a model. The 
objectives of this chapter are:  
 To investigate whether the loss of Dhh gene (Dhh) would have an effect on 
peripheral B cell subsets differentiation. 
 To investigate the consequences of the loss of Dhh on B cell activation, survival, 
cytokine secretion and antibody production. 
 To investigate whether there are any differences in the activities of rDhh and 
rShh treatment on B cell function.  
 
6.2. Results 
6.2.1. Peripheral B cell subsets in Dhh-/- mice. 
 
 
After observing the effects of the addition of exogenous rShh to B cells in a mixed 
splenocyte culture as well as purified B cell cultures, we went on to look at a situation 
where one of the Hh is not expressed. To this end, we analysed B cell development in 
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mice deficient for the Dhh gene. In mice, where the Shh gene or the Ihh gene has been 
knocked out, the embryos suffer devastating effects resulting in embryonic death. The 
Shh-/- embryos exhibit axial mis-patterning as well as skeletal and lung defects while 
the Ihh-/- embryos die at mid gestation or before birth possibly as a result of yolk sac 
angiogenesis or defects in cartilage formation and patterning (Chiang et al., 1996, 
Cridland et al., 2009). However, when the Dhh gene is knocked out the mice are viable 
but males are infertile (Bitgood et al., 1996) hence we analysed adult Dhh-/- mice in our 
study. The Dhh-/- mouse was generated by removing exons 1, 2 and 3 which encode a 
highly conserved 19kDa peptide required for the signalling activities of Hh protein and 
replacing them with a construct encoding neomycin phosphotransferase. Hence, no 
functional protein would be produced in mice homozygous for this deletion (Bitgood et 
al., 1996). In Chapter 5, treatment of B cells with rShh was found to regulate peripheral 
B cell differentiation at different time points post-activation. Thus, we asked the 
question, whether there are any differences in representation of peripheral B cell subsets 
in the spleen of Dhh-/- mice compared to the Dhh+/+ control.  
 
Purified splenic B cells isolated from Dhh-/- and Dhh+/+ mice were stained 
immediately with a combination of anti-IgM-PE, anti-CD23-PE-Cy7 and anti-CD21-
APC before analysis by flow cytometry in order to identify the peripheral B cell subsets. 
Figure 6.1, shows dot-plots representing the peripheral B cell subsets in the Dhh+/+ and 
Dhh-/- mice. Peripheral B cell subsets were gated as described in Section 5.2.2.1. Little 
differences were observed between the subsets of B cells in the Dhh+/+ and Dhh-/-. 
However, there was an increased presence of the T1 population in the Dhh-/- compared 
to the Dhh+/+, from 28.0% in the Dhh+/+ to 32.8% in the Dhh-/-. There was also an 
increased T2/FO-II population, from 26.6% in the Dhh+/+ to 30.1% in the Dhh-/-. 
Fewer differentiated FO-I B cells and fewer MZ B cells were observed in the Dhh-/- 
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compared to the Dhh+/+. These results suggest that in Dhh-/-, there is probably an 
impaired differentiation of B cells in the spleen. There was an apparent build-up of the 
more immature B cells in the Dhh-/- compared to the Dhh+/+ suggesting that there may 
be an arrest in differentiation after T2 cell development. 
 
Figure 6.1. There is an increased immature B cells in Dhh-/- 
 
The dot-plots shown are representative of one experiment where splenic purified B cells 
isolated from Dhh-/- and Dhh+/+ were stained using a combination of CD23, CD21 and 
IgM in order to characterise B cell subsets in Dhh+/+ (A) and Dhh-/- (B). 
 
 
6.2.2. The activation and survival of B cells isolated from Dhh-/- mice compared 
to their littermate controls.   
 
 
B cells cultured as a mixed splenocyte population as well as purified B cells were 
shown to display increased B cell survival as assessed by Annexin-V expression and 
increased B cell activation as judged by CD23 expression at 18hours post-activation 
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after treatment with rShh and the opposite was observed at 40hours post-activation in 
Chapter 3 and 4 respectively. Hence, it was of interest to investigate if there were any 
differences in survival and activation of B cells isolated from Dhh-/- compared to the 
Dhh+/+ littermates. 
 
Purified B cells isolated from Dhh-/- and Dhh+/+ were activated with 5μg/ml anti-
CD40/IgM before treatment with 0.05μg/ml rShh to both sets of cells. Exogenous rShh 
was added to both sets of cells in order to investigate whether addition of exogenous 
rShh to the cultures of B cells isolated from Dhh-/- mice could rescue any defects 
caused by lack of expression of Dhh. At 18hours and 40hours post-activation, cultured 
B cells were stained as described in Section 3.2.1. 
 
Figure 6.2, shows data on the activation of B cells at 18hours (Figure 6.2A) and at 
40hours (Figure 6.2B) post-activation stimulus. Surprisingly, at 18hours post-activation, 
there was an increased percentage of CD23+ B cells in B cells isolated from the Dhh-/- 
compared to its Dhh+/+ littermate. Treatment of B cell cultures obtained from Dhh+/+ 
mice with rShh also showed increased CD23+ B cells as was also observed previously 
in Chapter 3 and 4. However, interestingly, B cells isolated from Dhh-/- mice treated 
with rShh resulted in an apparent decrease in B cell activation as judged by a reduction 
in CD23 expression (Figure 6.2A). 
 
Following 40hours post-activation (Figure 6.2B), CD23+ B cells in treated Dhh+/+ 
mice had decreased as previously observed in the case of the purified B cell (Chapter 4) 
and mixed cell experiments (Chapter 3). However, the number in percentage of CD23+ 
B cells isolated from the Dhh-/- mice had significantly increased by approximately 1.2 
fold compared to B cells isolated from the Dhh+/+ mice and when treated with rShh, 
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this increase in CD23 staining was reduced back to baseline level. This data suggests 
that when rShh is reintroduced to the B cell cultures isolated from Dhh-/- the signal 
transduced by rShh acts to negatively regulate expression of CD23 both at 18 and 
40hours post-activation. However, all of these observed trends were small and did not 
yield statistically significant differences between the different groups. 
 
Figure 6.2. B cells isolated from Dhh-/- had increased activation  
 
Purified B cells isolated from Dhh-/- and Dhh+/+ mice were activated with anti-5μg/ml 
CD40/IgM and were treated with 0.05μg/ml rShh. Cells were collected and analysed at 
18hours (A) and 40hours (B) post-stimulation. B cell activation was determined using anti-
CD23. The results shown in the bar chart are representative of six independent experiments. 
The significance of the differences observed in fold changes in CD23+ cells was assessed 
by Student t-test *p≤0.05.  
 
 
Figure 6.3, shows data on survival of B cells isolated from Dhh-/- and Dhh+/+ at 
18hours (A) and 40hours (B) post-activation. At 18hours post-activation (Figure 6.3A), 
there was a significant decrease in apoptosis of B cells treated with rShh in both strains 
of mice but at 40hours more death is seen in treated B cells isolated from Dhh+/+ 
(Figure 6.3B). B cells isolated from Dhh-/- mice also had a reduced apoptosis at 
18hours post-activation, but unlike B cells isolated from Dhh+/+ mice, they also 
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survived better at 40hours. For example, at 40hours post-activation, there was a nearly 
significant decrease in apoptosis by approximately 40% in B cells isolated from Dhh-/- 
mice compared to the Dhh+/+ control. Interestingly, treatment of B cells isolated from 
Dhh-/- did not increase levels of B cell death (Figure 6.3B).  These data are consistent 
with the idea that the death of B cells following 40hours post-activation stimulus, is in 
part, due to Hh signalling.  
 
These results indicate that the negative regulatory effect observed at 40hours in our 
culture of mixed B cells and purified B cells with respect to activation and survival is 
lost when the Dhh gene is knocked out as the Dhh-/- B cells displayed increased B cell 
activation as judged by CD23 expression and increased B cell survival at both time 
points, thus indicating that the removal of Dhh gene can exert a positive effect for B cell 
function in respect of activation and survival. 
 
Figure 6.3. B cells isolated from Dhh-/- have increased survival 
Purified B cells isolated from Dhh-/- and Dhh+/+ mice were activated with anti-CD40/IgM 
and were treated with 0.05μg/ml rShh. Cells were collected and analysed at 18hours (A) 
and 40hours (B) post-stimulation. B cell survival was determined using annexin-V. The 
results shown in the bar chart are representative of five independent experiments. The 
significance of the differences observed in fold changes in annexin-V+ cells was assessed 
by Students ttest *p≤0.05.  
 
  
 125 
6.2.3. B cell differentiation in Dhh-/- and Dhh+/+ 
 
In Chapter 4, it was observed that Hh signalling induces the differentiation of CD23-
CD25+ B cells in purified B cell cultures at 40hours and the identification of the three 
different B cell subset, which include, CD23+CD25-, CD23+CD25+ and CD23-CD25. 
In Chapter 5, it was shown that CD23+CD25- contains mostly FO-I B cells, 
CD23+CD25+ contains a mix of FO-I, FO-II and T2-MZP B cells and CD23-CD25+ 
contains cells of the memory B cell phenotype and MZ. We therefore analysed whether 
there are any differences in the representation of these subsets at 40hours in the absence 
of Dhh. In order to do this, the differentiation of B cells was analysed using the 
expression of CD23 and CD25 following 40hours in culture. 
 
Figure 6.4 shows the representation of the different B cell subsets in the Dhh-/- and 
Dhh+/+ cultures at 40hours. Compared to the B cells isolated from the Dhh+/+ mice, 
there was an increased presence of CD23+CD25- B cell subset (Figure 6.4A), and 
reduced number of CD23+CD25+ (Figure 6.4B) and CD23-CD25+ (Figure 6.4C) 
subsets in the B cells isolated from the Dhh-/-mice. For example, there was a significant 
increase of CD23+CD25- B cells by approximately, 1.2 fold in the case of the Dhh-/- 
mice compared to the Dhh+/+ littermate control (Figure 6.4A). Treatment of B cells 
isolated from the Dhh+/+ mice with rShh, caused a decrease in the number of 
CD23+CD25- subset (Figure 6.4A), and an accompanying increase in the number of 
CD23+CD25+ (Figure 6.4B) and CD23+CD25- (Figure 6.4C). Treatment of B cells 
isolated from Dhh-/- mice with rShh resulted in a reduced number of CD23+CD25-, 
however, not significant (Figure 6.4A) and a significantly increase number of 
CD23+CD25+ compared to the Dhh-/- control (Figure 6.4B). 
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These results suggest that in the case of the B cell isolated from Dhh-/- mice, there is an 
increased number of FO-I B cells, a reduced number of CD23+CD25+ containing FO-
II, T2 and T2-MZP cells and a reduced presence of CD23-CD25+ containing memory B 
cells and MZ. Thus, suggesting that Hh signalling may play a role in diverting the 
differentiation of the T2 B cell towards either the FO-I B cell or towards the T2-MZP B 
cell. 
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Figure 6.4. B cells isolated from Dhh-/- have increased differentiation to CD23+CD25- B 
cells 
Purified B cells isolated from Dhh-/- and Dhh+/+ with or without treatment with 0.05μg/ml 
rShh were analysed for their representation CD23+CD25- (A), CD23+CD25+ (B) and 
CD23-CD25 (C) at 40hours post-activation. The results shown in the bar chart are 
representative of three independent experiments. The significance of the differences 
observed in fold changes in percentage of the B cell subsets was assessed by Students t test 
*p≤0.05, **p≤0.01. 
6.2.4. IL-10 intracellular staining and secretion in B cells isolated from Dhh-/- 
mice 
 
We observed, that treatment of B cells with rShh at 40hours post-activation, caused an 
increase in the expression and secretion of IL-10 by purified B cells (Chapter 4, Section 
4.2.4) as well as a reduced B cell post- T2 differentiation in B cells isolated from Dhh-/- 
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mice. It was of interest therefore to analyse IL-10 secretion by B cells isolated from 
Dhh-/- compared to Dhh+/+ mice.  
 
Purified B cells isolated from Dhh-/- and Dhh+/+ mice were cultured as described in 
Section 4.2.8. In Chapter 4, we showed that IL-10 expression was restricted to B cells 
that are CD23+CD25+ and so we focussed on analysing this subset. Figure 6.5A shows 
data on IL-10+ B cells as assessed by flow cytometry. In CD23+CD25+ B cells, there is 
a significant reduction in IL-10+ B cells of approximately 40% in B cells isolated from 
Dhh-/- mice compared to Dhh+/+ mice. Addition of exogenous rShh to B cells isolated 
from Dhh-/- did not increase IL-10 expression by these B cells. 
 
Figure 6.5. B cells isolated from Dhh-/- have reduced IL-10 secretion 
 
Purified B cells isolated from Dhh-/- and Dhh+/+ mice were activated with anti-CD40/IgM 
and were treated with 0.05μg/ml rShh. Cells were collected and analysed for IL-10 
expression (A) and supernatants were analysed for IL-10 secretion using ELISA (B) at 
40hours post-stimulation. The results shown in the bar chart are representative of three 
independent experiments. The significance of the differences observed in fold changes in 
IL-10+ B cells and IL-10 secretion was assessed by Students t test *p≤0.05, **p≤0.01.  
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To validate the finding of the IL-10 intracellular staining study, IL-10 secretion was 
analysed in supernatants isolated from all cultures at 40hours. Figure 6.5B shows IL-10 
secretion in B cells isolated from Dhh-/- and Dhh+/+ mice at 40hours post-activation. 
There was an increased secretion of IL-10 by treated B cells isolated from Dhh+/+ 
mice, but in the case of B cells isolated from Dhh-/- mice, there was less secretion of 
IL-10 compared to B cells isolated from Dhh+/+. For example, there is an increase in 
IL-10 secretion in B cells from 1.7ng/ml in the case of Dhh-/- to 2.3ng/ml in the case of 
the Dhh+/+ mice. This is consistent with the finding that at 40hours post-activation in B 
cells isolated from Dhh-/-, we are observing more B cells positive for CD23, which 
could be FO-I B cells and less differentiation towards T2-MZP, which is thought to be 
Bregs which secrete IL-10 (Blair et al., 2008). It therefore correlates that B cells 
isolated from Dhh-/- mice would secrete less IL-10 when compared to the Dhh+/+ 
littermate. These results suggest that B cells isolated from Dhh-/- are less able to 
differentiate towards T2-MZP B cells thus show reduced IL-10 secretion compared to 
Dhh+/+.  
 
6.2.5. CD27 expression in B cells isolated from Dhh-/- mice. 
 
Having observed that expression of CD27 is up-regulated in CD23-CD25+ in B cells 
treated with rShh (Chapter 4) and further characterising these cells to exhibit a memory 
B cell phenotype in Chapter 5 using CD80 and IgD. We therefore investigated if there 
are any differences in expression of CD27 in B cells isolated from Dhh-/- and Dhh+/+ 
mice  
 
Figure 6.6, shows CD27 expression at 40hours post-activation on CD23-CD25+ B cells, 
there was a significant decrease of approximately 11% in CD27 expression on the B 
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cells isolated from Dhh-/- mice compared to Dhh+/+. Treatment of B cells isolated from 
Dhh+/+ with rShh increased CD27 expression as observed in the purified B cell culture 
(Chapter 4, Section 4.25). There was a slight decrease in CD27+ B cells in treated B 
cells isolated from Dhh-/- and compared to B cells isolated from Dhh-/-. These results 
suggest that B cells isolated from Dhh-/- have a reduced ability to differentiate towards 
B cells that display a memory B cell phenotype when compared to B cells isolated from 
Dhh+/+. 
 
Figure 6.6. B cells isolated from Dhh-/- have reduced CD27+ B cells 
Purified B cells isolated from Dhh-/- and Dhh+/+ mice were activated with anti-CD40/IgM 
and were treated with 0.05μg/ml rShh. CD23-CD25+ B cells were analysed for CD27 
expression at 40hours post-activation. The results shown in the bar chart are representative 
of three independent experiments. The significance of the differences observed in fold 
changes in CD27+ B cells was assessed by Students ttest *p≤0.05, **p=0.01.  
 
6.2.6. B cells from Dhh-/- produce increased amount of antibody 
 
 
Having identified a possible role for Hh signalling in both up-regulating and down-
regulating the production of antibodies by activated purified B cells in chapter 4, it was 
important to analyse what effect the absence of Dhh gene expression might have on 
antibody production. Hence, antibody production by B cells isolated from Dhh-/- was 
investigated. 
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Figure 6.7, shows antibody secretion by B cells isolated from the Dhh-/- and Dhh+/+ 
mice following 18 and 40hours post-activation. Interestingly, there is a massive increase 
in the production of IgG1 by B cells isolated from Dhh-/- compared to the Dhh+/+ at 
both time points. Consistent with previous data shown in chapter 4, treatment of B cells 
with rShh resulted in an up-regulation of IgG1 secretion at 18hours but these levels did 
not increase following 40hours in culture and indeed by this time point levels of 
secretion of IgG1 by untreated B cells had caught up. (Figure 6.9) This data is 
consistent with the idea that uncontrolled activation may occur in B cells leading to 
enhanced antibody production in the absence of the Dhh gene. Also, there was an 
increased number of the FO-I B cell observed in the cultures of B cells isolated from 
Dhh-/- mice following 40hours in culture when compared to the Dhh+/+ control, and 
thus these additional FO-I cells may go on to form germinal centres (Cariappa et al., 
2007), leading to an increased antibody secretion. 
 
Figure 6.7. B cells isolated from Dhh-/- secrete increased IgG1 
 
Purified B cells isolated from Dhh-/- and Dhh+/+ were activated with 5μg/ml anti-
CD40/IgM and treated with 0.05μg/ml rShh. Supernatants were analyzed for IgG1 
production after 18 and 40hours post-activation using ELISA. The results shown in the bar 
chart are representative of four independent experiments. The significance of the 
differences observed in fold change was assessed by Students t test **p≤0.01. 
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6.2.7. IL-6 secretion in Dhh-/- and Dhh+/+ 
 
Interleukin 6 (IL-6) was first identified as a B cell stimulating factor; it is involved in 
driving plasma cells to secrete more antibodies (Urashima et al., 1996). Following 
40hours in culture, the B cells isolated from Dhh-/- mice showed an increased IgG1 
secretion compared to the Dhh+/+ and the same phenomenon was observed in the 
presence of exogenous rShh. We would hypothesise therefore that this increased 
antibody secretion by B cells isolated from Dhh-/- mice might be accompanied by an 
increased secretion of IL-6 by these same B cells.  
 
Figure 6.8, shows IL-6 secretion by B cells isolated from Dhh-/- and Dhh+/+ mice. As 
predicted, at 18 and 40hours post-activation stimulus, there was an observed trend with 
increasing secretion in IL-6 secretion by B cells isolated from Dhh-/- compared to 
Dhh+/+ mice. However, this increase in IL-6 secretion was not significantly different. 
For example, at 40hours post-activation, B cells isolated from Dhh+/+ mice secreted 
approximately 0.1ng/ml IL-6, which has increased to approximately 0.23ng/ml IL-6 in 
the case of the Dhh-/- mice. These data suggest that Hh signalling may act to decrease 
the secretion of IL-6 by B cells following stimulation via the BCR. 
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Figure 6.8. B cells isolated from Dhh-/- have an increased IL-6 secretion 
 
Purified B cells isolated from Dhh-/- and Dhh+/+ mice were activated with anti-CD40/IgM 
and were treated with 0.05μg/ml rShh. Supernatants were analysed for IL-6 secretion using 
ELISA at 18 and 40hours post-stimulation. The results shown in the bar chart are 
representative of three independent experiments.  
 
6.2.8. The effect of exogenous recombinant Dhh on B cell development 
 
After observing the effect that the removal of Dhh gene had on B cell development, it 
was important to ascertain the effect that the addition of exogenous recombinant Dhh  
(rDhh) would have on B cell development and compare it with the effect of treating B 
cells with the closely related rShh protein.  
 
Purified splenic B cells from BALB/c mice were activated with 5μg/ml anti-CD40/IgM 
before treatment with either 0.05μg/ml rShh or rDhh.  Because a more pronounce effect 
on differentiation of B cells was observed at 40hours post-activation, the effect of rDhh 
would be investigated at this time point and compared with that induced by rShh. 
Following 40hours post-activation, B cells were stained with a combination of anti-
CD23-PE, anti-CD27-FITC, anti-CD25-APC and B220-PE-CY5 or anti-CD23-PE, Annexin-V-
FITC, anti-CD25-APC and B220- PE-CY5.  
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Figure 6.9, shows B cell activation (Figure 6.9A) and survival (Figure 6.9B) at 40hours 
as judged by CD23 and annexin-V respectively. As observed previously, addition of 
rShh decreases B cell activation as judged by CD23 expression following 40hours post-
stimulation (Figure 6.9A). However, when the effect of rDhh is compared to that 
induced by rShh, there was less activation observed when rShh is added. This effect was 
also observed when B cell survival was analysed. Using Annexin-V, (Figure 6.9B), 
there was increased B cell death with treatment with both homologs of Hh as judged 
using annexin-V, however the effect is higher in the presence of rShh. 
 
Figure 6.9. The effect of Hh signalling in B cells is more potent with treatment with rShh 
Purified B cells were activated with 5μg/ml anti-CD40/IgM and were treated with 
0.05μg/ml rDhh or rShh. Cells were collected and analysed for activation (A) and survival 
(B) at 40hours post-stimulation. B cell activation and survival was determined using anti -
CD23 and annexin-V respectively. The result shown in the bar chart is representative of 
three independent experiments. The significance of the differences observed in fold 
changes in CD23+ cells was assessed by Student t test *p≤0.05, **p≤0.01.  
 
After observing that the effect of Hh signalling on B cell activation and survival was 
more potent with treatment with rShh compared to rDhh, we investigated whether there 
would be any differences in the representation of the three subsets arising in our culture 
following 40hours in culture.  
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Figure 6.10, shows the different B cell subset representation at 40hours. There is a 
reduced CD23+CD25- B cell subset (Figure 6.10A), increased CD23+CD25+ (Figure 
6.10B) and CD23-CD25+ (Figure 6.10C) in the presence of both rHh homologues 
compared to the control. This is consistent with results obtained that demonstrated that 
culture with rShh could reduce the representation of CD23+CD25-, which has been 
characterised to be FO-I at 40hours compared to the control. However, the effects are 
more potent in the presence of rShh compared to rDhh. 
 
Figure 6.10. Representation of B cell subsets at 40hours 
 
Purified B cells were activated with 5μg/ml anti-CD40/IgM and treated with either 
0.05μg/ml rDhh or rShh and were analysed for their representation of CD23+CD25 - (A), 
CD23+CD25+ (B) and CD23-CD25 (C) at 40hours post-activation. The results shown in 
the bar chart are representative of three independent experiments. The signif icance of the 
differences observed in fold changes in percentage of the B cell subsets was assessed by 
Students t-test *p≤0.05. 
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After observing that in the presence of rShh there is an increased B cell differentiation 
towards B cells that contain memory B cell phenotype and MZ in Chapter 4 and 5, we 
wanted to investigate whether there would be any differences observed when rDhh was 
added to the cultures in comparison to addition of rShh. CD27 expression was analysed 
on B cells that formed CD23-CD25+, following 40hours in culture as this population 
have been previously shown to be positive for CD27 (Chapter 4, Section 4.2.5). Figure 
6.11, shows CD27 expression on purified B cells after treatment with either rShh or 
rDhh at 40hours post-activation. Interestingly, treatment of B cells with rDhh 
significantly reduced CD27+ B cells compared to the control and B cells treated with 
rShh. For example, control B cells contained 17.6 % CD27+ B cells, which decreased to 
8.6% in B cells treated with 0.05μg/ml rDhh. Treatment of B cells with 0.05μg/ml rShh 
has increased CD27+ B cells to 33.0% (Figure 6.11A). There were increased CD27+ B 
cells when rShh is added to B cells compared to the stimulated control. These results 
were significant (Figure 6.11B). 
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Figure 6.11. Treatment of B cells with rDhh reduces CD27+ B cells 
 
The histogram (A) shown is from one experiment representing three independent 
experiments where purified B cells were activated with anti-CD40/IgM and were treated 
with either 0.05μg/ml rDhh or rShh. CD23-CD25+ B cells were analysed for CD27 
expression and in (B) a bar chart of CD27+ B cells at 40hours post-activation. The results 
shown in the bar chart are representative of three independent experiments. The 
significance of the differences observed in fold changes in CD27+ B cells was assessed by 
Students ttest *p≤0.05, **p≤0.01.  
 
The results obtained suggest that B cells treated with rDhh, have a reduced ability to 
differentiate towards the memory B cell subset. This result was unexpected and requires 
further investigation. 
 
After observing that in the presence of rDhh, there was reduced CD27 expression, we 
asked whether there would be any differences in IL-10 expression by B cells cultured 
together with rDhh as culture with rShh had been shown previously to increase IL-10 
expression at 40hours (Chapter 4).  
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Figure 6.12, shows a preliminary data on IL-10+ B cells in the presence of rDhh. IL-10 
expression was analysed on CD23+CD25+ B cells subset. There was no difference in 
IL-10+ B cells observed in B cells treated with rDhh and the control. Addition of 
0.05μg/ml rShh showed increased intensity of IL-10 staining compared to the control as 
previously observed. For example, there were approximately, 11% of B cells expressing 
IL-10 in the control, which is similar to about 10% in the presence of 0.05μg/ml rDhh, 
This percentage increases in the presence of 0.05μg/ml rShh to approximately 17%.  
 
 
Figure 6.12. Treatment of B cells with rDhh did not increase IL-10+ B cell 
 
Purified B cells were activated with anti-CD40/IgM and were treated with 0.05μg/ml rDhh 
or rShh. Cells were collected and analysed for the percentage of IL-10+ B cells 40hours 
post-stimulation. The result shown in the bar chart is representative of a single experiment.  
 
 
The results observed in B cells treated with rDhh suggest that the different homologs of 
Hh protein have different effects on B cell function and that Shh is more potent than 
Dhh in our assays. 
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6.3. Discussion 
 
 
In previous chapters, data presented demonstrated that treatment of B cells with rShh 
can increase the response of B cells by increasing differentiation towards FO-I, antibody 
production, cytokine secretion at earlier time point but also can subsequently dampen 
down to the response and drive B cell differentiation towards B cells that display a 
memory B cell phenotype at a latter time point thus suggesting that Hh signalling can 
regulate the immune response of B cells. It became of interest to investigate the effect 
of the loss of Hh gene would have on B cell development. 
 
The percentages of peripheral B cell subsets were first investigated. The data presented 
in this chapter shows that there was more T1 and T2/FO-II B cells in number of 
percentage from the cells isolated from the spleen of Dhh-/- mice compared to the 
Dhh+/+. Thus, indicating that there was more immature B cells in the Dhh-/- compared 
to Dhh+/+. These results suggest that there is a partial arrest in B cell development in 
the spleen isolated from Dhh-/- mice. Removal of the Dhh gene has previously been 
shown to have a negative effect on development. Lau et al, (2012), showed that deletion 
of the Dhh gene led to impaired erythropoiesis (development of red blood cells) (Lau et 
al., 2012). Thus, it is possible that deletion of the Dhh gene arrests B cell development 
in the periphery, as there was an accumulation of immature B cells observed. 
 
When B cells were activated, B cells isolated from Dhh-/- displayed increased 
activation as judged by CD23 and increased survival as judged as annexin-V at 18hours 
and 40hours post-activation stimulus. They also displayed an increased FO-I 
differentiation and less T2-MZP B cells. Differentiation of B cells to FO-I is 
characterised by strong BCR signalling and it is Btk-dependent (Pilla and Cariappa, 
2009). It was also observed that B cells isolated from Dhh-/- displayed less ability to 
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differentiate into CD27+ B cells and also T2-MZP, hence less IL-10 secretion. Hence, 
deletion of Dhh gene results in impaired differentiation post-activation stimulus. 
 
This apparent enhanced activation of B cells leading to a loss of regulation of antibody 
secretion may cause self-reactive antibodies to be secreted by B cells, which should 
otherwise have been deleted. Importantly, survival of B cells isolated from Dhh-/- mice 
was shown to be elevated following both 18hours and 40hours post-activation relative 
to the Dhh+/+ control suggesting that negative selection of autoreactive B cells in the 
spleen may have been impaired.  This loss of regulation can lead to autoimmunity. The 
increased antibody production observed by B cells isolated from Dhh-/- mice might be 
due to the lack of the negative regulatory effect caused by Hh signalling. These results 
suggest that in the Dhh-/- mice, B cells are pushed earlier than would be expected to the 
FO-I phenotype and that there is less ability of B cells to differentiate to become more 
mature memory B cells suggesting an impaired B cell differentiation in the periphery. 
FO-I B cells have the ability to form GCs and secrete antibody (Cariappa et al., 2007) 
and hence, increased antibody production was observed by B cells isolated from Dhh-/- 
mice. This increased antibody production by B cells obtained from Dhh-/- might result 
in the development of autoimmune disease as it has been reported that increased Btk 
signalling which is required for FO-I differentiation can lead to auto-antibodies which 
causes lupus like symptoms (Kil et al., 2012).  
 
Having observed the effects of loss of the Dhh gene on B cell development together, it 
is of interest to investigate the effects of addition of rDhh to purified B cells in culture 
and if there’s any difference from the effects caused by rShh. The findings in this 
chapter demonstrate that treatment of B cells with rDhh had a weaker impact on B cell 
differentiation compared to rShh. It might be due to the fact that the B cells bind to both 
proteins with different affinities. Also, it has been previously shown that of all the Hh 
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homologs, Shh has the strongest activity, followed by Ihh and then Dhh as assesed 
using an alkaline phosphatase transcriptional reporter assay (Pathi et al., 2001). 
 
The findings of this chapter suggests that although Dhh gene is required for proper 
development of B cell in the periphery, the other homologs of Hh might need to be 
present in the spleen or secreted by the B cells in order to get proper B cell development 
in the periphery. Next, differences in gene expression of B cells isolated from Dhh-/- 
and Dhh+/+ and after treatment with rShh shall be analysed using gene expression 
microarrays in order to access what differential transcriptome profiles underlay the 
phenotypic differences we observed in the Dhh-/- compared to Dhh+/+. We also will 
investigate the genes modulated by Hh signalling in B cells, with regards to survival, 
activation, and B cell differentiation. 
 
6.4. Conclusion 
 
In this chapter, it was observed that there is a partial arrest in B cell differentiation in 
the periphery of Dhh-/- mice resulting in a skewing in particular B cell subset 
representation. We showed that in the absence of the Dhh gene, there is an increased 
antibody production by B cells accompanied by an increased activation and survival of 
B cells. Hence, deletion of Dhh may form a mechanism by which autoimmune diseases 
may develop. It was also demonstrated that treatment of B cells with rDhh did not 
induce the differentiation of B cells displaying memory B cell like phenotype. The next 
chapter extends the findings observed in this chapter by carrying out a molecular gene 
analysis in order to assess whether there are any differentially genes expressed in B 
cells isolated from Dhh-/- and Dhh+/+ and after they are treated with rShh. 
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Chapter 7: Microarray analysis of the transcriptome of B 
cells isolated from Dhh-/-, Dhh+/+ and Dhh+/+ 
mice in the presence of exogenous Hh signalling 
 
7.1. Introduction 
7.1.1. BCR signalling pathway and components 
 
 
The B cell receptor (BCR) complex is a transmembrane complex that is non-covalently 
associated with a disulphide linked Igα and Igβ heterodimer which each have a single 
immuno receptor tyrosine based activation motif (ITAM) located on their cytoplasmic 
tails, These are composed of two tyrosine residues (Hendriks et al., 2014, Seda and 
Mraz, 2015). Activation of the B cell via ligation of the BCR, leads to signalling via 
phosphorylation of the ITAMs on the Igα/β heterodimer. This chain of events then leads 
to subsequent activation of downstream kinases and transcription factors including Btk 
and nuclear factor of activated T cells (NFAT) (Hendriks et al., 2014).  
 
Bruton’s tyrosine kinase (Btk), a 77kD non-receptor tyrosine kinase that is expressed 
specifically in myeloid cells and B cells, is a key component of the BCR signalling 
pathway. The cystolic TEC kinase is activated when BCR signalling promotes its 
recruitment to the cell membrane via P13K mediated actions and subsequent 
phosphorylation by syk. This increases Btk kinase activity, which leads to an increase in 
calcium flux and activation of transcription factors NfκB and calcium dependent nuclear 
factor of activated T cells (NFAT) (Loder et al., 1999, Hendriks et al., 2014). In mice 
and humans, precise regulation of Btk expression levels is essential for normal B cell 
function and differentiation, as mutations in Btk, lead to an absence of mature B cells 
and agammaglobunemia (Hendriks et al., 2014, Seda and Mraz, 2015). Btk is also an 
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important regulator of B cell proliferation and cell survival and may therefore play a 
role in the development of various B cell malignancies (Hendriks et al., 2014).  
 
BCR signalling is crucial for B cell development, however, the signal mediated by 
ligation of BCR and its signalling component need to be tightly regulated as overactive 
BCR signalling has been linked to the pathology of a number of diseases such as B cell 
chronic lymphoctic leukaemia (B-CLL) (Woyach et al., 2012). 
 
7.1.2. Objectives 
 
Data presented in Chapter 6, revealed that B cells isolated from Dhh-/- exhibited altered 
peripheral B cell differentiation compared to Dhh+/+. In Chapters 3, 4 and 5, Hh 
signalling has been shown to regulate B cell survival, activation, proliferation and 
differentiation.  The aim of this chapter is to identify molecular targets that are regulated 
by Hh signalling using microarray analysis. The objectives of this chapter are: 
 To identify differentially expressed genes in B cells isolated from Dhh-/- 
compared to Dhh+/+. 
 To identify differentially expressed genes in B cells treated with exogenous rShh 
compared to untreated control using gene expression microarrays.  
 To validate the differential expression of genes identified using gene expression 
microarrays by qRT-PCR. 
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7.2. Results 
7.2.1. Gene expression in B cells isolated from Dhh-/-, Dhh+/+ and Dhh+/+ in the 
presence of Hh at 18hours and at 40hours post-activation stimulus  
 
 
In order to investigate whether there are any differences in the transcriptional profile of 
B cells isolated from Dhh-/- compared to Dhh+/+ in the presence and absence of 
treatment with 0.05μg/ml rShh following 18 and 40hours post-activation stimulus, a 
whole exon expression microarray gene analysis was carried out on RNA isolated from 
these B cells. PCA was then applied to the data obtained from this analysis in order to 
identify areas of greatest variation in gene expression between the sample sets (Section 
2.8). PCA uses a mathematical formula and procedures to transform the original data to 
a new co-ordinate data represented by principal components (PCs) (Ringner, 2008). PCs 
are the linear combinations of Eigen vectors and the variable. PCA approach ranks the 
largest Eigen value, where there is maximum variance, as the first principal component 
(PC1) and the smallest Eigen values, where there is the least variance, the last PC. 
Using PCA, samples can be plotted making it visually possible to access similarities and 
differences between samples and determine whether they can be grouped (Ringner, 
2008). 
 
Figure 7.1, shows PCA results generated from activated purified B cell samples isolated 
from Dhh-/-, Dhh+/+ B cells cultured with or without treatment with 0.05μg/ml rShh at 
18 and 40hours post-activation stimulus. It was observed that the sample data separated 
most based on time. Principal Component (PC) 1 (Comp1, Row A, Column 1), the 
largest component for variation, shows that there are clear differences in gene 
expression profiles from 18 to 40hours in culture, for all samples taken at 18hours post-
activation stimulus (Circles) all cluster together, while samples taken at 40hours 
(Triangles) also cluster together and separately from the 18hours samples (Figure 7.1). 
  
 145 
This result suggests that the phenotypes in culture at 18hours post-activation stimulus 
are distinct from the phenotype observed at the latter time in culture. This result is to be 
expected, as all cells will have undergone extensive differentiation in response to the 
various stimuli during this time period. 
 
More interestingly, in the case of PC3 (Comp 3(See Row C, Column 3) following 
18hours post-activation stimulus (circles), it was observed that B cells isolated from 
Dhh-/- (red) cluster differently from B cells isolated from Dhh+/+ (black), thus 
indicating that there are genes within this component that are differentially expressed in 
B cell samples isolated from Dhh-/- compared to the Dhh+/+ littermate at this time 
point. However, there were no differences observed in the other components as no 
significantly separated clusters were identified between samples. This suggests that the 
genes grouped within Comp3 only contribute to the difference observed between B cells 
isolated from Dhh-/- and Dhh+/+ mice. Additionally, neither of the components could 
identify the samples according to treatment or time points and thus target genes 
expressed differentially in the 18hours samples and 40hours samples would need to be 
identified individually. 
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Figure 7.1. PCA analysis gene expressio of activated B cell samples 18 and 40 hours post-
culture following rShh treatment 
 
B cells were isolated from Dhh-/- and Dhh+/+ and were activated using 5μg/ml anti-
CD40/IgM and treated with or without rShh (0.05μg/ml). After 18 and 40hours culturing, 
RNA samples were purified and analysed using microarray analysis. Comp1 showed that 
there are differences between the transcriptome profiles of B cell samples at 18hours and 
40hours in culture. Differences were observed between the transcriptome profiles of B 
cells isolated from Dhh-/ and Dhh+/+ mice within Comp3. 
 
In order to identify more easily whether there are any distinct differences in gene 
expression profiles at the different time points, a PCA was carried out on samples at the 
individual time points alone. 
 To simplify the analysis of the different sample Figure 7.2, shows PCA analysis of B 
cell samples following 18hours in culture. PC1, the largest component did not show any 
clear distinct differences in samples. However, when PC2 (Row B, Column 2) was 
analysed, it was observed that there were differences in the gene transcriptome profile 
of B cells isolated from Dhh-/- (red circles) and Dhh+/+ mice (black circles) as both 
samples separate out on this component. However, when the other components were 
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analysed, it was observed that there was no distinct differences between samples (Figure 
7.2). There was also no clear differences observed between B cells isolated from 
Dhh+/+ treated with exogenous rShh and the untreated control at 18hours post-
activation stimulus (Figure 7.2). This finding suggests that at 18hours post-activation, 
there are only differences in PC2 between the genes expressed in B cells isolated from 
Dhh-/- and Dhh+/+ mice.  
 
Figure 7.2. PCA analysis of B cell sample of 18hours post-activation stimulus 
 
B cells were isolated from Dhh-/- and Dhh+/+ and were activated using 5μg/ml anti-
CD40/IgM and treated with or without rShh (0.05μg/ml). After 18hours of culturing, RNA 
samples were purified and analysed using microarray analysis. Comp2 shows that B cell 
samples isolated from Dhh-/- have a different transcriptome profile from Dhh+/+ as 
represented by the broken line. 
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We also investigated more closely the differences in gene expression observed 
following 40hours in culture using PCA. Figure 7.3, shows PCA analysis of the 
different sample sets following 40hours in culture. It was observed, that there was no 
clear differences in gene expression between samples in PC1, PC2, and PC3. However, 
in the case of PC4 (Row D, Column 4), there was a significant difference in gene 
expression profile in purified B cells isolated from Dhh-/- and Dhh+/+. Interestingly, in 
PC4 (Row D, Column 4), the samples derived from Dhh+/+ samples and rShh-treated 
Dhh+/+ samples are all grouped together, suggesting the genes contained within PC4 
can reflect the difference in transcriptome profiles between the B cells isolated from 
wild-type and knockout mice. This data may include the genes that are responsible for 
the impaired B cell development observed in the Dhh-/- at 18hours and 40hours post-
activation stimulus as shown in Chapter 6. Additionally, when considering PC5 (Row E, 
Column 5) (Figure 7.3), it was observed that B cells isolated from Dhh+/+ that were 
treated with exogenous rShh significantly separate from the untreated control at this 
time point and thus may represent the different phenotypes observed between the 
untreated control and treated B cells as shown in Chapter 4. 
 
Taken together these data suggest that the transcriptional profile of B cells vary between 
the different sample sets following 18 and 40hours in culture, also that there are 
differentially expressed genes in B cells isolated from Dhh-/- and Dhh+/+ mice. Thus, it 
became important to identify more closely genes that are differentially expressed 
between these two conditions. To do this, PCA analysis was carried out on B cells 
isolated only from Dhh-/- and Dhh+/+ following 18 and 40hours post-activation in 
culture. 
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Figure 7.3. PCA analysis of B cell sample at 40hours post-activation stimulus 
 
B cells were isolated from Dhh-/- and Dhh+/+ and were activated using 5μg/ml anti-
CD40/IgM and treated with or without rShh (0.05μg/ml). After 40hours culturing, RNA 
samples were purified and analysed using microarray analysis. Differences were observed 
between the transcriptome profiles of B cells isolated from Dhh-/- and Dhh+/+ mice within 
Comp4. Comp5 showed that there were differences in transcriptome profile of B cells 
treated with rShh and the untreated control. 
 
 
7.2.2. Differentially expressed genes in B cells isolated from Dhh-/- and Dhh+/+ at 
18 and 40hours 
 
PCA was first carried out between B cells samples isolated from Dhh-/- and Dhh+/+ 
following 18hours in culture to identify whether there are any differentially expressed 
genes. Figure 7.4A, shows a 2-dimensional PCA analysis at 18hours post-activation. At 
18hours post-activation stimulus, PC1 the largest component and PC3 the smallest 
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component for variation did not show any differences between the B cell samples. 
However, PC2 (Comp 2), the second largest component for variation showed that 
samples of B cells isolated from Dhh-/- were distinguished from samples from the 
Dhh+/+. It was observed that there were 32% of genes that were differentially expressed 
between B cell samples isolated from Dhh-/- and Dhh+/+ mice. Thus, suggesting that 
the transcriptome profile of B cells isolated from Dhh-/- differs from Dhh+/+ littermate 
and the gene candidates generated from PC2 is causing the variation between both 
profiles. 
 
The genes involved in the Hh signalling pathway including Smo, Ptch, Gli1 and Gli3 
were investigated specifically (Figure 7.4B). These genes all had low PC2 scores 
suggesting that they are expressed differently in the transcriptome profile of B cells 
isolated from Dhh-/- and Dhh+/+ mice and expression of these genes may be more 
likely associated with B cells isolated from Dhh+/+ mice (Figure 7.4B). This suggests 
that there is a reduced expression of Smo, Gli1 and Gli3 in B cells isolated from Dhh-/- 
compared to Dhh+/+ littermate. It has been reported that upon activation of B cells, 
Smo expression is up-regulated (Sacedon et al., 2005), thus indicating that the B cells 
become Hh responsive. The reduced expression of Smo observed in B cells isolated 
from Dhh-/- suggests that they are less Hh responsive. Additionally, Gli-1 is itself a 
target gene of the Hh signalling pathway and Gli3 is activated by Smo signalling and 
antagonises the Hh signalling pathway (Briscoe and Therond, 2013). This suggests that 
the reduced Smo signalling in B cells isolated from Dhh-/- leads to a reduced activation 
of the Gli proteins. Thus suggesting that they are less Hh responsive compared to the 
wild type. 
Interestingly, expression of Btk (Bishop, 2004), Nfatc1 (Bhattacharyya et al., 2011) and 
the B cell activation marker, CD69 (Patterson et al., 2006) all had high PC2 scores 
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(Figure 7.4B) thus indicating that there is an increased gene expression in B cell 
samples isolated from Dhh-/- compared to Dhh+/+ mice. 
 
Figure 7.4. PCA analysis of B cell samples isolated from Dhh-/- and Dhh+/+ at 18hours 
post-activation stimulus 
 
B cells were isolated from Dhh-/- and Dhh+/+ and were activated using 5μg/ml anti-
CD40/IgM. After 18hours of culturing, RNA samples were purified and analysed using 
microarray analysis. PCA analysis (A) and candidate genes identified from Comp2 (B). 
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We performed the same closer inspection of PCA analysis of samples collected 
following 40hours post-activation stimulus (Figure 7.5A). Analysis of PC1 and PC2 did 
not show any difference in B cell samples isolated from Dhh-/- compared to Dhh+/+. 
However, when PC3 was analysed it was observed that 24% of the genes were causing 
variation in B cells isolated from Dhh-/- and Dhh+/+. This suggests that the genes 
contained within PC3 contribute to the different gene expression profile of B cells 
isolated from Dhh-/- compared to Dhh+/+. 
 
In Chapter 6, it was demonstrated that there were differences observed in B cell 
activation following 40hours in culture in B cells isolated from Dhh-/- compared to 
Dhh+/+ mice. It was also observed that there was an increased IL-6 secretion and 
reduced IL-10 secretion at this time point in B cells isolated from Dhh-/- compared to 
the Dhh+/+. There was also an increased B cell differentiation towards FO-I B cell and 
the transition from T2 to FO-I B cell is known to be, Btk dependent. This made Btk a 
good candidate gene for further investigation.  
 
Figure 7.5B shows candidate gene contained within PC3 that are differentially 
expressed following 40hours in culture. It was observed that IL-6 had a low PC3 score 
thus indicating that changes in its gene expression may contribute to the phenotype 
observed in B cells isolated from Dhh-/-. Also, IL-10 had a high PC3 score thus 
suggesting it is associated with B cells isolated from Dhh+/+ compared to Dhh-/- 
(Figure 7.5B). These results confirm the findings observed in Chapter 6. Other genes, 
found to be differentially expressed between B cells isolated by PCA at 40hours, 
include CD37, a marker, whose ablation can inhibit humoral production (Knobeloch et 
al., 2000), pro-proliferation protein; Ccnd2, anti-apoptotic protein; Bcl2, which all had a 
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low PC3 score, thus are more associated with B cell samples isolated from Dhh-/-  
(Figure 7.5B). 
 
The results discussed above indicate that there are clear differences in gene expression 
in B cells isolated from Dhh-/- and Dhh+/+ mice at different time points, and expression 
of these genes thus might account for the differences observed in their respective B cell 
maturation in the spleen. However, expression of these candidate genes needs to be 
validated using qRT-PCR. 
 
 
 
 
 
  
 154 
 
 
Figure 7.5. PCA analysis of B cell isolated from Dhh-/- and Dhh+/+ at 40hours post-
activation stimulus 
 
B cells were isolated from Dhh-/- and Dhh+/+ and were activated using 5μg/ml anti-
CD40/IgM. After 18hours of culturing, RNA samples were purified and analysed using 
microarray analysis. PCA analysis (A) and candidate genes identified from Comp2 (B). 
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7.2.3. Genes differentially expressed in B cells isolated from Dhh+/+ after 
treatment with exogenous rShh  
 
In previous chapters (Chapter 3, 4 and 5), the treatment of B cells with exogenous rShh 
has been shown to regulate B cell activation, survival and differentiation at different 
time points. Thus, it was equally important to identify the target genes regulated by Hh 
signalling in B cells when treated with exogenous rShh at the different time points in 
order to understand the molecular mechanisms that underpin these observations. Data 
presented in Figure 7.3, showed using PCA analysis that there are a number of 
differentially expressed gene profiles between B cells isolated from Dhh-/-, Dhh+/+ 
treated with exogenous rShh and Dhh+/+ control following 40hours in culture. Hence, a 
further PCA analysis was carried out in order to identify the genes causing variation 
between rShh treated and untreated B cells isolated from Dhh+/+ mice at both time 
points. 
 
Figure 7.6A, shows the PCA analysis of the data obtained at 18hours post-activation 
showing data from B cell samples isolated from Dhh+/+ and with treatment with rShh. 
The largest component, PC1 did not show any significant differences, neither did PC2. 
However, analysis of PC3 showed that 30% of genes varied between the rShh treated 
and untreated samples.  Figure 7.6B, shows PCA analysis of data obtained at 40hours 
post-activation stimulus showing data from B cell samples isolated from Dhh+/+ and 
with treatment with rShh. It was observed that neither PC1, PC2, PC3 showed any 
variability between the rShh treated B cell samples and the untreated control. 
 
The results obtained suggest that treatment of B cells with exogenous Hh can activate 
different signalling pathways involved in the regulation of B cell function at 18hours 
post-activation and these genes may contribute to the phenotypic differences observed 
in B cells treated with exogenous rShh at 40hours post-activation stimulus. However, by 
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40hours post activation stimulus the patterns of gene transcription between treated and 
untreated samples have stabilised and are closely related. Thus, candidate genes 
generated within PC3 at 18hours (Figure 7.6A), were selected to be analysed further. 
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Figure 7.6. PCA analysis of Hh treated B cells and the control at 18hours and 40hours 
post-activation stimulus 
B cells were isolated from Dhh+/+were activated using 5μg/ml anti -CD40/IgM and treated 
with or without rShh (0.05μg/ml). After 18hours (A) and 40hours (B) of culturing, RNA 
samples were analysed by micro-array analysis. 
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The gene list generated in respect of PC3 was investigated closely. Genes of interest 
that were identified from this analysis included genes involved in the BCR signalling 
pathway, as well as the induction of B cell differentiation and apoptosis, Interestingly, 
expression of other morphogens such as BMP also varied indicating that there is an 
interplay between these two morphogens families in regulating peripheral B cell 
development (Figure 7.7A).  
 
We found that genes involved in preventing the apoptotic pathway such as the pro-
survival factors Bcl2 and Traf2 as well as those genes with pro-apoptotic activity such 
as Bnip3 (Liu and Frazier, 2015), were identified as genes contributing to the variation 
in gene expression between samples. It was observed that Traf2, an anti-apoptotic 
protein (Bishop, 2004) had a high PC3 score (Figure 7.7A), thus indicating that major 
changes in its gene expression is contributing to the phenotype associated with B cells 
isolated from Dhh+/+ in the presence of exogenous rShh.  
 
 Further verification of Traf2 expression using qRT-PCR showed that by 18hours post-
activation stimulus, there was a significant increase in expression of approximately 
6fold in the rShh treated cells compared to the untreated control (Figure 7.7B). 
Interestingly, the levels of Traf2 decreased significantly between 18 and 40hours post-
stimulus in B cells treated with rShh. These results suggest that Hh signalling can 
modulate B cell survival via the up-regulation of anti-apoptotic protein such as Traf2 at 
18hours post-activation stimulus. This is consistent with the increased survival of B 
cells observed using annexin-V staining after 18hours in our culture as shown in 
Chapters 3 and 4. The down-regulation of Traf2 expression at 40hours post-stimulus is 
also consistent with the annexin-V data, suggesting that Hh signalling can induce B cell 
apoptosis via down-regulation of Traf2. Overexpression of Traf2 activates the NfκB and 
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MAPK pathways, which can then increase B cell survival (Bishop, 2004). Also, Traf2 
expression has been shown to favour FO B cell differentiation and survival (Perez-
Chacon et al., 2012), and it has been reported that Traf2 expression leads to the 
synergistic activation of B cells, and production of immunoglobulin and IL-6 (Bishop, 
2004). Thus, the increased Traf2 expression observed in B cells treated with rShh, 
might play a role in the increased FO-I differentiation driven by exogenous rShh 
(Chapter 5) and thus lead to the increased IL-6 secretion and antibody production 
(Chapter 4) observed in our culture in treated B cell samples. 
 
The expression of Bnip3 was also verified using qRT-PCR. BCL2/ adenovirus E1B 
19kDa interacting protein (Bnip3) is a pro-apoptotic protein that contributes to cell 
death through the activation of the mitochondrial pathway of apoptosis. Bnip3 has a c-
terminal transmembrane domain, which is required for mitochondrial targeting and for 
its pro-death function. Upon activation of Bnip3, it localises to the mitochondria, where 
it collapses mitochondria membrane potential, increases reactive oxygen species, and 
increases mitochondrial swelling thus leading to activation of cell death. Interestingly, 
over expression of Bnip3 has been shown to occur in a number of tumours including 
follicular lymphoma indicating that Bnip3 may act as both a tumour suppressor as well 
as a tumour promoter (Sington et al., 2007). 
 
Figure 7.7C, shows qRT-PCR data on Bnip3 expression in purified B cells treated with 
rShh and untreated B cells after 18 and 40hours post-activation stimulus. At 18hours 
post-activation, there were low levels of Bnip3 expressed in both the treated and 
untreated samples. Interestingly, by 40hours post-activation stimulus, expression of 
Bnip3 had increased in both samples but it had increased significantly by approximately 
5-fold in B cells treated with exogenous rShh compared to the untreated control only. 
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This correlates with the induction of a significant increase in cell death in the presence 
of rShh following 40hours in culture as shown in Chapter 3 and 4. 
 
These results suggest that Hh signalling can regulate B cell survival following 18 and 
40hours post-activation stimulus via the up-regulation of the anti-apoptotic protein 
Traf2 and the pro-apoptotic protein Bnip3 respectively thus indicating that Hh 
signalling can induce both survival and death in B cells. The finding that a morphogen 
can induce apparently opposing physiological processes is not a new finding and has 
previously been published as occurring during thymocyte development (Outram et al., 
2009) and may reflect a complex negative feedback process maintained by Hh 
signalling. 
 
Other genes, identified using microarray gene analysis as being differentially expressed 
include genes whose expression is involved in the BCR signalling pathway, such as Btk 
and Nfatc1 (Figure 7.7A). Further verification using qRT-PCR, showed that both Btk 
and Nfatc1 are differentially expressed in B cells treated with rShh compared to 
untreated B cells. 
 
Figure 7.7D shows qRT-PCR data of Btk expression in purified B cells treated with 
rShh and the control untreated at 18 and 40hours post-activation stimulus. At 18hours 
post-activation, there was a nearly significant 3-fold increase in Btk expression in B 
cells treated with rShh compared to the untreated control. At 40hours post-activation 
stimulus, Btk expression had become very similar between the treated and untreated 
samples. In the control untreated B cells, Btk expression had increased, however, there 
has been a decrease in Btk expression in B cells treated with rShh. These results support 
the findings observed in chapter 5, which showed that the treatment of B cells with rShh 
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drives an increased B cell differentiation towards Btk dependent FO-I B cells at 18hours 
post-activation stimulus compared to the untreated control (Pillai and Cariappa, 2009) 
and by 40hours a decrease in Btk dependent FO-I 
 
Figure 7.7E, shows qRT-PCR data for Nfatc1 expression in untreated B cells as well as 
B cells treated with rShh. At 18hours post-activation, Nfatc1 expression is increased in 
B cells treated with rShh by approximately 1.6 fold compared to the control, however, 
this was not significant. At 40hours post-activation stimulus, the levels of Nfatc1 have 
decreased in B cells treated with 0.05μg/ml rShh but the control has expressed more 
Nfatc1 between 18 and 40hours post-activation stimulus. This pattern of expression 
mirrors the expression observed with Btk expression and suggests that their expression 
may be co-regulated. It has been reported that mice with complete deletion of Nfatc1 
showed an increase in IL-10 secreting B cells and they exhibited a mild clinical course 
of experimental autoimmune encephalomyelitis (EAE), a mouse model for human 
multiple sclerosis (Bhattacharyya et al., 2011). The data presented in this chapter, 
showed that at 40hours post-activation stimulus, treatment of purified B cells with 
exogenous rShh decreased Nfatc1 expression and thus may correlate with the increased 
IL-10 secretion observed in our purified B cell culture in the presence of rShh (Chapter 
4).  
 
These results indicate that treatment of B cells with exogenous rShh can potentiate the 
BCR signal possibly by inducing an up-regulation of expression of kinases involved in 
the BCR signalling pathway and, as a result, enhancing survival. However, this signal 
might be too strong and thus induce activation induced cell death (AICD) that can lead 
to the up-regulation of pro-apoptotic protein such as Bnip3, which in turn may increase 
cell death at 40hours post-activation stimulus.  
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Data presented in Chapter 3, demonstrated that the effect of Hh signalling in B cells is, 
in part, due to the effects of BMP signalling occurring downstream of the Hh signal. 
Additionally, PCA analysis of microarray data obtained from samples derived from 
treated and untreated samples identified a pattern of differential expression for Bmp2/4 
causing variation between control and treated samples (Figure 7.7A). Further 
verification using qRT-PCR, revealed that at 18hours post-activation stimulus, there is 
an increase, albeit not significant, in gene expression of Bmp2 (Figure 7.7F) and Bmp4 
(Figure 7.7G) in B cells treated with exogenous rShh compared to untreated control. At 
40hours post-activation stimulus, gene expression of Bmp2/4 had decreased in B cells 
treated with rShh compared to control. 
 
These data suggests that treatment of B cells with rShh, can up-regulate BMP 
expression and therefore the BMP signalling pathway at 18hours post-activation 
stimulus. The downstream effects of the activated BMP signalling pathway may then 
only be observed at the later time-point of 40hours in culture. These data indicate that 
the effects of rShh on peripheral B cell development may occur, in part due to an 
involvement of an interplay with another morphogen, BMP. 
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Figure 7.7. qRT-PCR verification of candidate genes 
The PCA shows the different candidate genes identified from PC3 at  18hours post-
activation stimulus in B cells treated with rShh and the control (A). Purified B cells were 
activated and treated with rShh. At 18 and 40hours, RNA was analysed for expression of 
Traf2 (B), Bnip3 (C), Btk (D), Nfatc1 (E), Bmp2 (F) and Bmp4 (G) using qRT-PCR. The 
bar chart is representative of two or three biological experiments. The significance of the 
gene expression was analysed by Student t test (**p≤0.01 *p≤0.05). 
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7.3. Discussion 
 
It has been reported in previous chapters that treatment of B cells with exogenous rShh 
can regulate peripheral B cell differentiation and survival. Additionally, in Chapter 6, it 
was shown that there was an impaired B cell development in B cells isolated from Dhh-
/- compared to Dhh+/+. The aim of this chapter was to investigate the molecular targets 
of Hh signalling that is used in regulating peripheral B cell development. In this study, 
we used microarray gene expression analysis to investigate whether there are any 
differences in the transcriptome profile of B cells isolated from Dhh-/- and 
Dhh+/+mice. Also, to investigate the differences in gene expression profile of B cells 
treated with rShh and the untreated control.  
 
The data presented in this chapter reveals that, using PCA, we could identify set of 
differentially expressed genes in B cells isolated from Dhh-/- compared to Dhh+/+ at 18 
and 40hours post-activation stimulus. These genes might be responsible for the 
impaired B cell development observed in the Dhh-/- as well as the altered levels of Ig 
and cytokine secretion observed in cultures (Chapter 6). Candidate genes identified 
would be required to be verified using qRT-PCR in order to identify whether the 
findings in relation to altered gene expression were significant. The data presented here 
also demonstrates that treatment of B cells with exogenous rShh resulted in the 
differential expression of genes such as Traf2, Btk, Nfatc1 Bnip3 and Bmp2/4 in treated 
samples compared to the untreated control at 18hours post-activation stimulus. 
However, by 40hours in culture, our PCA analysis revealed that there was no significant 
difference between treated and untreated B cell samples, thus indicating that while Hh 
target genes are induced at 18hours in our culture system by 40hours in culture, they 
have exerted their biological effects and have been subsequently down regulated. 
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These findings indicate that treatment of B cells with rShh at 18hours post-activation 
stimulus could strengthen BCR signalling thus accelerating B cell activation, 
differentiation and survival with an associated up-regulation of gene expression of Btk, 
Nfatc1 and Traf2. Increased Btk expression may drive the expansion of B cells towards 
the Btk-dependent, FO-I B cell rather than to the Btk independent MZ B cell. Consistent 
with this idea, phenotypic analysis of the differentiation of B cells in culture showed 
that in the presence of exogenous rShh, there was an increase in the presence of FO-I B 
cells at 18hours post-activation stimulus (Chapter 5).  However, by 40hours post-
activation stimulus, possibly due to the increased strength of the BCR signal induced at 
18hours by rShh treatment; there is an increased induction of apoptosis in B cell 
possibly due to the induction of activated induced cell death or via the up-regulation of 
pro-apoptotic protein Bnip3, resulting in the reduced presence of FO-I B cells. This is 
accompanied by decreased Btk and Nfatc1 expression at this later time point. 
 
It has been reported that auto-reactive and anergic B cells rely on Btk signalling in order 
to mature and survive during onset of the autoimmune disease, Type 1 diabetes 
(Bonami et al., 2014). Also, over-expression of Btk can induce spontaneous formation 
of GC and plasma cell formation, eventually giving rise to autoantibodies, which leads 
to development of lupus like symptoms in mice (Kil et al., 2012). It would be of 
interest, therefore, to identify if the increased antibody production observed in the 
presence of rShh protein reported in Chapter 4 contains within it a higher proportion of 
autoantibody compared to the untreated control. 
 
Additionally, it was demonstrated in this chapter that treatment of B cells with rShh 
could lead to an increased expression of Bmp2 and Bmp4 at 18hours post-activation 
stimulus. In B cells, BMP signalling has been shown to inhibit antibody production and 
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increase B cell apoptosis (Huse et al., 2011). Thus, the induction of expression of these 
proteins, might contribute to arrested production of antibody as well as the increased 
apoptosis observed in treated B cells at 40hours post-activation stimulus. This suggests 
an interplay between the two morphogens families, Hh and BMP, in regulating 
peripheral B cell development. 
 
 
7.4. Conclusion  
 
In conclusion, the findings in this chapter indicate that Hh signalling may induce an 
accelerated B cell mediated immune response in response to antigens by up-regulating 
target genes involved in transmitting the signal through the BCR as well as in the 
control of survival and death of B cells.  It is possible that this programme of 
accelerated development can also induce B cell death thus resulting in down-regulation 
of these effects in order to avoid the onset of pathology. However, in autoimmune 
diseases such as SLE and multiple sclerosis and B cell lymphomas, Hh signalling might 
have lost the ability to negatively regulate these effects, or the negative effects are 
silenced in these pathologies.  
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Chapter 8: General discussion and future directions  
 
 
8.1. Discussion 
 
Hh signalling has been reported to regulate a plethora of functions in a wide variety of 
tissues. In T cells, Hh signalling has been shown to play a role in both thymic (Outram 
et al., 2000) and peripheral T cell development (Chan et al., 2006, Rowbotham et al., 
2007). However, little is known about the role of Hh signalling in peripheral B cell 
development. With this gap in the literature in mind, the research presented in this thesis 
shows an analysis of the effect of Hh signalling in peripheral B cell development using 
mouse splenic B cells as a model. 
 
Firstly, the effect of rShh treatment on B cell activation and survival in a mixed 
splenocyte population was investigated (Chapter 3). It was demonstrated that treatment 
of B cells in a mixed splenocyte population with exogenous rShh could increase B cell 
activation as judged using CD23 and survival as judged using annexin-V at 18hours 
post-activation stimulus. This finding is consistent with the findings of Sacedon et al 
2005. However, by 40hours post-activation stimulus, it was observed that treatment of 
B cells with rShh increased B cell apoptosis and arrested, or decreased activation 
(Chapter 3, Figure 3.4). This suggested that Hh signalling could regulate both activation 
and survival of B cells. The increased apoptosis observed with treatment with rShh at 
40hours in our culture was hypothesised to involve the actions of another morphogen, 
BMP. Using noggin, a BMP inhibitor, it was demonstrated that the effect of Hh 
treatment on B cells at 40hours post-activation stimulus was inhibited upon addition of 
Noggin to the cultures (Chapter 3, Figure 3.6). These data suggested that Hh signalling 
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can have an effect on B cell development and this may be mediated, in part, by BMP 
signalling.  
 
In the following chapter (Chapter 4), the effect of rShh treatment on purified B cells 
was explored in order to investigate whether or not the observed effects in the mixed 
splenocyte cultures was intrinsic to B cells or required the presence of another cell type 
in the spleen. The findings in Chapter 4, demonstrated that treatment of purified B cells 
with rShh can also increase B cell activation (as judged by CD23 expression) and 
survival (as judged using Annexin-V) at 18hours post-activation stimulus and at 
40hours post-activation stimulus, rShh treatment arrested, or decreased, activation and 
survival as observed in the mixed cell culture (Chapter 4, Figure 4.1 and 4.2). These 
data indicated that the effects of Hh treatment observed in B cells, were intrinsic to B 
cells and did not require the presence of any other cellular subset in the spleen.  
Analysis of the late B cell activation marker, CD25, revealed that treatment of purified 
B cells with exogenous rShh could increase expression of this marker at 40hours post-
activation stimulus. Further analysis of the co-expression of early B cell activation 
marker, CD23, and late B cell activation marker, CD25, lead to the identification of 
three subsets named subset I, II and III, which are, CD23+CD25-. CD23+CD25+ and 
CD23-CD25+ respectively. It was observed that rShh treatment could increase the 
representation of CD23-CD25+ B cells at 40hours post-activation stimulus and decrease 
the representation of subset I (CD23+CD25-). Further characterisation of these subsets 
revealed that subset I CD23+CD25- was negative for the Breg marker, IL-10 and 
human memory B cell marker, CD27. However, subset II CD23+CD25+ was positive 
for IL-10, and rShh treatment increases the percentage of IL-10+ B cells at 40hours 
post-activation stimulus. Further verification using ELISA, showed that rShh treatment 
of purified B cells could increase IL-10 secretion compared to the untreated control. 
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Subset III CD23-CD25+ B cells were negative for IL-10 expression and positive for 
expression of the human memory B cell marker, CD27, with rShh treatment increasing 
the percentage of CD27+ B cells at 40hours post-activation stimulus. These results 
suggest that Hh signalling can regulate B cell differentiation towards B cells that 
express IL-10 and CD27. The production of antibody and IL-6 was also investigated. It 
was demonstrated that rShh treatment of B cells could increase antibody secretion and 
IL-6 secretion at 18hours post-activation stimulus and at 40hours post-activation 
stimulus, an arrest in secretion was observed. However, it must be considered, that the 
data observed in respect to antibody and IL-6 secretion at 40hours post-activation 
stimulus could be due to the observed increase in apoptosis. 
 
Having observed in Chapter 4, that three subsets were arising in our culture and that 
following treatment with rShh, the representation of these subsets was altered, further 
characterisation of these subsets was carried out in order to identify the true identity and 
functions of these subsets. In Chapter 5, CD23+CD25-, CD23+CD25+ and CD23-
CD25+ B cells were sorted and analysed in isolation. It was demonstrated that 
CD23+CD25- B cells were FO-I B cells (Pillai and Cariappa, 2009), with treatment of 
Hh inducing B cell death in these cells by 40hours in culture (Chapter 5, Figure 5.3 & 
5.12). CD23+CD25+ B cells were shown to be a mix of cells including FO-I, T2/FO-II 
and T2-MZP, while CD23-CD25+ B cells were shown to contain MZ B cells and 
memory B cells as these cells were CD80high (Chapter 5, Figure 5.7). Additionally, at 
18hours post-activation stimulus, treatment of B cells with rShh increased B cell 
differentiation towards FO-I B cells and at 40hours post-activation stimulus; it was 
observed that there is a decrease in FO-I representation and an emergence of T2-MZP B 
cells. These results suggested that treatment of B cells with exogenous Hh could affect 
the differentiation of peripheral B cells. It is possible that exogenous Hh treatment can 
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strengthen the BCR signal, which could, in turn, increase B cell activation, survival and 
differentiation towards the Btk dependent FO-I cell at 18hours in our culture, however, 
at 40hours in culture, due to the strong signal induced in FO-I B cells, they are induced 
to die, possibly as a result of activation induced cell death (AICD), hence increased 
apoptosis at 40hours post-activation stimulus was observed.   
 
The investigation was furthered by investigating the effect of the loss of Hh signalling 
on B cell development using Dhh knockout mice as a model. In Chapter 6, it was 
demonstrated that B cells isolated from Dhh-/- exhibited a skewed peripheral B cell 
development. At 40hours post-activation stimulus, it was observed that they had an 
increased representation of Btk dependent FO-I, increased IL-6 and IgG1 secretion, and 
decreased IL-10 secretion when compared to the wild-type littermate. These results 
indicated that the loss of Dhh, can affect peripheral B cell development.  
 
In order to elucidate the molecular mechanism by which Hh signalling regulates B cell 
development and to investigate whether there are any differences in the transcriptome 
profile of B cells isolated from Dhh-/- and Dhh+/+, a microarray analysis was 
performed (Chapter 7). It was demonstrated using PCA, there were differences in the 
transcriptome profile of B cells isolated from Dhh-/- compared to the Dhh+/+ control. It 
was observed that genes including CD37, Btk, IL-10, and IL-6 were differentially 
expressed between B cells isolated from Dhh-/- and the Dhh+/+. It was also 
demonstrated using qRT-PCR that treatment of B cells with exogenous rShh can lead to 
increased expression of the BCR signal kinase, Btk, transcription factor, Nfatc1, anti-
apoptotic protein, Traf2 at 18hours post-activation stimulus. At 40hours post-activation 
stimulus, it was observed that there was a decrease in expression of these genes, 
however, it was demonstrated that there was also an increase in pro-apoptotic protein 
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Bnip3. Exogenous Hh treatment was also shown to increase the expression of Bmp2/4. 
These results suggest that Hh signalling could regulate peripheral B cell development 
via strengthening the BCR signalling pathway and by inducing expression of BMP. 
In summary, it was demonstrated in this thesis, that treatment of B cells at 18hours post-
activation with exogenous Hh can potentiate the BCR signal by increasing components 
of the BCR signalling pathway including Btk, Nfatc1 and Traf2. This increased 
expression could lead to an increased B cell activation and survival and ultimately, an 
increased differentiation towards FO-I, which can secrete antibody and IL-6. However, 
at 40hours post-activation stimulus, the increased BCR signal (induced at 18hours post-
stimulus with exogenous Hh treatment) could possibly induce activation induced cell 
death in FO-I B cells or increase the expression of pro-apoptotic proteins such as Bnip3, 
which, then leads to an increased apoptosis and an arrest in antibody production and IL-
6 secretion and a decrease in Btk, Nfatc1 and Traf2 expression.  The reduced Btk 
expression at 40hours post-activation stimulus, might lead to the B cells differentiating 
into Btk independent T2-MZP, and MZ B cells which can secrete IL-10 as well as 
memory B cells at this latter time point. Figure 8.1, shows a model of events observed 
occurring with Hh treatment. 
However, in the case of B cells isolated from Dhh-/-, there is an increased 
differentiation of B cells towards the Btk dependent FO-I at 40hours post-activation 
stimulus, which leads to an increased IL-6 and IgG1 secretion at this time point. It is 
possible that peripheral B cell development require the presence of Dhh to mediate the 
apparent arrest in B cell development observed at the later time point in our cultures and 
for the ability to divert B cell differentiation away from FO-I and towards other B cell 
lineages. Hence, it can be assumed that lack of exogenous Hh treatment or the absence 
of one of the homologue of Hh protein, can lead to the BCR signal not being potentiated 
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in these cells and therefore activation induced cell death is not induced. This could 
result in increased survival of the FO-I B cells.  It was observed using PCA, that there 
was an increased expression of Btk in B cells isolated from Dhh-/- compared to the 
wild-type. This increased Btk expression may drive increased Btk dependent 
differentiation of FO-I B cells with the associated decrease in differentiation towards 
T2-MZP and MZ B cells observed in B cell cultures isolated from Dhh-/- mice. This 
hypothesis is also consistent with the observed reduced IL-10 secretion by B cells 
isolated from Dhh-/- mice.  This apparently unregulated immune response by B cells 
isolated from Dhh-/- could lead to the development of autoimmunity as over-expression 
of Btk, has been shown to lead to the survival of auto-reactive B cells which cause 
symptoms of auto-immune diseases (Kil et al., 2012). This possibility needs to be 
investigated and the findings used to develop potential new therapeutics for use in the 
treatment of B cell mediated autoimmune disease. A proposed model of events of the 
role of Shh in peripheral B cell development is shown in Figure 8.1. 
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Figure 8.1 A proposed model of events illustrating the effect of exogenous Hh on 
peripheral B cell development. 
A schematic model illustrating the effect of rShh observed in peripheral B cell 
development, 18hours (Red), 40hours (Green) and Dhh-/- 40hours (Purple). At 
18hours, Hh treatment can drive FO-I differentiation characterised by an increase in 
Btk, Nfatc1, Traf2 as well as antibody and IL-6 secretion. At 40hours, Hh treatment is 
leading to an increased B cell death via the induction of pro-apoptotic protein Bnip3. 
There is also an increased differentiation towards T2-MZP B cells that can secrete 
IL-10. However, in Dhh-/-, the effect observed at 40hours, was similar to the effect 
of Hh treatment at 18hours and if unregulated can lead to autoimmunity. Perhaps, the 
effect observed at 40hours with rShh, can possibly be used as an interventional 
therapy in autoimmunity. 
8.2. Future directions 
 
This thesis provides new evidence that Hh signalling may be able to strengthen the BCR 
signal thus accelerating the immune response and subsequently lead to a down-
regulation of the immune response via different mechanisms including the up-regulation 
of apoptosis.  
In 2005, Sacedon et al., (2005), showed that all GC B cells express Ptch and 30% co-
expressed Smo, which increases following B cell activation. Shh signalling was shown 
to be a physiological requirement for GC B cell survival (Sacedon et al., 2005). 
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Additionally, it was reported in this thesis that treatment of isolated CD23+CD25- B 
cells, which were characterised to be FO-I B cells, with rShh, lead to an increased death. 
Hence, it is possible, that FO-I B cells may have lost the ability to respond to a Hh 
signal or no longer express the receptors for Hh. It is also possible that they require the 
presence of another B cell subset to secrete Hh protein. Thus, it would be important to 
characterise the different peripheral B cell subset including, T1, T2, FO-I, FO-II, T2-
MZP and MZ in terms of their expression for the Hh signalling component including 
Ptch, Smo and Gli proteins. Using, flow cytometry, the expression of Ptch and Smo 
could be investigated in the peripheral B cell subsets. Using RT-PCR, the expression of 
the Gli proteins in the different peripheral subsets could be investigated. Also, it was 
observed that treatment of B cells with exogenous rShh, could increase the expression 
of genes including Bnip3, Traf2, Btk, Nfatc1 and Bmp2/4. It would be important to 
investigate whether these genes are induced differently in the different peripheral 
subsets observed in our culture including CD23+CD25-, (subset I) CD23+CD25+ 
(subset II) and CD23-CD25+ (subset III). Thus, it would be important to sort the subsets, 
and examine them in isolation for their expression of these genes. A pilot experiment 
has been carried out, although inconclusive, it remains very promising. 
 
Additionally, it would be important to investigate whether the increased differentiation 
to T2-MZP B cells at 40hours post-activation stimulus that can secrete IL-10 could have 
any therapeutic effect. It has been reported by Evans et al., (2007), that T2-MZP B cells 
were able to prevent and ameliorate disease in a mouse model of experimental arthritis 
(Evans et al., 2007). It is possible that the increased IL-10 observed following rShh 
treatment of B cells could have the ability to suppress autoimmune disease. An in-vivo 
study using a mouse model in which a pro-inflammatory disease has been induced could 
be used to investigate whether the disease would be milder following treatment with 
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exogenous Hh. Using a different mouse model for autoimmunity such as the EAE 
mouse model (a mouse model for multiple sclerosis) Exogenous Hh could be given 
intravenously, in order to investigate whether; it would increase differentiation towards 
T2-MZP B cells that can secrete IL-10 and reduce disease pathology. This would open 
the possibility of using Hh signalling for therapy in autoimmunity. 
 
The microarray analysis done in this study to identify whether there are any differences 
in the gene expression profile in B cells isolated from Dhh-/- compared to Dhh+/+ was 
carried out with a limited amount of samples and thus needs to be supported with 
further experiments. However, it was observed that there were differentially expressed 
genes in B cells isolated from Dhh-/- compared to Dhh+/+ including CD37. CD37 is a 
tetraspanin that is expressed in mature B cells and has been reported to be highly 
expressed in B cell lymphomas including, B-CLL and leukaemia. Inactivation of CD37 
has been shown to lead to a reduced secretion of antibody (Flinn, 2011). In this thesis, it 
was demonstrated that there was increased IgG1 secretion in B cells isolated from Dhh-
/- compared to the wildtype. It is possible that the increased IgG1 secretion is due to an 
increased expression of CD37 in B cells isolated from Dhh-/-. Hence, the expression of 
this gene should be validated using RT-PCR. Additionally, there was increased FO-I 
differentiation in B cells isolated from Dhh-/- compared to the wild-type. It would be 
important to investigate the expression of the components of the BCR signalling 
pathway, including Btk, Nfatc1 and Traf2 in B cells isolated from Dhh-/- mice. 
 
It was also demonstrated in this thesis, that exogenous rShh treatment could increase the 
expression of BMP proteins (Bmp2/4). Thus indicating the effect of Hh signalling may, 
in part, due to downstream BMP signalling. An investigation into the exact mechanism 
by which Hh and BMP signalling interact to regulate B cell development would be of 
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interest as BMP signalling is regulated by a number of secreted proteins including 
twisted gastrulation which is produced by activated B cells (Tsalavos et al., 2011). It 
would be important to investigate whether the effect observed in this thesis with rShh 
treatment on B cells at 40hours post-activation stimulus would be any different in the 
absence of BMP proteins. Using a BMPR1a knockout mouse, these effects could be 
investigated, as there is a possibility that Hh and BMP signalling pathway interact at 
checkpoints during peripheral B cell development. This study would influence future 
studies and open the possibility for use in therapeutics in B cell mediated immune 
diseases. 
 
8.3. Significance of findings 
 
The results described in this study provide a new understanding of the role Hh 
signalling plays in the regulation of peripheral B cell development. It demonstrates for 
the first time that Hh treatment of B cells with rShh can potentiate the B cell immune 
response but can also lead to increased death of B cells. Thus causing a subsequent 
down-regulation of the immune response, which can prevent the onset of disease. This 
study also reveals some of the molecular targets of the Hh signalling pathway that is 
used in regulating peripheral B cell development. Moreover, treatment of B cells with 
exogenous Hh induced the increased expression of BMP proteins thus indicating an 
interplay for these morphogens in regulating peripheral B cell development. Taken 
together, these data suggest that, it is possible that targeting the Hh signalling pathway 
could be used as an interventional therapy for the treatment of B cell autoimmune 
diseases and B cell lymphoma. 
  
 177 
References 
 
Agematsu, K., Hokibara, S., Nagumo, H. and Komiyama, A. (2000) 'CD27: a memory B-
cell marker', Immunol Today, 21(5), pp. 204-6. 
Ali, I. H. and Brazil, D. P. (2014) 'Bone morphogenetic proteins and their antagonists: 
current and emerging clinical uses', Br J Pharmacol, 171(15), pp. 3620-32. 
Allman, D. and Pillai, S. (2008) 'Peripheral B cell subsets', Curr Opin Immunol, 20(2), pp. 
149-57. 
Amu, S., Gjertsson, I. and Brisslert, M. (2010) 'Functional characterization of murine CD25 
expressing B cells', Scand J Immunol, 71(4), pp. 275-82. 
Amu, S., Gjertsson, I., Tarkowski, A. and Brisslert, M. (2006) 'B-cell CD25 expression in 
murine primary and secondary lymphoid tissue', Scand J Immunol, 64(5), pp. 482-
92. 
Amu, S., Tarkowski, A., Dorner, T., Bokarewa, M. and Brisslert, M. (2007) 'The human 
immunomodulatory CD25+ B cell population belongs to the memory B cell pool', 
Scand J Immunol, 66(1), pp. 77-86. 
Anderson, D. M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, A., Giri, J., 
Copeland, N. G., Gilbert, D. J., Jenkins, N. A. and et al. (1995) 'Functional 
characterization of the human interleukin-15 receptor alpha chain and close linkage 
of IL15RA and IL2RA genes', J Biol Chem, 270(50), pp. 29862-9. 
Atwood, S. X., Whitson, R. J. and Oro, A. E. (2013) '"Patch"ing up our tumor signaling 
knowledge', J Invest Dermatol, 133(5), pp. 1131-3. 
Bajestan, S. N., Umehara, F., Shirahama, Y., Itoh, K., Sharghi-Namini, S., Jessen, K. R., 
Mirsky, R. and Osame, M. (2006) 'Desert hedgehog-patched 2 expression in 
peripheral nerves during Wallerian degeneration and regeneration', J Neurobiol, 
66(3), pp. 243-55. 
Berglund, L. J., Avery, D. T., Ma, C. S., Moens, L., Deenick, E. K., Bustamante, J., 
Boisson-Dupuis, S., Wong, M., Adelstein, S., Arkwright, P. D., Bacchetta, R., 
Bezrodnik, L., Dadi, H., Roifman, C. M., Fulcher, D. A., Ziegler, J. B., Smart, J. M., 
Kobayashi, M., Picard, C., Durandy, A., Cook, M. C., Casanova, J. L., Uzel, G. and 
Tangye, S. G. (2013) 'IL-21 signalling via STAT3 primes human naive B cells to 
respond to IL-2 to enhance their differentiation into plasmablasts', Blood, 122(24), 
pp. 3940-50. 
Berland, R. and Wortis, H. H. (2002) 'Origins and functions of B-1 cells with notes on the 
role of CD5', Annu Rev Immunol, 20, pp. 253-300. 
  
 178 
Bhardwaj, G., Murdoch, B., Wu, D., Baker, D. P., Williams, K. P., Chadwick, K., Ling, L. 
E., Karanu, F. N. and Bhatia, M. (2001) 'Sonic hedgehog induces the proliferation 
of primitive human hematopoietic cells via BMP regulation', Nat Immunol, 2(2), pp. 
172-80. 
Bhatia, M., Bonnet, D., Wu, D., Murdoch, B., Wrana, J., Gallacher, L. and Dick, J. E. 
(1999) 'Bone morphogenetic proteins regulate the developmental program of human 
hematopoietic stem cells', J Exp Med, 189(7), pp. 1139-48. 
Bhattacharyya, S., Deb, J., Patra, A. K., Thuy Pham, D. A., Chen, W., Vaeth, M., 
Berberich-Siebelt, F., Klein-Hessling, S., Lamperti, E. D., Reifenberg, K., Jellusova, 
J., Schweizer, A., Nitschke, L., Leich, E., Rosenwald, A., Brunner, C., Engelmann, 
S., Bommhardt, U., Avots, A., Muller, M. R., Kondo, E. and Serfling, E. (2011) 
'NFATc1 affects mouse splenic B cell function by controlling the calcineurin--
NFAT signaling network', J Exp Med, 208(4), pp. 823-39. 
Bijlsma, M. F., Peppelenbosch, M. P. and Spek, C. A. (2006) 'Hedgehog morphogen in 
cardiovascular disease', Circulation, 114(18), pp. 1985-91. 
Bishop, G. A. (2004) 'The multifaceted roles of TRAFs in the regulation of B-cell function', 
Nat Rev Immunol, 4(10), pp. 775-86. 
Bitgood, M. J. and McMahon, A. P. (1995) 'Hedgehog and Bmp genes are coexpressed at 
many diverse sites of cell-cell interaction in the mouse embryo', Dev Biol, 172(1), 
pp. 126-38. 
Bitgood, M. J., Shen, L. and McMahon, A. P. (1996) 'Sertoli cell signaling by Desert 
hedgehog regulates the male germline', Curr Biol, 6(3), pp. 298-304. 
Blair, P., Ehrenstein, M. R. and Mauri, C. (2008) 'Immunoregulatory potential of T2-MZP 
B cells', Fut Rheumatol, 3(1), pp. 79-84. 
Bolha, L., Dušanić, D., Narat, M. and Oven, I. (2012) 'Comparison of methods for relative 
quantification of gene expression using real-time PCR', Acta agriculturae Slovenica, 
100(2). 
Bonami, R. H., Sullivan, A. M., Case, J. B., Steinberg, H. E., Hoek, K. L., Khan, W. N. and 
Kendall, P. L. (2014) 'Bruton's tyrosine kinase promotes persistence of mature anti-
insulin B cells', J Immunol, 192(4), pp. 1459-70. 
Bonnefoy, J. Y., Lecoanet-Henchoz, S., Aubry, J. P., Gauchat, J. F. and Graber, P. (1995) 
'CD23 and B-cell activation', Curr Opin Immunol, 7(3), pp. 355-9. 
Brazil, D. P., Church, R. H., Surae, S., Godson, C. and Martin, F. (2015) 'BMP signalling: 
agony and antagony in the family', Trends Cell Biol. 
Brennan, D., Chen, X., Cheng, L., Mahoney, M. and Riobo, N. A. (2012) 'Noncanonical 
Hedgehog signaling', Vitam Horm, 88, pp. 55-72. 
  
 179 
 
Briscoe, J. and Rohatgi, R. (2012) 'Singapore signalling: the 2012 hedgehog pathway 
cocktail', EMBO Rep, 13(7), pp. 580-3. 
Briscoe, J. and Therond, P. P. (2013) 'The mechanisms of Hedgehog signalling and its roles 
in development and disease', Nat Rev Mol Cell Biol, 14(7), pp. 416-29. 
Brisslert, M., Bokarewa, M., Larsson, P., Wing, K., Collins, L. V. and Tarkowski, A. 
(2006) 'Phenotypic and functional characterization of human CD25+ B cells', 
Immunology, 117(4), pp. 548-57. 
Burglin, T. R. (2008) 'The Hedgehog protein family', Genome Biol, 9(11), pp. 241. 
Burlinson, E. L., Graber, P., Bonnefoy, J. Y., Ozanne, B. W. and Cushley, W. (1996) 
'Soluble CD40 ligand induces expression of CD25 and CD23 in resting human 
tonsillar B lymphocytes', Eur J Immunol, 26(5), pp. 1069-73. 
Busslinger, M. (2004) 'Transcriptional control of early B cell development', Annu Rev 
Immunol, 22, pp. 55-79. 
Cambier, J. C., Gauld, S. B., Merrell, K. T. and Vilen, B. J. (2007) 'B-cell anergy: from 
transgenic models to naturally occurring anergic B cells?', Nat Rev Immunol, 7(8), 
pp. 633-43. 
Cariappa, A., Boboila, C., Moran, S. T., Liu, H., Shi, H. N. and Pillai, S. (2007) 'The 
Recirculating B Cell Pool Contains Two Functionally Distinct, Long-Lived, 
Posttransitional, Follicular B Cell Populations', The Journal of Immunology, 179(4), 
pp. 2270-2281. 
Carsetti, R. (2004) 'Characterization of B-cell maturation in the peripheral immune system', 
Methods Mol Biol, 271, pp. 25-35. 
Carsetti, R., Rosado, M. M. and Wardmann, H. (2004) 'Peripheral development of B cells in 
mouse and man', Immunol Rev, 197, pp. 179-91. 
Cerutti, A., Cols, M. and Puga, I. (2013) 'Marginal zone B cells: virtues of innate-like 
antibody-producing lymphocytes', Nat Rev Immunol, 13(2), pp. 118-32. 
Cesta, M. F. (2006) 'Normal structure, function, and histology of the spleen', Toxicol Pathol, 
34(5), pp. 455-65. 
Chan, V. S., Chau, S. Y., Tian, L., Chen, Y., Kwong, S. K., Quackenbush, J., Dallman, M., 
Lamb, J. and Tam, P. K. (2006) 'Sonic hedgehog promotes CD4+ T lymphocyte 
proliferation and modulates the expression of a subset of CD28-targeted genes', Int 
Immunol, 18(12), pp. 1627-36. 
Chiang, C., Litingtung, Y., Lee, E., Young, K. E., Corden, J. L., Westphal, H. and Beachy, 
P. A. (1996) 'Cyclopia and defective axial patterning in mice lacking Sonic 
hedgehog gene function', Nature, 383(6599), pp. 407-13. 
  
 180 
Cooksey, C. J. (2014) 'Quirks of dye nomenclature. 3. Trypan blue', Biotech Histochem, 
89(8), pp. 564-7. 
Cooper, C. L., Hardy, R. R., Reth, M. and Desiderio, S. (2012) 'Non-cell-autonomous 
hedgehog signaling promotes murine B lymphopoiesis from hematopoietic 
progenitors', Blood, 119(23), pp. 5438-48. 
Cooper, M. D. (2015) 'The early history of B cells', Nat Rev Immunol, 15(3), pp. 191-7. 
Corominas, M., Mestre, M., Bas, J., Verdaguer, J., Valls, A., Romeu, A. and Buendia, E. 
(1993) 'CD23 expression on B-lymphocytes and its modulation by cytokines in 
allergic patients', Clin Exp Allergy, 23(7), pp. 612-7. 
Couper, K. N., Blount, D. G. and Riley, E. M. (2008) 'IL-10: The Master Regulator of 
Immunity to Infection', The Journal of Immunology, 180(9), pp. 5771-5777. 
Cridland, S. O., Keys, J. R., Papathanasiou, P. and Perkins, A. C. (2009) 'Indian hedgehog 
supports definitive erythropoiesis', Blood Cells Mol Dis, 43(2), pp. 149-55. 
Dayer, J. M. and Choy, E. (2010) 'Therapeutic targets in rheumatoid arthritis: the 
interleukin-6 receptor', Rheumatology (Oxford), 49(1), pp. 15-24. 
Decker, S., Zirlik, K., Djebatchie, L., Hartmann, D., Ihorst, G., Schmitt-Graeff, A., 
Herchenbach, D., Jumaa, H., Warmuth, M., Veelken, H. and Dierks, C. (2012) 
'Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for 
Hedgehog-inhibitor responsiveness in CLL', Blood, 119(4), pp. 997-1007. 
Dienz, O., Eaton, S. M., Bond, J. P., Neveu, W., Moquin, D., Noubade, R., Briso, E. M., 
Charland, C., Leonard, W. J., Ciliberto, G., Teuscher, C., Haynes, L. and Rincon, M. 
(2009) 'The induction of antibody production by IL-6 is indirectly mediated by IL-
21 produced by CD4+ T cells', J Exp Med, 206(1), pp. 69-78. 
Dierks, C., Grbic, J., Zirlik, K., Beigi, R., Englund, N. P., Guo, G. R., Veelken, H., 
Engelhardt, M., Mertelsmann, R., Kelleher, J. F., Schultz, P. and Warmuth, M. 
(2007) 'Essential role of stromally induced hedgehog signaling in B-cell 
malignancies', Nat Med, 13(8), pp. 944-51. 
Dinarello, C. A. (2000) 'Proinflammatory cytokines', Chest, 118(2), pp. 503-8. 
Ditzel, M. (2011) 'A Prickly Subject: Apoptotic regulation by hedgehog Morphogens ', The 
Open Signaling Journal, 3, pp. 9-19. 
Eibel, H., Kraus, H., Sic, H., Kienzler, A. K. and Rizzi, M. (2014) 'B cell biology: an 
overview', Curr Allergy Asthma Rep, 14(5), pp. 434. 
Eldar, A., Dorfman, R., Weiss, D., Ashe, H., Shilo, B. Z. and Barkai, N. (2002) 'Robustness 
of the BMP morphogen gradient in Drosophila embryonic patterning', Nature, 
419(6904), pp. 304-8. 
  
 181 
Evans, J. G., Chavez-Rueda, K. A., Eddaoudi, A., Meyer-Bahlburg, A., Rawlings, D. J., 
Ehrenstein, M. R. and Mauri, C. (2007) 'Novel Suppressive Function of Transitional 
2 B Cells in Experimental Arthritis', The Journal of Immunology, 178(12), pp. 
7868-7878. 
Flinn, I. W. (2011) 'CD37: the comeback kid', Blood, 118(15), pp. 4007-8. 
Fraga, D., Meulia, T. and Fenster, S. (2008) ‘Real-time PCR’, Current Protocols Essential 
Laboratory Techniques, pp. 10.3.1 – 10.3.33. 
Fukuda, N., Saitoh, M., Kobayashi, N. and Miyazono, K. (2006) 'Execution of BMP-4-
induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell 
hybridoma cells', Oncogene, 25(25), pp. 3509-17. 
Furmanski, A. L., Saldana, J. I., Ono, M., Sahni, H., Paschalidis, N., D'Acquisto, F. and 
Crompton, T. (2013) 'Tissue-derived hedgehog proteins modulate Th differentiation 
and disease', J Immunol, 190(6), pp. 2641-9. 
Garraud, O., Borhis, G., Badr, G., Degrelle, S., Pozzetto, B., Cognasse, F. and Richard, Y. 
(2012) 'Revisiting the B-cell compartment in mouse and humans: more than one B-
cell subset exists in the marginal zone and beyond', BMC Immunol, 13, pp. 63. 
Good-Jacobson, K. L., Song, E., Anderson, S., Sharpe, A. H. and Shlomchik, M. J. (2012) 
'CD80 expression on B cells regulates murine T follicular helper development, 
germinal center B cell survival, and plasma cell generation', J Immunol, 188(9), pp. 
4217-25. 
Goode, I., Xu, H. and Ildstad, S. T. (2014) 'Regulatory B cells: the new "it" cell', Transplant 
Proc, 46(1), pp. 3-8. 
Guo, X. and Wang, X. F. (2009) 'Signaling cross-talk between TGF-beta/BMP and other 
pathways', Cell Res, 19(1), pp. 71-88. 
Gupta, S., Takebe, N. and Lorusso, P. (2010) 'Targeting the Hedgehog pathway in cancer', 
Ther Adv Med Oncol, 2(4), pp. 237-50. 
Hardy, R. R. and Hayakawa, K. (2001) 'B cell development pathways', Annu Rev Immunol, 
19, pp. 595-621. 
Hardy, R. R., Kincade, P. W. and Dorshkind, K. (2007) 'The protean nature of cells in the B 
lymphocyte lineage', Immunity, 26(6), pp. 703-14. 
Harwood, N. E. and Batista, F. D. (2010) 'Early events in B cell activation', Annu Rev 
Immunol, 28, pp. 185-210. 
Hawkins, E. D., Hommel, M., Turner, M. L., Battye, F. L., Markham, J. F. and Hodgkin, P. 
D. (2007) 'Measuring lymphocyte proliferation, survival and differentiation using 
CFSE time-series data', Nat Protoc, 2(9), pp. 2057-67. 
  
 182 
Hegde, G. V., Peterson, K. J., Emanuel, K., Mittal, A. K., Joshi, A. D., Dickinson, J. D., 
Kollessery, G. J., Bociek, R. G., Bierman, P., Vose, J. M., Weisenburger, D. D. and 
Joshi, S. S. (2008) 'Hedgehog-induced survival of B-cell chronic lymphocytic 
leukemia cells in a stromal cell microenvironment: a potential new therapeutic 
target', Mol Cancer Res, 6(12), pp. 1928-36. 
Hendriks, R. W., Yuvaraj, S. and Kil, L. P. (2014) 'Targeting Bruton's tyrosine kinase in B 
cell malignancies', Nat Rev Cancer, 14(4), pp. 219-32. 
Heretsch, P., Tzagkaroulaki, L. and Giannis, A. (2010) 'Modulators of the hedgehog 
signaling pathway', Bioorg Med Chem, 18(18), pp. 6613-24. 
Hunter, C. A. and Jones, S. A. (2015) 'IL-6 as a keystone cytokine in health and disease', 
Nat Immunol, 16(5), pp. 448-457. 
Huse, K., Bakkebo, M., Oksvold, M. P., Forfang, L., Hilden, V. I., Stokke, T., Smeland, E. 
B. and Myklebust, J. H. (2011) 'Bone morphogenetic proteins inhibit CD40L/IL-21-
induced Ig production in human B cells: differential effects of BMP-6 and BMP-7', 
Eur J Immunol, 41(11), pp. 3135-45. 
Ichii, M., Oritani, K. and Kanakura, Y. (2014) 'Early B lymphocyte development: 
Similarities and differences in human and mouse', World J Stem Cells, 6(4), pp. 
421-31. 
Ingham, P. W. (2012) 'Hedgehog signaling', Cold Spring Harb Perspect Biol, 4(6). 
Ingham, P. W. and McMahon, A. P. (2001) 'Hedgehog signaling in animal development: 
paradigms and principles', Genes Dev, 15(23), pp. 3059-87. 
Kalampokis, I., Yoshizaki, A. and Tedder, T. F. (2013) 'IL-10-producing regulatory B cells 
(B10 cells) in autoimmune disease', Arthritis Res Ther, 15 Suppl 1, pp. S1. 
Katoh, Y. and Katoh, M. (2009) 'Hedgehog target genes: mechanisms of carcinogenesis 
induced by aberrant hedgehog signaling activation', Curr Mol Med, 9(7), pp. 873-86. 
Kersten, C., Sivertsen, E. A., Hystad, M. E., Forfang, L., Smeland, E. B. and Myklebust, J. 
H. (2005) 'BMP-6 inhibits growth of mature human B cells; induction of Smad 
phosphorylation and upregulation of Id1', BMC Immunol, 6, pp. 9. 
Kil, L. P., de Bruijn, M. J., van Nimwegen, M., Corneth, O. B., van Hamburg, J. P., Dingjan, 
G. M., Thaiss, F., Rimmelzwaan, G. F., Elewaut, D., Delsing, D., van Loo, P. F. and 
Hendriks, R. W. (2012) 'Btk levels set the threshold for B-cell activation and 
negative selection of autoreactive B cells in mice', Blood, 119(16), pp. 3744-56. 
Kim, K. H., Kim, J. M., Choi, Y. L., Shin, Y. K., Lee, H. C., Seong, I. O., Kim, B. K., Chae, 
S. W., Chung, Y. S. and Kim, S. H. (2009) 'Expression of sonic hedgehog signaling 
molecules in normal, hyperplastic and carcinomatous endometrium', Pathol Int, 
59(5), pp. 279-87. 
  
 183 
Kishimoto, T. (2010) 'IL-6: from its discovery to clinical applications', Int Immunol, 22(5), 
pp. 347-52. 
Kleiman, E., Salyakina, D., De Heusch, M., Hoek, K. L., Llanes, J. M., Castro, I., Wright, J. 
A., Clark, E. S., Dykxhoorn, D. M., Capobianco, E., Takeda, A., Renauld, J. C. and 
Khan, W. N. (2015) 'Distinct Transcriptomic Features are Associated with 
Transitional and Mature B-Cell Populations in the Mouse Spleen', Front Immunol, 6, 
pp. 30. 
Knobeloch, K. P., Wright, M. D., Ochsenbein, A. F., Liesenfeld, O., Lohler, J., Zinkernagel, 
R. M., Horak, I. and Orinska, Z. (2000) 'Targeted inactivation of the tetraspanin 
CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory 
conditions', Mol Cell Biol, 20(15), pp. 5363-9. 
Kobune, M., Kato, J., Kawano, Y., Sasaki, K., Uchida, H., Takada, K., Takahashi, S., 
Takimoto, R. and Niitsu, Y. (2008) 'Adenoviral vector-mediated transfer of the 
Indian hedgehog gene modulates lymphomyelopoiesis in vivo', Stem Cells, 26(2), 
pp. 534-42. 
Kurosaki, T. and Hikida, M. (2009) 'Tyrosine kinases and their substrates in B lymphocytes', 
Immunol Rev, 228(1), pp. 132-48. 
Kurosaki, T., Kometani, K. and Ise, W. (2015) 'Memory B cells', Nat Rev Immunol, 15(3), 
pp. 149-59. 
La Rosa, I., Camargo, L., Pereira, M. M., Fernandez-Martin, R., Paz, D. A. and Salamone, 
D. F. (2011) 'Effects of bone morphogenic protein 4 (BMP4) and its inhibitor, 
Noggin, on in vitro maturation and culture of bovine preimplantation embryos', 
Reprod Biol Endocrinol, 9, pp. 18. 
Lau, C. I., Outram, S. V., Saldana, J. I., Furmanski, A. L., Dessens, J. T. and Crompton, T. 
(2012) 'Regulation of murine normal and stress-induced erythropoiesis by Desert 
Hedgehog', Blood, 119(20), pp. 4741-51. 
LeBien, T. W. and Tedder, T. F. (2008) 'B lymphocytes: how they develop and function', 
Blood, 112(5), pp. 1570-80. 
Liu, K. E. and Frazier, W. A. (2015) 'Phosphorylation of the BNIP3 C-Terminus Inhibits 
Mitochondrial Damage and Cell Death without Blocking Autophagy', PLoS One, 
10(6), pp. e0129667. 
Liu, Z., Xu, J., He, J., Zheng, Y., Li, H., Lu, Y., Qian, J., Lin, P., Weber, D. M., Yang, J. 
and Yi, Q. (2014) 'A critical role of autocrine sonic hedgehog signaling in human 
CD138+ myeloma cell survival and drug resistance', Blood, 124(13), pp. 2061-71. 
  
 184 
Lo, K. W., Jiang, T., Gagnon, K. A., Nelson, C. and Laurencin, C. T. (2014) 'Small-
molecule based musculoskeletal regenerative engineering', Trends Biotechnol, 32(2), 
pp. 74-81. 
Loder, F., Mutschler, B., Ray, R. J., Paige, C. J., Sideras, P., Torres, R., Lamers, M. C. and 
Carsetti, R. (1999) 'B cell development in the spleen takes place in discrete steps 
and is determined by the quality of B cell receptor-derived signals', J Exp Med, 
190(1), pp. 75-89. 
Lowrey, J. A., Stewart, G. A., Lindey, S., Hoyne, G. F., Dallman, M. J., Howie, S. E. M. 
and Lamb, J. R. (2002) 'Sonic Hedgehog Promotes Cell Cycle Progression in 
Activated Peripheral CD4+ T Lymphocytes', The Journal of Immunology, 169(4), 
pp. 1869-1875. 
Lund, F. E. (2008) 'Cytokine-producing B lymphocytes-key regulators of immunity', Curr 
Opin Immunol, 20(3), pp. 332-8. 
Luu, V. P., Vazquez, M. I. and Zlotnik, A. (2014) 'B cells participate in tolerance and 
autoimmunity through cytokine production', Autoimmunity, 47(1), pp. 1-12. 
Maeda, K., Mehta, H., Drevets, D. A. and Coggeshall, K. M. (2010) 'IL-6 increases B-cell 
IgG production in a feed-forward proinflammatory mechanism to skew 
hematopoiesis and elevate myeloid production', Blood, 115(23), pp. 4699-706. 
Mak, K. K., Kronenberg, H. M., Chuang, P. T., Mackem, S. and Yang, Y. (2008) 'Indian 
hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy', 
Development, 135(11), pp. 1947-56. 
Mann, R. K. and Beachy, P. A. (2004) 'Novel lipid modifications of secreted protein 
signals', Annu Rev Biochem, 73, pp. 891-923. 
Matthias, P. and Rolink, A. G. (2005) 'Transcriptional networks in developing and mature B 
cells', Nat Rev Immunol, 5(6), pp. 497-508. 
Mauri, C. and Blair, P. A. (2014) 'The incognito journey of a regulatory B cell', Immunity, 
41(6), pp. 878-80. 
Mauri, C. and Bosma, A. (2012) 'Immune regulatory function of B cells', Annu Rev 
Immunol, 30, pp. 221-41. 
Mauri, C., Gray, D., Mushtaq, N. and Londei, M. (2003) 'Prevention of Arthritis by 
Interleukin 10-producing B Cells', Journal of Experimental Medicine, 197(4), pp. 
489-501. 
McMahon, J. A., Takada, S., Zimmerman, L. B., Fan, C. M., Harland, R. M. and McMahon, 
A. P. (1998) 'Noggin-mediated antagonism of BMP signaling is required for growth 
and patterning of the neural tube and somite', Genes Dev, 12(10), pp. 1438-52. 
  
 185 
Mebius, R. E. and Kraal, G. (2005) 'Structure and function of the spleen', Nat Rev Immunol, 
5(8), pp. 606-16. 
Mehlen, P., Mille, F. and Thibert, C. (2005) 'Morphogens and cell survival during 
development', J Neurobiol, 64(4), pp. 357-66. 
Merrell, K. T., Benschop, R. J., Gauld, S. B., Aviszus, K., Decote-Ricardo, D., Wysocki, L. 
J. and Cambier, J. C. (2006) 'Identification of anergic B cells within a wild-type 
repertoire', Immunity, 25(6), pp. 953-62. 
Metzler, G., Kolhatkar, N. S. and Rawlings, D. J. (2015) 'BCR and co-receptor crosstalk 
facilitate the positive selection of self-reactive transitional B cells', Curr Opin 
Immunol, 37, pp. 46-53. 
Mille, F., Thibert, C., Fombonne, J., Rama, N., Guix, C., Hayashi, H., Corset, V., Reed, J. C. 
and Mehlen, P. (2009) 'The Patched dependence receptor triggers apoptosis through 
a DRAL-caspase-9 complex', Nat Cell Biol, 11(6), pp. 739-46. 
Mills, L. D., Zhang, Y., Marler, R. J., Herreros-Villanueva, M., Zhang, L., Almada, L. L., 
Couch, F., Wetmore, C., Pasca di Magliano, M. and Fernandez-Zapico, M. E. 
(2013) 'Loss of the transcription factor GLI1 identifies a signaling network in the 
tumor microenvironment mediating KRAS oncogene-induced transformation', J 
Biol Chem, 288(17), pp. 11786-94. 
Miyazono, K., Kamiya, Y. and Morikawa, M. (2010) 'Bone morphogenetic protein 
receptors and signal transduction', J Biochem, 147(1), pp. 35-51. 
Miyazono, K., Maeda, S. and Imamura, T. (2005) 'BMP receptor signaling: transcriptional 
targets, regulation of signals, and signaling cross-talk', Cytokine Growth Factor Rev, 
16(3), pp. 251-63. 
Mizoguchi, E., Mizoguchi, A., Preffer, F. I. and Bhan, A. K. (2000) 'Regulatory role of 
mature B cells in a murine model of inflammatory bowel disease', Int Immunol, 
12(5), pp. 597-605. 
Moens, L. and Tangye, S. G. (2014) 'Cytokine-Mediated Regulation of Plasma Cell 
Generation: IL-21 Takes Center Stage', Front Immunol, 5, pp. 65. 
Muller, P., Rogers, K. W., Yu, S. R., Brand, M. and Schier, A. F. (2013) 'Morphogen 
transport', Development, 140(8), pp. 1621-38. 
Mullor, J. L., Sanchez, P. and Ruiz i Altaba, A. (2002) 'Pathways and consequences: 
Hedgehog signaling in human disease', Trends Cell Biol, 12(12), pp. 562-9. 
Nagasawa, T. (2006) 'Microenvironmental niches in the bone marrow required for B-cell 
development', Nat Rev Immunol, 6(2), pp. 107-16. 
  
 186 
Nikolic, T., Dingjan, G. M., Leenen, P. J. and Hendriks, R. W. (2002) 'A subfraction of 
B220(+) cells in murine bone marrow and spleen does not belong to the B cell 
lineage but has dendritic cell characteristics', Eur J Immunol, 32(3), pp. 686-92. 
Nohe, A. (2004) 'Signal transduction of bone morphogenetic protein receptors', Cellular 
Signalling, 16(3), pp. 291-299. 
Nusslein-Volhard, C. and Wieschaus, E. (1980) 'Mutations affecting segment number and 
polarity in Drosophila', Nature, 287(5785), pp. 795-801. 
O'Hara, W. A., Azar, W. J., Behringer, R. R., Renfree, M. B. and Pask, A. J. (2011) 'Desert 
hedgehog is a mammal-specific gene expressed during testicular and ovarian 
development in a marsupial', BMC Dev Biol, 11, pp. 72. 
Oka, S., Mori, N., Matsuyama, S., Takamori, Y. and Kubo, K. (2000) 'Presence of B220 
within thymocytes and its expression on the cell surface during apoptosis', 
Immunology, 100(4), pp. 417-23. 
Olteanu, H., Fenske, T. S., Harrington, A. M., Szabo, A., He, P. and Kroft, S. H. (2011) 
'CD23 expression in follicular lymphoma: clinicopathologic correlations', Am J Clin 
Pathol, 135(1), pp. 46-53. 
Outram, S. V., Hager-Theodorides, A. L., Shah, D. K., Rowbotham, N. J., Drakopoulou, E., 
Ross, S. E., Lanske, B., Dessens, J. T. and Crompton, T. (2009) 'Indian hedgehog 
(Ihh) both promotes and restricts thymocyte differentiation', Blood, 113(10), pp. 
2217-28. 
Outram, S. V., Varas, A., Pepicelli, C. V. and Crompton, T. (2000) 'Hedgehog signaling 
regulates differentiation from double-negative to double-positive thymocyte', 
Immunity, 13(2), pp. 187-97. 
Pasca di Magliano, M. and Hebrok, M. (2003) 'Hedgehog signalling in cancer formation 
and maintenance', Nat Rev Cancer, 3(12), pp. 903-11. 
Park, C. S. and Choi, Y. S. (2005) 'How do follicular dendritic cells interact intimately with 
B cells in the germinal centre?', Immunology, 114(1), pp. 2-10. 
Parmantier, E., Lynn, B., Lawson, D., Turmaine, M., Namini, S. S., Chakrabarti, L., 
McMahon, A. P., Jessen, K. R. and Mirsky, R. (1999) 'Schwann cell-derived Desert 
hedgehog controls the development of peripheral nerve sheaths', Neuron, 23(4), pp. 
713-24. 
Pathi, S., Pagan-Westphal, S., Baker, D. P., Garber, E. A., Rayhorn, P., Bumcrot, D., Tabin, 
C. J., Blake Pepinsky, R. and Williams, K. P. (2001) 'Comparative biological 
responses to human Sonic, Indian, and Desert hedgehog', Mech Dev, 106(1-2), pp. 
107-17. 
  
 187 
Patterson, H. C., Kraus, M., Kim, Y. M., Ploegh, H. and Rajewsky, K. (2006) 'The B cell 
receptor promotes B cell activation and proliferation through a non-ITAM tyrosine 
in the Igalpha cytoplasmic domain', Immunity, 25(1), pp. 55-65. 
Paul, W. E. (2010) 'What determines Th2 differentiation, in vitro and in vivo?', Immunol 
Cell Biol, 88(3), pp. 236-9. 
Peacock, C. D., Wang, Q., Gesell, G. S., Corcoran-Schwartz, I. M., Jones, E., Kim, J., 
Devereux, W. L., Rhodes, J. T., Huff, C. A., Beachy, P. A., Watkins, D. N. and 
Matsui, W. (2007) 'Hedgehog signaling maintains a tumor stem cell compartment in 
multiple myeloma', Proc Natl Acad Sci U S A, 104(10), pp. 4048-53. 
Perez-Chacon, G., Llobet, D., Pardo, C., Pindado, J., Choi, Y., Reed, J. C. and Zapata, J. M. 
(2012) 'TNFR-associated factor 2 deficiency in B lymphocytes predisposes to 
chronic lymphocytic leukemia/small lymphocytic lymphoma in mice', J Immunol, 
189(2), pp. 1053-61. 
Perez-Vera, P., Reyes-Leon, A. and Fuentes-Panana, E. M. (2011) 'Signaling proteins and 
transcription factors in normal and malignant early B cell development', Bone 
Marrow Res, 2011, pp. 502751. 
Perry, J. M., Harandi, O. F., Porayette, P., Hegde, S., Kannan, A. K. and Paulson, R. F. 
(2009) 'Maintenance of the BMP4-dependent stress erythropoiesis pathway in the 
murine spleen requires hedgehog signaling', Blood, 113(4), pp. 911-8. 
Pfaffl, M. W. (2001) 'A new mathematical model for relative quantification in real-time RT-
PCR', Nucleic Acids Res, 29(9), pp. e45. 
Pieper, K., Grimbacher, B. and Eibel, H. (2013) 'B-cell biology and development', J Allergy 
Clin Immunol, 131(4), pp. 959-71. 
Pillai, S. and Cariappa, A. (2009) 'The follicular versus marginal zone B lymphocyte cell 
fate decision', Nat Rev Immunol, 9(11), pp. 767-77. 
Porro, C. and Soleti, R., Benameur, T., Maffione, A.B., Andriantsitohaina, R., Martinez, 
M.C. (2009) 'Sonic hedgehog pathway as a target fo therapy in angiogenesis-related 
diseases', Current Siganl Transduction Therapy, 4, pp. 31-45. 
Ringner, M. (2008) 'What is principal component analysis?', Nat Biotechnol, 26(3), pp. 303-
4. 
Robbins, D. J., Fei, D. L. and Riobo, N. A. (2012) 'The Hedgehog signal transduction 
network', Sci Signal, 5(246), pp. re6. 
Roberts, D. J., Johnson, R. L., Burke, A. C., Nelson, C. E., Morgan, B. A. and Tabin, C. 
(1995) 'Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes 
during induction and regionalization of the chick hindgut', Development, 121(10), 
pp. 3163-74. 
  
 188 
Rogers, K. W. and Schier, A. F. (2011) 'Morphogen gradients: from generation to 
interpretation', Annu Rev Cell Dev Biol, 27, pp. 377-407. 
Rosado, M. M., Scarsella, M., Cascioli, S., Giorda, E. and Carsetti, R. (2014) 'Purification 
and immunophenotypic characterization of murine MZ and T2-MZP cells', Methods 
Mol Biol, 1190, pp. 3-16. 
Rowbotham, N. J., Hager-Theodorides, A. L., Cebecauer, M., Shah, D. K., Drakopoulou, E., 
Dyson, J., Outram, S. V. and Crompton, T. (2007) 'Activation of the Hedgehog 
signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus 
and peripheral T-cell activation', Blood, 109(9), pp. 3757-66. 
Rumfelt, L. L., Zhou, Y., Rowley, B. M., Shinton, S. A. and Hardy, R. R. (2006) 'Lineage 
specification and plasticity in CD19- early B cell precursors', J Exp Med, 203(3), pp. 
675-87. 
Russell, M. C., Cowan, R. G., Harman, R. M., Walker, A. L. and Quirk, S. M. (2007) 'The 
hedgehog signaling pathway in the mouse ovary', Biol Reprod, 77(2), pp. 226-36. 
Sacedon, R., Diez, B., Nunez, V., Hernandez-Lopez, C., Gutierrez-Frias, C., Cejalvo, T., 
Outram, S. V., Crompton, T., Zapata, A. G., Vicente, A. and Varas, A. (2005) 
'Sonic hedgehog is produced by follicular dendritic cells and protects germinal 
center B cells from apoptosis', J Immunol, 174(3), pp. 1456-61. 
Sacedon, R., Varas, A., Hernandez-Lopez, C., Gutierrez-deFrias, C., Crompton, T., Zapata, 
A. G. and Vicente, A. (2003) 'Expression of hedgehog proteins in the human 
thymus', J Histochem Cytochem, 51(11), pp. 1557-66. 
Saraiva, M. and O'Garra, A. (2010) 'The regulation of IL-10 production by immune cells', 
Nat Rev Immunol, 10(3), pp. 170-81. 
Scheller, J., Chalaris, A., Schmidt-Arras, D. and Rose-John, S. (2011) 'The pro- and anti-
inflammatory properties of the cytokine interleukin-6', Biochim Biophys Acta, 
1813(5), pp. 878-88. 
Schmittgen, T. D. and Livak, K. J. (2008) 'Analyzing real-time PCR data by the 
comparative CT method', Nature Protocols, 3(6), pp. 1101-1108. 
Schroeder, H. W., Jr. and Cavacini, L. (2010) 'Structure and function of immunoglobulins', 
J Allergy Clin Immunol, 125(2 Suppl 2), pp. S41-52. 
Schumacher, M. A., Donnelly, J. M., Engevik, A. C., Xiao, C., Yang, L., Kenny, S., Varro, 
A., Hollande, F., Samuelson, L. C. and Zavros, Y. (2012) 'Gastric Sonic Hedgehog 
acts as a macrophage chemoattractant during the immune response to Helicobacter 
pylori', Gastroenterology, 142(5), pp. 1150-1159 e6. 
Seda, V. and Mraz, M. (2015) 'B-cell receptor signalling and its crosstalk with other 
pathways in normal and malignant cells', Eur J Haematol, 94(3), pp. 193-205. 
  
 189 
Segura, E., Wong, J. and Villadangos, J. A. (2009) 'Cutting edge: B220+CCR9- dendritic 
cells are not plasmacytoid dendritic cells but are precursors of conventional 
dendritic cells', J Immunol, 183(3), pp. 1514-7. 
Shah, D. K., Hager-Theodorides, A. L., Outram, S. V., Ross, S. E., Varas, A. and Crompton, 
T. (2004) 'Reduced thymocyte development in sonic hedgehog knockout embryos', 
J Immunol, 172(4), pp. 2296-306. 
Shapiro-Shelef, M. and Calame, K. (2005) 'Regulation of plasma-cell development', Nat 
Rev Immunol, 5(3), pp. 230-42. 
Singh, R. R., Kim, J. E., Davuluri, Y., Drakos, E., Cho-Vega, J. H., Amin, H. M. and Vega, 
F. (2010) 'Hedgehog signaling pathway is activated in diffuse large B-cell 
lymphoma and contributes to tumor cell survival and proliferation', Leukemia, 24(5), 
pp. 1025-36. 
Sington, J., Giatromanolaki, A., Campo, L., Turley, H., Pezzella, F. and Gatter, K. C. 
(2007) 'BNIP3 expression in follicular lymphoma', Histopathology, 50(5), pp. 555-
60. 
Smith, E. and Sigvardsson, M. (2004) 'The roles of transcription factors in B lymphocyte 
commitment, development, and transformation', J Leukoc Biol, 75(6), pp. 973-81. 
Stathopoulos, A. and Iber, D. (2013) 'Studies of morphogens: keep calm and carry on', 
Development, 140(20), pp. 4119-24. 
Strong, N., Millena, A. C., Walker, L., Chaudhary, J. and Khan, S. A. (2013) 'Inhibitor of 
differentiation 1 (Id1) and Id3 proteins play different roles in TGFbeta effects on 
cell proliferation and migration in prostate cancer cells', Prostate, 73(6), pp. 624-33. 
Su, T. T., Guo, B., Wei, B., Braun, J. and Rawlings, D. J. (2004) 'Signaling in transitional 
type 2 B cells is critical for peripheral B-cell development', Immunol Rev, 197, pp. 
161-78. 
Sugai, M., Gonda, H., Nambu, Y., Yokota, Y. and Shimizu, A. (2004) 'Role of Id proteins 
in B lymphocyte activation: new insights from knockout mouse studies', J Mol Med 
(Berl), 82(9), pp. 592-9. 
Tabata, T. and Takei, Y. (2004) 'Morphogens, their identification and regulation', 
Development, 131(4), pp. 703-12. 
Tangye, S. G. and Tarlinton, D. M. (2009) 'Memory B cells: effectors of long-lived immune 
responses', Eur J Immunol, 39(8), pp. 2065-75. 
Tarlinton, D. (2006) 'B-cell memory: are subsets necessary?', Nat Rev Immunol, 6(10), pp. 
785-90. 
  
 190 
Tobon, G. J., Izquierdo, J. H. and Canas, C. A. (2013) 'B lymphocytes: development, 
tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus', 
Autoimmune Dis, 2013, pp. 827254. 
Tolar, P., Sohn, H. W. and Pierce, S. K. (2008) 'Viewing the antigen-induced initiation of 
B-cell activation in living cells', Immunol Rev, 221, pp. 64-76. 
Trowbridge, J. J., Scott, M. P. and Bhatia, M. (2006) 'Hedgehog modulates cell cycle 
regulators in stem cells to control hematopoietic regeneration', Proc Natl Acad Sci 
U S A, 103(38), pp. 14134-9. 
Tsalavos, S., Segklia, K., Passa, O., Petryk, A., O'Connor, M. B. and Graf, D. (2011) 
'Involvement of twisted gastrulation in T cell-independent plasma cell production', J 
Immunol, 186(12), pp. 6860-70. 
Urashima, M., Chauhan, D., Hatziyanni, M., Ogata, A., Hollenbaugh, D., Aruffo, A. and 
Anderson, K. C. (1996) 'CD40 ligand triggers interleukin-6 mediated B cell 
differentiation', Leuk Res, 20(6), pp. 507-15. 
van Amelsfort, J. M., Jacobs, K. M., Bijlsma, J. W., Lafeber, F. P. and Taams, L. S. (2004) 
'CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the 
presence, phenotype, and function between peripheral blood and synovial fluid', 
Arthritis Rheum, 50(9), pp. 2775-85. 
van den Brink, G. R. (2007) 'Hedgehog signaling in development and homeostasis of the 
gastrointestinal tract', Physiol Rev, 87(4), pp. 1343-75. 
van Engeland, M., Nieland, L. J., Ramaekers, F. C., Schutte, B. and Reutelingsperger, C. P. 
(1998) 'Annexin V-affinity assay: a review on an apoptosis detection system based 
on phosphatidylserine exposure', Cytometry, 31(1), pp. 1-9. 
Varas, A., Hernandez-Lopez, C., Valencia, J., Mattavelli, S., Martinez, V. G., Hidalgo, L., 
Gutierrez-Frias, C., Zapata, A. G., Sacedon, R. and Vicente, A. (2008) 'Survival and 
function of human thymic dendritic cells are dependent on autocrine Hedgehog 
signaling', J Leukoc Biol, 83(6), pp. 1476-83. 
Varas, A., Martinez, V. G., Hernandez-Lopez, C., Hidalgo, L., Entrena, A., Valencia, J., 
Zapata, A., Sacedon, R. and Vicente, A. (2009) 'Role of BMP signalling in 
peripheral CD4+ T cell proliferation', Inmunologia, 28(3), pp. 125-130. 
Varjosalo, M. and Taipale, J. (2007) 'Hedgehog signaling', J Cell Sci, 120(Pt 1), pp. 3-6. 
Varjosalo, M. and Taipale, J. (2008) 'Hedgehog: functions and mechanisms', Genes Dev, 
22(18), pp. 2454-72. 
Vazquez, M. I., Catalan-Dibene, J. and Zlotnik, A. (2015) 'B cells responses and cytokine 
production are regulated by their immune microenvironment', Cytokine, 74(2), pp. 
318-26. 
  
 191 
Vidarsson, G., Dekkers, G. and Rispens, T. (2014) 'IgG subclasses and allotypes: from 
structure to effector functions', Front Immunol, 5, pp. 520. 
Wakelin, S. J., Forsythe, J. L., Garden, O. J. and Howie, S. E. (2008) 'Commercially 
available recombinant sonic hedgehog up-regulates Ptc and modulates the cytokine 
and chemokine expression of human macrophages: an effect mediated by endotoxin 
contamination?', Immunobiology, 213(1), pp. 25-38. 
Wang, Y. and McMahon, A. P. (2013) 'A novel site comes into sight', Elife, 2, pp. e01680. 
Wijgerde, M., Ooms, M., Hoogerbrugge, J. W. and Grootegoed, J. A. (2005) 'Hedgehog 
signaling in mouse ovary: Indian hedgehog and desert hedgehog from granulosa 
cells induce target gene expression in developing theca cells', Endocrinology, 
146(8), pp. 3558-66. 
Wortis, H. H., Teutsch, M., Higer, M., Zheng, J. and Parker, D. C. (1995) 'B-cell activation 
by crosslinking of surface IgM or ligation of CD40 involves alternative signal 
pathways and results in different B-cell phenotypes', Proc Natl Acad Sci U S A, 
92(8), pp. 3348-52. 
Woyach, J. A., Johnson, A. J. and Byrd, J. C. (2012) 'The B-cell receptor signaling pathway 
as a therapeutic target in CLL', Blood, 120(6), pp. 1175-84. 
Yamashita, H., Ten Dijke, P., Heldin, C. H. and Miyazono, K. (1996) 'Bone morphogenetic 
protein receptors', Bone, 19(6), pp. 569-74. 
Yoshioka, Y., Ono, M., Osaki, M., Konishi, I. and Sakaguchi, S. (2012) 'Differential effects 
of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation 
and differentiation', Eur J Immunol, 42(3), pp. 749-59. 
Yuseff, M. I., Pierobon, P., Reversat, A. and Lennon-Dumenil, A. M. (2013) 'How B cells 
capture, process and present antigens: a crucial role for cell polarity', Nat Rev 
Immunol, 13(7), pp. 475-86. 
Zhou, X., Liu, Z., Jang, F., Xiang, C., Li, Y. and He, Y. (2012) 'Autocrine Sonic hedgehog 
attenuates inflammation in cerulein-induced acute pancreatitis in mice via 
upregulation of IL-10', PLoS One, 7(8), pp. e44121. 
Zhu, L., Zhao, Z., Wei, Y., Marcotte, W., Jr., Wagner, T. E. and Yu, X. (2012) 'An IL-
12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural 
killer cell activation', Int J Oncol, 41(2), pp. 661-9. 
Zuccarino-Catania, G. V., Sadanand, S., Weisel, F. J., Tomayko, M. M., Meng, H., 
Kleinstein, S. H., Good-Jacobson, K. L. and Shlomchik, M. J. (2014) 'CD80 and 
PD-L2 define functionally distinct memory B cell subsets that are independent of 
antibody isotype', Nat Immunol, 15(7), pp. 631-7. 
  
 192 
Appendix 
 
Appendix 2.1 
 
A melting curve analysis was carried out to ensure the product of primer were the 
expected size and not the result of primer dimer. The image below shows an example of 
a melting curve. 
 
 
 
Figure 2: Image of a melting curve 
Change in fluorescence (y axis) with increasing temperature (x axis) is measured. As 
the temperature increases, the two strands of the amplicon breaks to form single 
stranded DNA triggering the fluorescent intercalating dye to dissociate from the DNA 
and stop fluorescing. 
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Appendix 2.2 
 
Below shows a worked example of the calculation of relative expression using the 
relative standard method. Standard curves are generated for both the gene of interest (in 
this example, Btk) and the house keeping gene, Hprt. The standard curve is shown 
below. A 1:10 serial dilution of the genes was carried out. The standard curves for both 
genes were generated by plotting the Ct values against the Log10 concentrations of the 
gene. 
 
 
The table below shows the average Ct value of the different samples. 
Sample Average Ct 
Btk 
Average Ct 
Hprt 
Control  
18hours 
23.21 22.34 
0.05μg/ml rShh 
18hours 
22.49 22.25 
Control  
40hours 
22.63 22.81 
0.05μg/ml rShh 
40hours 
22.52 22.05 
The equation obtained from the standard curve for Btk and Hprt was used to calculate 
the gene concentration in the different samples, shown below in the table. 
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Sample Concentration 
Btk 
Concentration 
Hprt 
Control  
18hours 
0.2360 0.0411 
0.05μg/ml rShh 
18hours 
0.4156 0.0436 
Control  
40hours 
0.3723 0.0303 
0.05μg/ml rShh 
40hours 
0.4070 0.0496 
 
Relative gene expression in each sample was obtained by dividing the concentration of 
the gene of interest (Btk) by the housekeeping gene (Hprt). The relative expression is 
shown below. 
Sample Relative expression 
Btk 
Control  
18hours 
5.744 
0.05μg/ml rShh 
18hours 
9.539 
Control  
40hours 
12.305 
0.05μg/ml rShh 
40hours 
8.201 
 
